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Molecular mechanism of action of the glucocorticoid receptor:  Role of ligand-
dependent receptor phosphorylation and half-life in determination of ligand-
specific transcriptional activity. 
 




Glucocorticoids mediate their effects by binding to the glucocorticoid receptor (GR), resulting in 
modulation of transcription of target genes via direct binding to DNA or tethering via protein-
protein interactions.  A central question is what determines the rank order of ligand-selective 
transcription with different GR ligands for the same gene in the same cell. Using a panel of 
twelve GR ligands, including agonists, partial agonists and antagonists, the relationship between 
the extent of GR phosphorylation at S226, GR turnover and transcriptional response, was 
investigated using a variety of biochemical approaches. Using a phospho-S226-specific GR 
antibody, ligand-selective S226 phosphorylation was shown to occur in both COS-1 and U2OS 
cells, while GR phosphorylation at S226 was shown to inhibit maximal transactivation and 
transrepression efficacy. Attempts to identify the kinases responsible for this interaction were 
inconclusive but suggested a combination of kinases is responsible for the in vivo 
phosphorylation of the hGR in these cells. Similarly the rate of GR degradation was different for 
the different ligands.  Interestingly, both ligand-selective GR phosphorylation and half-life were 
found to correlate with efficacy for transactivation and transrepression of model synthetic 











rate of GR turnover, suggesting a link between these functions. Furthermore experiments where 
transcription was blocked suggest that GR turnover does not require transcription. However, 
using a S226A GR mutant, as well as in experiments where GR turnover was blocked, it was 
established that neither phosphorylation of the GR at S226 nor GR degradation rate determines 
the rank order of ligand-selective GR transactivation. The mechanisms whereby GR 
phosphorylation influence GR-mediated transcription was further investigated using a triple 
phosphorylation deficient mutant. It was shown that phosphorylation at one or more of residues 
S203/S211/S226 is required for transactivation of a MMTV promoter but does not affect 
unliganded or agonist-induced GR degradation and acetylation. Additionally, it was shown that 
phosphorylation at S203/S211/S226 is not the sole determinant of co-activator p300 recruitment 
to the GR. Interestingly, GR-mediated transrepression via AP-1 is less sensitive to GR 
phosphorylation than GR-mediated transactivation, indicating different mechanisms in the role of 
GR phosphorylation on transactivation vs. transrepression. Pull-down and chromatin 
immunoprecipitation assays showed that phosphorylation of the GR at one or more of these 
residues are required for interaction of the GR with the co-activator GRIP-1 in vitro and for 
maximal recruitment of GR and GRIP-1 to the MMTV promoter in intact cells. Cellular 
fractionation showed that phosphorylation at these residues is not however required for GR 
nuclear localisation. Taken together these results support the conclusion that phosphorylation at 
one or more of S203/S211/S226 of the hGR is required for maximal transactivation response to 
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This thesis contains the following sections: 
 
1. Chapter 1:  Literature review.  This chapter gives a detailed overview of the relevant 
knowledge currently available in the literature on GR function and transcriptional 
regulation, with particular focus on ligand-selectivity, phosphorylation and degradation of 
the GR.   
2. Chapter 2: Thesis Rationale, Aims and Hypotheses. This chapter will briefly outline the 
relevant issues in the steroid receptor research field, explain the place of this thesis as 
being part of a larger investigation, and state the context, aims and hypotheses of this 
thesis. 
3. Chapter 3:  Materials and Methods. This chapter provides detailed information on the 
protocols used to obtain the results presented in chapters 4 to 7. 
4. Chapter 4:  Ligand-selective GR phosphorylation (Results and Discussion). The first 
part of this study used a phospho-S226 GR-specific antibody to determine ligand-
selective GR phosphorylation at S226 of transiently expressed hGR in COS-1, as well as 
stably transfected hGR in U2OS cells.  Furthermore, ligand-selective GR phosphorylation 
was correlated to efficacy and potency for transactivation and transrepression (Addendum 
E) obtained with hGR in COS-1 cells.  These efficacy and potency results were obtained 
by Elisabeth Stubsrud and Katharina Ronacher (previously from the same research group 
as the present author), as part of the larger investigation and are published (Stubsrud, 
2005;Ronacher et al., 2009). Additionally, the role of GR phosphorylation on ligand-











shortly be submitted for publication.  The cell culture work was performed by the present 
author, except for plating and maintenance of stock cultures, which was done by Carmen 
Langeveldt.   
5. Chapter 5:  Investigation into the kinases involved in GR phosphorylation (Results 
and Discussion). This section contains results and discussion on the kinases involved in 
GR phosphorylation at S226 and S211. The ability of specific kinase inhibitors (JNK, p38 
and CDK inhibitors), as well as over expression of wt and dominant negative kinases 
(JNK, p38 and CDK5), to inhibit GR phosphorylation at S226 and S211 was investigated 
in COS-1, LT2 and/or END-1 cells. All the results presented in this chapter were 
obtained by the present author, and all the cell work was performed by the present author.     
6. Chapter 6:  Ligand-selective GR degradation (Results and Discussion).  This section 
contains results and discussion on ligand-selective GR degradation, as well as correlations 
thereof to ligand-selective transactivation and transrepression (Addendum E).  
Additionally, an investigation into the relationship between ligand-selective GR 
degradation and transactivation is presented in this chapter.  These results will shortly be 
submitted for publication.  All the results presented in this chapter were obtained by the 
present author, and all the cell work was performed by the present author.     
7. Chapter 7:  Role of agonist-induced GR phosphorylation in GR mechanism of action 
(Results and Discussion).  This section present results and discussion on the relationship 
between agonist-induced GR phosphorylation and transcription, as well as between GR 
phosphorylation and GR degradation.  Additionally, this chapter presents results on the 
role of agonist-induced GR phosphorylation on additional GR functions, including 
acetylation and co-factor recruitment. The majority of these results have been submitted 
to the journal Biochemistry. All the results presented in this chapter were obtained by the 











8. Chapter 8:  Conclusions and future perspectives.  In this chapter, conclusions are 
discussed and drawn from the combined results in chapters 4 to 7.  Some perspectives 
about future research are also included. 
9. Addendum A:  Basic principles for evaluating transcriptional responses.  This section 
contains a discussion of the basic principles used in this study to evaluate the 
transcriptional responses, including potency, efficacy and ligand binding affinity. 
Additionally, this section contains an explanation of the basic principles used to perform 
the correlation analysis. 
10. Addendum B:  Panel of GR ligands.  This section contains a detailed discussion of the 
available literature on each of the ligands used in this study.  
11. Addendum C:  Antibodies. This addendum contains a list, as well as the specific dilutions 
and incubation times used, for all the antibodies that were used in this study. 
12. Addendum D:  Supporting data from the present author. This addendum contains 
supporting data (relevant to chapter 4) not provided in results chapter 4 of the manuscript.  
GR dose-response curves with an agonist and partial agonist at different GR 
concentrations are shown.  These results were obtained by the present author, and the cell 
work was performed by the present author.   
13. Addendum E:  Supporting data from other researchers. This addendum contains 
additional data that is used in this thesis for correlations and/or discussion, but that was 
performed by E. Stubsrud and K. Ronacher, as part of the larger investigation. Results on 
ligand-selective GR transactivation, phosphorylation at S211, as well as the role of GR 
phosphorylation at S211 on transactivation was obtained by E. Stubsrud (Stubsrud, 2005).  
Results obtained on ligand-selective GR binding, transrepression, as well as the effect of 
kinase inhibitors on transactivation and transrepression were obtained by K. Ronacher. 











present author worked closely together with E. Stubsrud in obtaining data on ligand-
selective GR phosphorylation at S211, and also performed all the correlation analyses 
shown in this addendum. 
14. Ronacher et al. 2009. The published research article that contains some of the data in 
addendum E.  The present author contributed to this research article, in terms of 
intellectual planning of the experiments and interpretation of the data. Furthermore, all the 
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Chapter 1 Literature review 
 
 
1.1 Nuclear Receptors 
 
Nuclear receptors (NRs) are ligand activated transcription factors that regulate transcription 
through binding of small lipophilic molecules (ligands).  Genes regulated by NRs can either be 
upregulated (transactivation) or down-regulated (transrepression) and play a role in most 
biological responses including the stress response, metabolism, immune function, growth, 
development and reproduction.  Since the isolation of the estrogen receptor (ER) in 1961 and the 
cloning of the estrogen, glucocorticoid and thyroid hormone receptors in the 1980s, 48 known 
human NRs have been characterised (Tata, 2005;Gronemeyer et al., 2004;Zhang et al., 2004).  
Based on evolutionary and sequence homology, NRs can be divided into six sub-families, which 
in turn can be divided up into different groups (Laudet, 1997;Nuclear Receptors Nomenclature 
Committee, 1999).  The large subfamily one, denoted NR1, contains the thyroid hormone 
receptor (TR), retinoic acid receptor (RAR), the peroxisome proliferators-activated receptor 
(PPAR) and the vitamin D receptor (VDR) to name but a few (Fig. 1.1). Of most interest in the 
second subfamily (NR2), is the retinoid X receptor (RXR), which function as partners for NRs 
that bind DNA as heterodimers and thereby play an important role in NR signalling.  Subfamily 
three (NR3) contains the steroid and sex hormone receptors, i.e. the glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR), progesterone receptor (PR), androgen receptor (AR) and the 
estrogen receptor (ER).  Subfamily four (NR4) and subfamily five (NR5) consist of the nerve 
growth factor IB-like and steroidogenic factor-like receptors, respectively, whereas subfamily six 











structure, consisting of three major domains, the highly variable N-terminal domain (NTD), the 
DNA binding domain (DBD) and the ligand binding domain (LBD).  Small lipophilic ligands 
bind to the LBD of most NRs, which is proposed to result in a conformational change in the 
receptor.  Most of these receptors (but not all) then bind to specific DNA sequences called 
hormone response elements (HREs), or other transcription factors, and regulate the transcription 
of a variety of genes (Reviewed in (Kumar and Thompson, 2005;Aranda and Pascual, 













Figure 1.1 Phylogenetic consensus tree of NRs.  Taken and modified from (Laudet, 1997).  Black circle 
represent the NRs and the arrows represent the PuGGTCA NRE which can be a single unit, a palindrome 












Nuclear receptors play a role in most physiological processes and are associated with a variety of 
diseases, including diabetes, obesity, cancer, atherosclerosis, cardiovascular diseases, 
osteoporosis and Alzheimer’s disease, to name but a few (Kersten et al., 2000;Shang et al., 
2000).  Furthermore, nuclear receptor ligands can easily be exchanged with a drug of choice and 
therefore nuclear receptors and their ligands are ideal drug targets. Extensive research has been 





Glucocorticoids (GCs) are the most commonly prescribed anti-inflammatory drugs in the 
treatment of asthma and rheumatoid arthritis, as well as in treatment of autoimmune diseases and 
pulmonary diseases and have been used pharmacologically since the availability of cortisone 
about 50 years ago (Moutsatsou P, 2008).  GCs suppress inflammation by down-regulating the 
expression of pro-inflammatory cytokines such as interleukin (IL) 1, or by up-regulating 
cytokines such as transforming growth factor (TGF)-1-3 and IL-10, which in turn suppress the 
production of pro-inflammatory mediators (Ashwell et al., 2000;Galon et al., 2002).  Due to their 
anti-inflammatory, as well as their antiemetic, antiedema and palliative properties, GCs are given 
as co-medication with chemotherapy in cancer patients (recently reviewed in (Moutsatsou P, 
2008;Lu et al., 2006). However, long-term treatment with GCs causes serious side effects, 
including neural and physiological disturbances such as psychosis and depression.  High levels of 
glucocorticoids, caused by chronic GC treatment, inhibit osteoblasts and collagen synthesis, as 
well as calcium absorption in the gastrointestinal tract and kidneys and thereby results in 











evidence for GCs negatively impacting bone formation came from a study that showed that local 
treatment with dexamethasone (dex) resulted in significant decrease in tibial growth, compared to 
the contralateral limb in rabbits (Baron et al., 1992).  Furthermore, recent studies also indicate 
that the co-treatment of GCs with chemotherapy in breast cancer hampers the responsiveness of 
the cancer to the chemotherapy (Montecucco et al., 1992). GCs also induce sex hormone 
deficiency and alter vitamin D metabolism, leading to deleterious effects on growth and skeletal 
integrity (Montecucco et al., 1992). 
 
By microarray analysis of GC-regulated genes, Galon et al. showed that GCs can have both 
positive and negative effects on inflammation and the immune response by either up-regulating 
or down-regulating a variety of genes, including pro-inflammatory and anti-inflammatory genes, 
as well as genes involved in cell trafficking and scavenger systems (Galon et al., 2002).  They, 
along with others hypothesize that the effect of GCs on inflammation and the immune response is 
context dependent and can be related to the state of disease, as well as by different sets of GR-
recruited transcription factors, including different co-activators and co-repressors (Galon et al., 
2002;Franchimont et al., 1999;Carroll, 1998;McKenna et al., 1999b).   
 
The hypothalamic-pituitary-adrenal (HPA) axis controls the synthesis of GCs in the adrenal 
cortex.  Endogenous GCs, e.g. cortisol (cort) in humans, are secreted into the blood stream in a 
continuous pulsatile pattern at a frequency of approximately 20 pulses per day (Fig. 1.2) which 
forms the basis of the diurnal rhythm in humans (Windle et al., 1998;Lightman et al., 2008).  
GCs can act in a negative feedback loop on the HPA axis, in different ways, involving both non-
genomic as well as genomic responses (Hinz and Hirschelmann, 2000;Keller-Wood and Dallman, 
1984).  GCs circulate in the body bound to corticosteroid-binding globulin and serum albumin 











to 20% of the genes in the human genome (Galon et al., 2002). The GR can repress the 
transcription of a variety of genes including pro-inflammatory genes, as well as transactivate the 
transcription of anti-inflammatory genes including IL-10 and annexin, which results in the 
desired anti-inflammatory effect of GCs.  However, as discussed above, the GR can also 
transactivate gene expression of a variety of genes involved in the negative side-effects of 
prolonged or chronic GC treatment (Recently reviewed in (Lowenberg et al., 2009)). A better 
understanding of the GR, as well as the development of GCs that can distinguish between the 
desired anti-inflammatory and the undesired side-effects, is therefore crucial for future 
pharmacological use of GCs.      
 
 
Figure 1.2   Cortisol secretion in a healthy human female.  At a frequency of approximately 20 pulses 
per day with a pulse mass of 115.1 nmol/L/min. Taken from (Lightman et al., 2008).  
 
 
1.3 GR gene and protein structure 
 
In 1989, the singular hGR gene was mapped to chromosome 5q31-32 and it was subsequently 
shown to comprise 10 exons spanning a 110 kb region (Francke and Foellmer, 1989;Theriault et 











encodes the 5’-untranslated region, while exon 2 (1197 bp) encodes most of the N-terminal 
region (Fig. 1.3).  Exon 3 (167 bp) and exon 4 (117 bp) each encodes a zinc-finger motif and 
together makes up the DBD, while exons 5, 6, 7, 8, 9 and 9 encode the LBD and the 3’-
untranslated region (Reviewed in (Zhou and Cidlowski, 2005)).  Alternative splicing of exon 9 
and 9 results in two different GR proteins, namely GR and GR, containing either exon 9 or 
9, respectively. These two proteins contain the same functional domains, however GR has a 
truncated LBD. In the absence of ligand, the classical GR is mainly cytoplasmic and 
translocates to the nucleus upon ligand binding.  In contrast, the GR isoform is mostly nuclear 
in the absence of ligand and has been shown to repress cytokine genes (IL5 and IL13) in HeLa 
cells in the absence of ligand through the recruitment of histone deacetylase 1 (HDAC1) (Kelly et 
al., 2008).  Recently microarray analysis has shown that overexpressed hGR in U2OS and COS-
1 cells can both upregulate and repress several genes in the absence of ligand and that binding of 
RU486 to the GR diminishes this capacity (Lewis-Tuffin et al., 2007). Additionally, the GR 
isoform has been shown to form heterodimers with the GRisoform and act as a dominant 
negative to transcriptional regulation by GR (Oakley et al., 1999;Oakley et al., 1996;Bamberger 
et al., 1995).  High expression levels of the human GR isoform have been reported in a variety 
of tissues, and more strikingly, increased GR expression has been identified in a variety of 
diseases related to GC resistance. For example 10 out of 12 patients with glucocorticoid-resistant 
colitis have been shown to contain high levels of hGRReviewed in (Lu and Cidlowski, 2004)).  
The increased expression of GR and its dominant negative effect on GR could account for GC 
resistance associated with various diseases and is under intensive investigation.   
 
Three additional GR splice variants, namely GR, GR-A and GR-P have also been identified.  











A lacks exons 5, 6 and 7 and GR-P lacks exons 8 and 9.  All three of the above mentioned splice 
variants (GR, GR-A and GR-P) have been found to be highly expressed in various GC resistant 
diseases, including GC resistance in childhood acute lymphoblastic leukaemia (Reviewed in (Lu 
and Cidlowski, 2004)).  Apart from the above mentioned isoforms, due to alternative splicing, 
both GR and GR mRNA can be differentially translated into multiple GR and GR isoforms 
that are truncated at the N-terminal (Recently reviewed in (Moutsatsou P, 2008)).  However, most 
of the above mentioned isoforms have a reduced (if any) transactivation potential as compared to 
GR.   
 
The classical GR protein consists of 777 amino acids and can be divided into 3 independent 
domains, namely the NTD, the DBD and the LBD (Fig. 1.4).  To date, the crystal structure of the 
whole GR protein, or any other steroid receptor, has not been solved.  For the GR, this is mainly 
due to an unordered NTD structure (Lu et al., 2006). The NTD is the most variable in both size 
and sequence homology between different species of GR.  Nevertheless, the NTD contains the 
transcriptional activation region 1 (AF1), which can act constitutively in the absence of the LBD 
and is required for maximal transcriptional activity (Dieken and Miesfeld, 1992;Godowski et al., 
1987;Giguere et al., 1986).  Interestingly, the AF1 region is not essential for life, as transgenic 
mice without the AF1 region still live (Mittelstadt and Ashwell, 2003).  Furthermore, the AF1 
region (comprising amino acids 77-262/282) binds selectively to several transcription factors, 
including TATA box-binding protein (TBP), CREB-binding protein (CBP) and steroid receptor 
co-activator 1 (SRC-1) (Kumar et al., 2001;Kumar and Thompson, 2005).  Additionally, the 
NTD is a major site for post-translational modifications such as phosphorylation and 














Figure 1.3 GR gene and multiple GR isoforms.  Modified from (Moutsatsou P, 2008) and (Zhou and 
Cidlowski, 2005).  
 
The DBD (65 amino acids) is the most conserved region and is composed of two highly 











atom is coordinated in a tethrahedral arrangement by four cysteines (Luisi et al., 1991;Freedman 
et al., 1988), with the resulting tertiary structure containing helices that interact specifically with 
DNA.  The amino acids of the first zinc finger are responsible for specific binding of the GR to 
its glucocorticoid response element (GRE), whereas the amino acids of the second zinc finger 
stabilize the GR:GRE interaction.  Additionally, the amino acids of the second zinc finger are 
also important for homodimerization of the GR (reviewed in (Kumar and Thompson, 2005)).  
The DBD also participates in interactions with other proteins, such as c-Jun and together with the 
LBD controls nuclear translocation, as both the DBD and the LBD contain nuclear localisation 
signal sequences (NLs) (Picard and Yamamoto, 1987) (Fig. 1.3).  The DBD is connected to the 
moderately conserved LBD through a flexible hinge region.     
 
 
Figure 1.4  Structural Organization of the hGR protein.  Taken and adapted from (Smoak and 
Cidlowski, 2004). 
 
The LBD (approximately 250 amino acids) is located at the carboxy-terminal end of the receptor 
and is responsible for recognition and binding of the hormone ligands (Fig. 1.4).  The crystal 
structure of the LBD of the GR, both in the presence of agonists or antagonists, as well as in the 
absence of hormone, indicates that the LBD of the GR consists of 12 -helices and 4 small  











as the top of the globule, thereby making a central hydrophobic ligand-binding pocket comprised 
of residues from helices 3, 4, 5, 6, 7, 10 and 12, as well as the  strands 1 and 2 (Bledsoe et al., 
2002).  Additionally, the LBD, along with the DBD and possibly the hinge region, plays an 
important role in receptor homodimerisation.  Two residues within the LBD, namely I628 and 
P625 have been shown to be important for homodimerisation of the GR LBD (Bledsoe et al., 
2002).  The LBD has also been shown to play a role in binding to the heat-shock proteins, as well 
as in co-factor recruitment through its ligand-dependent transactivation domain 2 (AF2) 
(Reviewed in (Bledsoe et al., 2004)).  
 
 
1.4 GR mechanism of action 
 
1.4.1 Ligand-binding and activation of the GR 
 
In the absence of hormone, the inactive GR monomer forms part of a larger heteromeric protein 
complex that resides in the cytoplasm and maintains the GR in a conformation suitable for 
ligand-binding (Wikstrom et al., 1987;Dalman et al., 1989;Picard et al., 1990) (Fig. 1.5).  This 
heteromeric protein complex includes heat-shock protein 90 (HSP90), 70 (HSP70), other heat-
shock proteins, immunophilins such as FK506 binding protein 51 (FKBP51), phosphatases such 
as protein phosphatase 5 (PP5) and p23 (Pratt and Toft, 1997;Wang et al., 2007b;Kumar and 
Thompson, 2005;Zhou and Cidlowski, 2005;Moutsatsou P, 2008).  Glucocorticoids are lipophilic 
hormones that passively diffuse over the plasma membrane.  Once inside the target cell, 
pharmacologically administered glucocorticoids are metabolised by 11-hydroxysteroid 











example cortisone into active cortisol (Reviewed in (Seckl, 2004;Tomlinson et al., 2004). 
Additionally, active cortisol, secreted from the adrenals, also travels through the blood and can 
passively diffuse over the plasma membrane (Lu et al., 2006). 
 
Figure 1.5 GR mechanism of action.  Taken and modified from (Gross and Cidlowski, 2008). TPR = 











The active glucocorticoid can then bind to the GR. It is generally accepted that upon binding, 
different ligands result in different conformational changes of the GR.  The crystal structure of 
the LBD of the GR bound by the agonist dex (Bledsoe et al., 2002;Kauppi et al., 2003), as well 
as the antagonist RU486 (Kauppi et al., 2003) revealed that the final position of helix-12 is very 
different in the presence of a GR agonist versus a GR antagonist (Fig. 1.6). Helix-12 contains the 
AF2 domain and binds co-factors through their LXXLL motif.  Agonist binding changes the 
position of helix-12 to fold over the ligand binding cavity and creates a favourable surface for the 
binding of co-activators, e.g. transcription intermediary factor 2, TIF2 (Fig. 1.6).  Upon 
antagonist binding, the position of helix-12 changes into a position that covers the co-activator 
cavity, preventing co-activators from binding (Kauppi et al., 2003).  More recently, results 
obtained with hydrogen/deuterium exchange mass spectrometry (HXMS) analysis, showed that 
different GR conformations occur in the presence of dex vs. RU486 as well different GR 
conformations with dex-mediated recruitment of TIF2, versus RU486-mediated recruitment of 
NCoR (Frego and Davidson, 2006). These ligand-induced conformational changes are 
accompanied by GR phosphorylation, as well as the release of the GR from the heteromeric HSP 















Figure 1.6 The crystal structure of the GR LBD.  The crystal structure of the GR LBD bound with the 
agonist dex (a) with the co-activator TIF-2 and with the antagonist RU486 (b).  Taken and adapted from 
(Kauppi et al., 2003). 
 
1.4.2 Nuclear translocation and dimerisation  
 
The unliganded GR shuttles continuously between cytoplasm and nucleus, but is at any given 
moment mostly cytoplasmic (Wikstrom et al., 1987;Hache et al., 1999).  For a long time it was 
believed that ligand binding, release from the heteromeric HSP complex and GR conformational 
change allows the GR to translocate to the nucleus, and that GR homodimerisation occurs on the 
DNA. However, more recent data supports a hypothesis that receptor dimerisation occurs before 
nuclear import and does not require DNA binding.  Savory et al. showed that GR dimerisation 
occurs in the cytoplasm (Savory et al., 2001).  Additionally, mutation of residue I628 in the LBD, 
as well as residues in the DBD, which are important for GR homodimerisation, still allows for 
nuclear translocation and GR mediated transrepression, but not transactivation (Bledsoe et al., 
2002;Reichardt et al., 1998). Furthermore, it was recently shown that a dissociated GC, 
Compound A (CpdA), does not lead to GR dimerisation, but still allows nuclear translocation and 











recent data therefore suggest that GR dimerisation is ligand-specific, that it occurs in the 
cytoplasm and does not require nuclear translocation.  However, dimerisation appears to be 
required for transactivation on some GREs (but not all), but not for transrepression via tethering.  
 
The major GR NLs is located in the hinge region, with two additional NLs within the DBD (Wan 
et al., 2001;Picard and Yamamoto, 1987).  Interestingly, when the LBD of the GR is removed, 
the remainder of the GR is constitutively nuclear in the absence of hormone (Picard et al., 1988).  
Additionally, an antibody that reacts with the major NLs can only react with the liganded, but not 
with the unliganded GR (Urda et al., 1989).  These two observations have lead to the hypothesis 
that the GR LBD itself, or the HSP90 bound to the LBD, masks the NLs and that the 
conformational change upon ligand binding and/or dissociation from the HSP90 complex 
exposes the NLs (Wan et al., 2001).  However, in the literature, there is increasing evidence 
indicating that HSP90 plays an important role in GR mobility within the nucleus (Elbi et al., 
2004).  Additionally, a recent paper demonstrated that two specific tetratricopeptide repeat (TPR) 
proteins, namely FK506-binding protein 52 (FKBP52) and FK506-binding protein 51 (FKBP51) 
play a crucial role in GR nuclear translocation and that these two TPR proteins bind directly to 
HSP90 (Banerjee et al., 2008).  Banerjee et al. demonstrated that when the unliganded GR is 
bound to FKBP51 (indirectly through HSP90) it is mostly cytoplasmic, however when the 
unliganded GR is bound to FKBP52, it is mostly nuclear.  Additionally, these authors have 
previously shown that ligand binding to the GR induces a switch from FKBP51 to FKBP52, 
which is accompanied by nuclear translocation (Davies et al., 2002).  Furthermore, FKBP52 has 
also been shown to bind the motor protein dynein, which moves along the microtubules 
(Silverstein et al., 1999;Czar et al., 1994).  Additionally, GR movement to the nucleus in 3T3 
mouse fibroblasts, has been shown to depend on FKBP52, dynein and microtubules (Harrell et 











The active GR interacts with the importin system and translocates via the nuclear pore into the 
nucleus (Elbi et al., 2004), where the receptor can then interact with critical regulatory sites of 
GC-responsive genes (Okamoto et al., 1993;Pratt, 1993).  The above mentioned nuclear import 




1.4.3 GR transcriptional regulation  
 
Once in the nucleus, the active GR can either bind directly to the DNA through binding to GREs 
or bind to other transcription factors (called tethering).  Thereafter the GR recruits the basal 
transcription machinery, co-factors (co-activators or co-repressors), as well as a variety of other 
transcription factors, including chromatin remodelling complexes, which facilitate GR mediated 
transactivation or transrepression (McKenna et al., 1999b;McKenna et al., 1999a).               
 
 
1.4.3.1 Different modes of DNA binding 
 
1.4.3.1.1 Direct DNA binding  
 
The DBD of the active GR binds to specific GRE sequences.  Classically these GREs are defined 
as imperfect palindromes of hexameric half sites, separated by a three base pair spacer, 5’-
GGTACAnnnTGTTCT-3’ (Nordeen et al., 1990;So et al., 2007;Schoneveld et al., 2004).  This 
15 bp core GR binding sequence varies slightly between GREs on different genes (mostly at the 











2008;Schoneveld et al., 2004).  Activated GR binds to these 15 bp core sequences and activates 
the respective genes (Fig. 1.7 A).  GC-responsive genes containing such simple-acting GREs 
include the serine/threonine protein kinase, tyrosine hydroxylase and tyrosine aminotransferase 
(TAT) genes (Schoneveld et al., 2004;Schmid et al., 1987).  On the mouse mammary tumor virus 
(MMTV) promoter, the GR binding to four GREs, mediates transactivation, even though the 
promoter contains binding sites for octamer transcription factors and TBP (Hebbar and Archer, 
2003).   
 
In contrast to the above mentioned simple-acting GREs, many genes contain glucocorticoid 
response units (GRUs), in which transcription not only depends on GR binding to the GRE, but 
also requires the binding of other transcription factors, including activator protein 1 (AP-1) 
proteins and TBP, to adjacent binding sites (Fig. 1.7 B).  On the proliferin gene, for example, GR 
binding to its GRE can either result in transactivation or transrepression, depending on the 
composition of the AP-1 proteins, c-jun and c-fos, on an adjacent AP-1 site (Miner and 
Yamamoto, 1992;Pearce et al., 1998).  Interestingly, many of the additional transcription factors 
required for transcription on composite GREs, are tissue specific, such as in the case of the 
hepatic genes involved in gluconeogenesis.  For example, on the rodent phenylalanine 
hydroxylase (PAH) gene, GR mediated transactivation requires the presence of cAMP-activated 
CREB protein, as well as binding of hepatocyte nuclear factor-1 (HNF1) to the enhancer, in 
addition to GR binding to GREs (Bristeau et al., 2001;Faust et al., 1996).  Additionally, these 
GRUs typically result in a higher level of induction than genes containing a simple GRE (Kassell 
and Herrlich, 2007;Schoneveld et al., 2004).  
 
The GR can also bind as a monomer to GRE half sites (GRE1/2) (Fig. 1.7 C).  To date, no GC 











composite GRE half sites, including the phenylalanine-hydroxylase (PAH) gene, as mentioned 
above, have been investigated and shown to bind GR monomers. Furthermore, genes lacking 
composite GRE half sites, but containing multiple GRE half sites, such as the 
phenylethanolamine N-methyltransferase (PNMT) gene, which encodes for an enzyme that 
converts noradrenaline to adrenaline, can induce transactivation via binding of GR monomers 
(Schoneveld et al., 2004;Adams et al., 2003;Aumais et al., 1996;Sabban et al., 1995).      
 
GR binding to negative glucocorticoid response elements (nGREs), such as occur in the pro-
opiomelanocortin (POMC), osteocalcin and prolactin promoters, results in transrepression of the 
respective genes (Drouin et al., 1993;Meyer et al., 1997a;Sakai et al., 1988) (Fig. 1.7 E). A good 
example of a nGRE is in GR negative feedback on the HPA axis through the corticotrophin-
releasing hormone (CRH) gene.  The promoter of this gene contains 3 nGRE half-sites, as well as 
an adjacent AP-1 binding site and mutation of either site results in a loss of GR-mediated 
transrepression (Malkoski and Dorin, 1999).  The nGRE has a similar recognition sequence to the 
well defined GRE, but contains more sequence variation (ATYACnnTnTGATCn).  Simple 
nGREs, as well as nGRE half sites, such as occur in the serotonin receptor gene promoter, have 
been found in GC-responsive genes.  Additionally, the GR can also repress transcription by 
competing with other transcription factors for DNA binding (Fig. 1.7 F).  In this case, the nGRE 
overlaps with the binding site of other transcription factors and GR binding to the nGRE 
interferes with the binding of other transcription factors to their binding sites (Kassell and 
Herrlich, 2007;Schoneveld et al., 2004;Meyer et al., 1997b).   












Figure 1.7  Mechanisms of GR transcriptional regulation.  Taken and modified from (Schoneveld et 
al., 2004). 
 
1.4.3.1.2 Tethering  
 
In certain genes, transcriptional regulation by the GR does not involve direct binding of the GR 
to DNA, but rather GR binding to other transcription factors on the DNA (Figs. 1.7 D and G).  
Examples of both GR-mediated transactivation (e.g. binding to Stat5 on the -casein gene), as 
well as transrepression (e.g. binding to AP-1 or NFB on the collagenase, IL6 and IL8 genes), 
have been reported (Kassell and Herrlich, 2007).  Interestingly, the DBD of the GR is required 
for this interaction (Heck et al., 1994;Liden et al., 1997;De Bosscher et al., 1997).  Furthermore, 
few examples of transactivation via tethering have been shown and the most well studied GR 
tethering examples are for repression of genes involved in inflammation via AP-1- and NFB-














After DNA binding, the GR recruits ATP-dependent chromatin remodelling complexes, as well 
as histone acetyltransferases (HATs), resulting in disruption of the higher order chromatin 
organisation and less condensed chromatin (Deroo and Archer T.K., 2001;Muchardt and Yaniv, 
1999;Lorch et al., 1999).  This process enables additional transcription factors to bind to their 
respective DNA binding sites.  An example is the MMTV gene wherein binding of active GR to 
multiple GRE half sites, results in the recruitment of an ATP-dependent chromatin remodelling 
complex and subsequent binding of NF-1, Oct and TBP to their respective sites (Hebbar and 
Archer, 2003;Schoneveld et al., 2004).   
 
Genes that are transcribed by RNA polymerase II are recognised by the basal transcription 
machinery.  Furthermore the NTD of the GR has been shown to interact with the general 
transcription factor TFIID (Ford et al., 1997) and binding of the GR to its GRE thus facilitates 
the recruitment of the basal transcription machinery.  Additionally, the GR can recruit several co-
factors, including CBP or the adenovirus E1A binding protein 300 (p300) and members of the 
SRC family, through its LBD (Frego and Davidson, 2006).  These co-factors can interact with the 
basal transcription machinery and act as transcriptional bridges between the GR and the basal 
transcription machinery, thereby regulating transcription (Reviewed in (Glass and Rosenfeld, 
2000)).  Some of these co-factors can acetylate and deacetylate the histones, thereby altering the 
higher order chromatin organisation and allowing additional transcription factors to bind the 
DNA and alter transcription (Vo and Goodman, 2001).   
 
Genetic profiling indicates that 12% of genes in immune cells are up-regulated upon dex 











transactivation is usually associated with the undesirable side-effects of pharmacological GC 
treatment, although there are some exceptions, including some anti-inflammatory genes, such as 
IL-10 and annexin (Newton, 2000). The positive anti-inflammatory effects of GCs are generally 
thought to be mediated via transrepression of inflammatory genes (e.g. through tethering with 
AP-1 and NFB).  
 
     
1.4.3.3 Transrepression 
 
GR binding to a nGRE results in transrepression of the respective gene, as found in the human 
immunodeficiency virus type 1 and the neuronal serotonin receptor genes (Soudeyns et al., 
1993;Ou et al., 2001).  The ability of the GR to transrepress AP-1- and NFB-mediated 
transcription of pro-inflammatory genes requires specific residues in the DBD of the GR.  
However, these pro-inflammatory genes do not contain nGREs and it has been shown that GR 
dimerisation is not needed for repression (Heck et al., 1994). Instead, it is believed that specific 
residues in the DBD of the GR may be important for protein-protein interactions between the GR 
and the AP-1 and NFB proteins.  Furthermore, protein-protein interactions between the GR and 
members of the AP-1 protein family, as well as with NFB proteins, have been shown on 
different GC-regulated genes (Reviewed in (Kassell and Herrlich, 2007)).  For instance, GR 
interferes with AP-1 protein function by preventing the binding of AP-1 proteins to the human 
IL-2 gene promoter, resulting in repression thereof (Paliogianni et al., 1993). However the 
precise mechanism by which the GR represses AP-1- and NFB- regulated genes is still unclear 
and has been extensively studied in recent years (Adcock et al., 2006;De Bosscher et al., 











1.5 Co-factor recruitment  
 
Traditionally primary co-factors have been categorised as being either co-activators or co-
repressors, depending on their effects on nuclear receptor driven transcription (Review by (van 
der Laan and Meijer, 2008)). Nuclear receptors interact directly with primary co-factors mostly 
through the AF2 region in the LBD of the receptor, but recruitment of co-factors through the AF1 
in the NTD of the GR has also been reported (Bledsoe et al., 2002;Warnmark et al., 2000;Kumar 
et al., 2001).  Many nuclear receptor co-factors have been identified, including the vitamin D 
interacting proteins (DRIPs), that form part of a larger mediator complex, and the thyroid 
receptor associated proteins (TRAPs) (Reviewed in (McKenna et al., 1999b)).     
 
The most well known and most extensively studied co-activators are the SRC or p160 family.  
These co-activators contain three LXXLL (L=leucine and X=any aa) motifs in their receptor-
interacting domains (RIDs), which are found in amphipathic helices on their surface via which 
they form direct ligand-dependent interactions with SRs (Heery et al., 1997;Li and Chen, 
1998;Voegel et al., 1998;Onate et al., 1998). The SRC family consists of SRC-1 (or NcoA1), 
SRC-2 (or TIF2 or GR interacting protein-1(GRIP-1)) and SRC-3 (or p/CIP, RAC3, ACTR or 
AIB1) (Carapeti et al., 1998;Ning et al., 1999;Anzick et al., 1997). The importance of the p160 
family of co-factors has been demonstrated in knockdown mice. SRC-1 -/- mice show partial 
resistance to hormone (estrogen, progesterone (prog), testosterone and thyroid hormones) and 
studies on these mice indicate that SRC-1 plays an important role in brain function and 
development (Weiss et al., 1999;Xu et al., 1998;Auger et al., 2000).  SRC-2 -/- mice showed 
significantly reduced male and female fertility, and results from these mice suggest that SRC-2 











2002).  Additionally, overexpression of SRC-2 in frogs caused severe developmental defects such 
as a loss of head structures, suggesting that SRC-2 also plays an important role in development 
(De la Calle-Mustienes and Gomez-Skarmeta, 2000).  SRC-3 -/- mice showed growth retardation 
and reduced adult body size, suggesting that SRC-3 is important for growth and development in 
mice.  Furthermore, results from these mice suggest that SRC-3 plays an important role in the 
development and function of the female reproductive system (Xu et al., 2000;Wang et al., 2000).    
 
SRC-1 is highly expressed in most tissues, including the brain, kidney and heart and has been 
shown to enhance transcriptional regulation of a broad range of nuclear receptors, including the 
PR, ER and GR (Torchia et al., 1997;Xu et al., 1998;Onate et al., 1995;Sheppard et al., 1998;Leo 
and Chen, 2000;Xu and Li, 2003).  For instance, overexpression of SRC-1 in HeLa cells 
increased ligand-mediated GR transactivation on a MMTV promoter by 3 fold (Li et al., 2002).  
TIF2 (found by Voegel et al.) and GRIP-1 (found by Hong et al.) are the human and murine 
equivalents, respectively, of SRC-2 (Voegel et al., 1996;Hong et al., 1996). Like SRC-1, SRC-2 
is expressed in multiple tissues, including the brain, heart and kidney and has been shown to 
enhance AF-1 and AF-2 dependent AR transactivation in CV1 cells on the MMTV promoter 
(Torchia et al., 1997;Ma et al., 1999).  Recruitment of secondary co-factors such as CBP/p300 
via SRC-2 to the ER in vitro has been shown to be necessary for the formation of the pre-
initiation complex, as well as the subsequent initiation of transcription (Kim et al., 2001). SRC-2 
has also been shown to enhance GR-mediated transactivation on a variety of different GC-
regulated promoters, in different cells (Rogatsky I, 2001;Ding et al., 1998;Grenier et al., 
2004;Szapary et al., 1999). Furthermore, photobleaching experiments have shown dex-mediated 
recruitment of the GR and SRC-2 to the MMTV promoter in the 3134 cell line (Becker et al., 
2002). SRC-2 recruitment to the GR, in response to dex stimulation on the endogenous 











collagenase 3 promoter, SRC-2 was shown to enhance dex-mediated transrepression (Rogatsky I, 
2001). In addition, in vitro recruitment of SRC-2 by the GR to a GRE, has been shown to be 
ligand-dependent and to be a major determinant of ligand-selective GR transactivation and 
transrepression (Ronacher et al., 2009). SRC-3 has been shown to interact with various different 
transcription factors, including CBP and RAR (Reviewed in (Leo and Chen, 2000;Xu and Li, 
2003)).  Interestingly, the intracellular localisation and the recruitment of the SRC family 
members to the GR is cell specific.  By comparing primary astrocytes and immortalized Schwann 
cells, Grenier et al. demonstrated that SRC-1 is predominantly found in the nucleus of astrocytes 
in the presence and absence of dex, whereas in Schwann cells, SRC-1 translocates to the nucleus 
only upon dex stimulation (Grenier et al., 2006).  In both cells, SRC-2 was found predominantly 
in the nucleus in the absence or presence of dex, whereas SRC-3 was found predominantly in the 
cytoplasm, with a small increase in nuclear SRC-3 upon dex stimulation.  Additionally, by 
overexpression or RNA interference of the individual SRCs, Grenier et al. showed that in 
Schwann cells, the GR preferably recruited SRC-1 or SRC-3 to a (GRE)2-TATA promoter-
reporter and knockdown of SRC-1 or SRC-3 reduced GR-mediated transactivation on the 
promoter by ~60%.  However, in astrocytes, the GR preferentially recruits SRC-2 or SRC-1 to 
the (GRE)2-TATA promoter and knockdown of SRC-2 or SRC-1 reduced GR-mediated 
transactivation on the promoter by 40-60%.  Additionally, stimulation with dex results in 
preferential GRIP-1 (SRC-2) versus SRC-1 recruitment to the GR, whereas prog-stimulated PR 
preferentially recruits SRC-1 over GRIP-1 (Li et al., 2003). More recent data suggest that 
recruitment of GRIP-1 versus SRC-1 to the GR may also be ligand-selective, where the more 
potent agonists dex and prednisolone (predn) appear to preferentially recruit GRIP-1 while the 
partial agonists MPA and aldosterone (ald) appear to preferentially recruit SRC-1 (Ronacher et 
al., 2009). Taken together, these results suggest that recruitment of the different members of the 











The most well known and studied co-repressors are NCoR and silencing mediator for retinoic 
acid and thyroid hormone receptors (SMRT) (Horlein et al., 1995;Chen and Evans, 1995;Sande 
and Privalsky, 1996).  Both NCoR and SMRT contain three highly related nuclear-receptor-
interaction domains (NRIDs) that can transfer active repression to the DBD of nuclear receptors, 
including the GR (Seol et al., 1996;Zamir et al., 1996;Ordentlich et al., 1999;Park et al., 
1999;Chen and Evans, 1995;Horlein et al., 1995).  Each of these NRIDs have a L-XXX/XXX1/L 
motif, which is similar to the LXXLL motif found in co-activators (Nagy et al., 1999;Perissi et 
al., 1999;McInerney et al., 1998).  The importance of NCoR was shown with knockdown mice, 
wherein NCoR -/- mice died in midgestation (Jepson et al., 2000).  NCoR has also been 
implicated as a major contributor to Huntington’s disease, by interacting with the gene product of 
the disease (Boutell et al., 1999).  Furthermore, mutations in the LBD of the thyroid hormone 
receptor, which results in enhanced ligand-independent recruitment of NCoR and/or SMRT, have 
been correlated with thyroid hormone resistance (Yoh et al., 1997). These co-repressors are 
believed to associate with steroid receptors and DNA-bound complexes in the absence of 
hormone and to repress transcription (Chen and Evans, 1995;Horlein et al., 1995). Indeed direct 
interactions between NCoR and SMRT with different HDACs, including HDAC 1 and HDAC 2, 
which deacetylate histones and result in more condense “inaccessible” chromatin, have been 
shown (Li et al., 2000;Wen et al., 2000;Jones et al., 2001).  Additionally specific domains of 
NCoR and SMRT, which have no intrinsic HDAC activity, have also been shown to interact 
directly with HDAC 4 and HDAC 5 (Huang et al., 2000;Hu and Lazar, 1999).  Recruitment of 
ligand-activated steroid receptors and associated co-activators, is believed to remove co-
repressors from the DNA-complex (Leo and Chen, 2000).  Additionally, both NCoR and SMRT 
have been shown to be recruited to a variety of ER- and PR- responsive genes in the presence of 
receptor antagonists, but not receptor agonists, and to induce repression of the specific genes 











Recently, the recruitment of NCoR and SMRT by agonist stimulated GR, was shown to repress 
GR-mediated transactivation on the human MTIIa promoter, in COS-7 and HeLa cells (Hong et 
al., 2009). There are increasing amounts of data showing that agonist-bound GR, PR and AR can 
recruit NCoR and SMRT (Ronacher et al., 2009;Wang and Simons, Jr., 2005;Wang et al., 
2007a;Wang et al., 2004;Yoon and Wong, 2006;Cheng et al., 2002). It therefore seems that 
agonists do not recruit co-activators exclusively, while antagonists recruit only co-repressors. 
Furthermore, in both transactivation and transrepression models, recruitment of co-activators and 
co-repressors is possible. Taken together, it seems that co-factor recruitment is a complex 
process.  To this extent, Lefstin and Yamamoto proposed that the specific GRE on a target gene 
functions as an allosteric “ligand”, which triggers a structural change in the steroid receptor 
protein after DNA binding and that this change signals the recruitment of co-factors  (Lefstin et 
al., 1994;Lefstin and Yamamoto, 1998).  In agreement with this hypothesis, Heneghan et al. 
recently showed, by statistical thermodynamic analysis of in vitro proteins that SRC-2 interacts 
only weakly with the PR in the absence of DNA, but strongly in the presence of DNA (Heneghan 
et al., 2007).  Furthermore, Rogatsky et al. showed that changes in the composition of the 
regulatory elements on the DNA can result in GRIP-1 acting as a co-activator or co-repressor in 
U2OS cells via an AP-1 promoter (Rogatsky I, 2001). Similarly, some reports in the literature 
suggest that SMRT can act as a co-activator and not as a co-repressor for the GR (Ronacher et 
al., 2009;Song et al., 2001).  Taken together, these results indicate that the “classical” definition 
of co-activator vs. co-repressor needs to be revised and further studies are needed to better 
understand the precise role of the co-factors in transcriptional regulation of the GR.      
 
Most of the co-factors described above, can recruit secondary co-factors to the DNA, including 
CBP, p300 and the mammalian homologs of yeast Sin3 (HDAC1/HDAC2) (Reviewed in (Glass 











histones, resulting in a less condensed chromatin structure, thereby enhancing transcription.  
Recruitment of p300, by SRCs, to a MMTV promoter in Xenopus oocytes has been shown to be 
required for ligand-selective activation of the AR and thyroid hormone receptor (Huang et al., 
2003).  Overexpression of p300 in HeLa cells increased GR ligand-induced transactivation on a 
MMTV promoter by three fold (Li et al., 2002).  Furthermore the HAT activity of p300 was 
shown to be required for this increase and more strikingly, when endogenous p300 was inhibited, 
an almost complete loss of ligand-mediated GR transactivation was found (Li et al., 2002).  In 
contrast, HDAC1 and HDAC2 have histone deacetyltransferase (HDAC) activity that 
deacetylates histones and results in a more condense chromatin structure and inhibition of 
transcription (Heinzel et al., 1997;Nagy et al., 1997).  Taken together, the recruitment of primary 
co-factors, as well as secondary co-factors by specific steroid receptors appears to modulate 
transcription in a ligand-, cell- and gene-specific manner.    
  
       
1.6 GR degradation/turnover 
 
Both GR mRNA and GR protein levels are down-regulated in response to agonist (Dong et al., 
1988;Hoeck et al., 1989;Webster et al., 1997). It has been proposed that agonist-mediated GR 
degradation occurs after transcription and is due to ligand-dissociation from the GR which 
initiates GR dissociation from the DNA and subsequent GR degradation.  Using live cell imaging 
and fluorescent in situ hybridisation (FISH) to directly visualise green fluorescent protein (GFP)- 
labelled GR binding to multiple MMTV promoters, Stavreva et al. demonstrated that stimulation 
with dex or cort results in GR recruitment to the MMTV promoters within 5 minutes (Stavreva et 











is recruited to the MMTV promoter in response to agonist.  These authors proposed that after 
transcription, the ligand dissociates from GR:DNA complex, which signals the recruitment of the 
proteasome to the DNA and degradation of the GR (Stavreva et al., 2004).  Additionally, when 
GR degradation is inhibited, by means of a proteasome inhibitor, GR-mediated transactivation is 
increased (Deroo et al., 2002;Wallace and Cidlowski, 2001;Garside et al., 2006). One 
interpretation of this data is that GR degradation occurs after GR-mediated transcription and 
ligand dissociation.  However, in the literature there is a substantial amount of evidence showing 
that the unliganded GR is also degraded (Wallace and Cidlowski, 2001;Dong et al., 
1988;Webster et al., 1997). If GR-mediated transcription was required for GR degradation, the 
unliganded GR, which is not transcriptionally active, should not be degraded. This implies that 
GR-mediated transcription is not required for GR degradation. However, whether GR-mediated 
transcription is required for agonist-induced GR degradation has not directly been shown.   
Furthermore, when FRAP was used to determine the nuclear mobility of ligands that covalently 
bind to the GR (Dex-Mes and Dex-Cl), it was found that both ligands showed nuclear mobilities 
similar to that of dex (Meijsing et al., 2007).  If ligand-dissociation was a prerequisite for GR 
dissociation from the DNA, and subsequent degradation of the GR, then these covalently bound 
GR ligands should restrict GR nuclear mobility, suggesting that ligand dissociation is not a 
prerequisite for GR dissociation from the DNA. Additionally, Meising et al. compared the rate of 
dex dissociation from the GR (t1/2 ~ 20 minutes) to the rate of dex-GR dissociation from the DNA 
( < 2 seconds) and further concluded that ligand-dissociation is not required for GR:DNA 
dissociation (Meijsing et al., 2007). Taken together, these results suggest that ligand dissociation 
is not needed for GR dissociation from the DNA.  
 
The liganded- and unliganded-GR has been shown to be degraded through the 











2001).  Proteasomal degradation can occur either in the nucleus, or the GR can first be exported 
to the cytoplasm and then be degraded (Liu and DeFranco, 2000).  Results with the rat GR have 
identified the calreticulin-mediated nuclear export (NES-CRM-1) pathway in playing a role in 
GR nuclear export, since when a classical nuclear export signal (NES) is cloned into the GR, 
nuclear export is greatly enhanced.  However more recent work does not support the involvement 
of the NES-CRM-1 pathway in rat or human GR nuclear export (Holaska et al., 2001;Holaska et 
al., 2002;Walther et al., 2003;Savory et al., 1999;Liu and DeFranco, 2000).  
 
By comparing saturation binding curves in HeLa cells, over different time points, Cidlowksi and 
Cidlowski observed that the GR protein levels decreased over time (Cidlowski and Cidlowski, 
1981).  This decrease was only observed with the GR agonists dex and cort, while prog only 
slightly decreased GR protein levels and the ER agonist estradiol and AR agonist 
dihydrotestosterone (DHT) did not reduce the GR levels at all. This result suggests that GR 
degradation occurs in a ligand-selective manner. Later Dong et al. used rat hepatoma cells to 
show that the unliganded GR protein is degraded slowly over time with a half-life of about 25 
hours, while stimulation with dex dramatically decreased the half-life to 11 hours (Dong et al., 
1988).  This result shows that the unliganded GR is degraded slowly over time and that 
stimulation with an agonist, results in a quicker rate of GR degradation.  The half-life, or time it 
takes to degrade 50% of the GR protein, varies considerably in the literature, indicating potential 
cell- or species-specific differences in GR degradation.  By using cycloheximide to stop de novo 
protein synthesis, Webster et al. was able to demonstrate that the half-life of the unliganded GR 
in COS-1 cells is roughly 20 hours, while stimulation with the GR agonist dex resulted in a 
dramatic increase in GR degradation with a half-life of only 9 hours (Webster et al., 1997).  
Hoeck et al. used [35S] methionine pulse chase experiments to show that the half-life of the 











life to 3 hours (Hoeck et al., 1989).  Interestingly, in the same study, Hoeck et al. showed that the 
dex induced degradation of the GR is dose-dependent and that the GR ligand RU486 was also 
capable of increasing the degradation of the GR, albeit to a lesser extent than dex.  Taken 
together, it seems that GR degradation is ligand-dependent, wherein agonists results in the fastest 
and antagonists result in the slowest rate of GR degradation. However, the rate of GR degradation 
in response to other ligands, i.e. other than dex, cort, prog and RU486, has not been determined.  
 
Like the other members of the steroid receptor family, the GR is degraded by the UPP, as 
mentioned above (Wallace and Cidlowski, 2001).  In this pathway, proteins are covalently linked 
to a chain of ubiquitin moieties at specific lysine residues found in so-called PEST (amino acid 
sequence of Pro (P), Glu (E), Ser (S), and Thr (T)) degradation motifs by proteins with ligase 
activity (Hershko and Ciechanover, 1998;Dvorak et al., 2005).  The importance of the E3 ligase 
CHIP (carboxy terminus of heat shock 70-interacting protein E3 ligase) in GR degradation was 
shown in HT22 hippocampal cells naturally deficient in CHIP.  These cells did not demonstrate 
dex-mediated GR degradation, but overexpression of CHIP restored dex-mediated GR 
degradation (Wang and DeFranco, 2005).  Specific ubiquitin-binding subunits of the proteasome 
recognise these ubiquitin moieties and bind to them, resulting in degradation by proteolysis 
(Hershko and Ciechanover, 1998;Dvorak et al., 2005).  A recent study showed that calpain, 
which is a calcium-activated cysteine protease, is the protease responsible for degradation of the 
ligand-activated GR in COS-7 cells (Kim et al., 2008).   
 
The discovery of proteasome inhibitors has significantly enhanced our understanding of receptor 
degradation (Lee and Goldberg, 1998).  Proteasomal inhibition results in a decrease in 
transcription of the PR, AR and ER (Lange et al., 2000;Sheflin et al., 2000) This suggests that 











However, whether proteasomal degradation of the GR is required for transcription appears 
controversial.  Proteasomal inhibition results in an increase in hGR- and mGR-mediated 
transcription on stable or transiently transfected MMTV and GRE-TATA-luc promoters in 
human breast cancer, COS-1 and HeLa cells (Deroo et al., 2002;Wallace and Cidlowski, 
2001;Garside et al., 2006). This suggests that proteasomal degradation of the GR is not required 
for GR-mediated transcription, but rather acts as a “shut-down” mechanism to stop transcription 
and prevent over-stimulation. However in mouse hippocampal cell lines and primary rat 
hippocampal neurons, the endogenous GR is not degraded in a dex-dependent manner. 
Interestingly, in these cells proteasomal inhibition results in an increase in GR-mediated 
transactivation on an MMTV promoter, in a manner similar to the above mentioned studies.  This 
increase in GR-mediated transcription is not due to inhibition of GR degradation, since the GR is 
not degraded in a dex-mediated manner in these cells (Wang et al., 2002a). Proteasome inhibitors 
have been shown to directly influence the basal transcription machinery and chromatin structure 
(Kinyamu and Archer, 2007;Dantuma et al., 2006), thereby increasing transcription. However 
whether the increase in GR-mediated transcription, in the mouse hippocampal cell lines and 
primary rat hippocampal neurons, is due to indirect effects of the proteasome inhibitor on the 
basal transcription machinery and chromatin structure, is not known. Proteasomal inhibition also 
reduces the mobility of the GR in the nucleus, the association of the GR with the nuclear matrix 
and reduces the clearance of the GR from the nucleus (Conway-Campbell et al., 2007).  This can 
also result in an increase in GR-mediated transcription, which can falsely be interpreted to imply 
that degradation “restricts” GR-mediated transcription. Nevertheless, an interesting study, on the 
MMTV promoter, in cell line 3617, showed that inhibition of the proteasome resulted in an 
increase in dex-mediated transactivation, with concomitant decrease in corticosterone-mediated 
transactivation (Stavreva et al., 2004).  This result implies that the relationship between 











degradation has been shown to correlate with the RBAs of the different ligands for the ER 
(Preisler-Mashek et al., 2002).  Additionally, a recent paper showed with microarrays that 
inhibiting the proteasome had similar effects on both the GR and the ER, in that several GR- and 
ER- responsive genes were upregulated and down-regulated, depending on the specific gene 
(Kinyamu et al., 2008).  The relationship between GR transcription and degradation is complex, 
possibly involving cell-, ligand- and gene-specific regulation, and warrants further investigation.   
 
 
1.7 Post-translational modifications  
 
The GR, as well as the other members of the SR family, undergoes several post-translational 
modifications, including ubiquitination, sumoylation, acetylation and phosphorylation (Fig. 1.8), 
which play an important role in modulating its biological actions (Reviewed in (Duma et al., 
2006;Faus and Haendler, 2006). 
 
 
1.7.1 Ubiquitination  
 
Ubiquitination is a post-translational covalent modification, which targets proteins for 
degradation by the UPP, as mentioned above (Wallace and Cidlowski, 2001).  Ubiquitin is a 76 
amino acid protein that is covalently linked to proteins, including all the steroid receptors, in a 
three step process.  First, ubiquitin is activated by an E1 enzyme, where after E2 conjugating 
enzymes transfers the activated ubiquitin to a specific E3 ubiquitin ligase, which in turn 











GR contains a PEST motif at lysine 419 (K419) (Fig. 1.8) and mutation of the mouse analogue 
(K426) to the human K419, results in stabilisation of the mGR protein and increased 
transactivation on a GRE-TAT promoter in HeLa and COS-1 cells (Wallace and Cidlowski, 
2001).  Furthermore, overexpression of the E3 ligase CHIP has been shown to restore GC-
mediated endogenous mGR degradation in HT22 cells, in which GC-induced GR degradation 
does not normally occur (Wang and DeFranco, 2005).  Interestingly, overexpression of CHIP 
also resulted in reduced mGR mediated-transactivation on an MMTV promoter in HT22 cells, 
which is consistent with the current thinking that increased GR degradation, by ubiquitination, 
decreases GR-mediated transcription.  
 
 
Figure 1.8  Post-translational modifications of the human GR.  Taken and modified from (Faus and 
Haendler, 2006;Ismaili and Garabedian, 2004;Galliher-Beckley et al., 2008). P: phosphorylation; A: 
acetylation; U: ubiquitination; S: sumoylation. 
  
 
1.7.2 Sumoylation  
 
Sumoylation is the covalent attachment of a small ubiquitin-related modifier-1 (SUMO-1) to 
proteins (Le Drean et al., 2002).  The process of sumoylation is similar to that of ubiquitination 
and involves substrate recognition and SUMO linkage to a lysine residue by a specific enzyme 
named Ubc9 (Duma et al., 2006).  Three sumoylation sites in the hGR have been identified, 











conserved in the rGR.  Overexpression of SUMO-1 results in enhanced degradation of 
overexpressed rGR in COS-7 cells, indicating a role for sumoylation in GR stability (Le Drean et 
al., 2002).  The effect of GR sumoylation is likely promoter specific, since the simultaneous 
mutation of all three rat equivalent GR sumoylation sites did not affect rGR dex-mediated 
transactivation on the MMTV promoter (containing 4x GREs), but enhanced dex-mediated 
transactivation on a GRE promoter (containing 2x GREs), as well as on a 4xGRE-tk-luc 
promoter in COS-7 cells with expressed rGR at saturating concentrations of dex (Tian et al., 
2002;Le Drean et al., 2002).   
 
 
1.7.3 Acetylation  
 
Acetylation is the addition of an acetyl group to a protein and is carried out by proteins that 
possess HAT activity.  The removal of the acetyl group is done by proteins that contain HDAC 
activity, such as HDAC1 to HDAC17. Ligand-selective acetylation of both the ER and the AR 
has been shown to be required for maximal transcription on multiple promoters and is directly 
mediated by the HAT activity of p300 (Wang et al., 2001;Kim et al., 2006;Fu et al., 2000;Fu et 
al., 2004). Additionally, AR acetylation and phosphorylation have been shown to be functionally 
linked (Fu et al., 2004).  Mutation of an AR acetylation site reduces ligand-dependent AR 
phosphorylation, whereas mutation of the AR phosphorylation site, reduces HDAC-mediated 
deacetylation of the AR.  Furthermore, AR acetylation has also been implicated in enhanced 
growth of human prostate cancer cells in vivo (Fu et al., 2002).  Results in the literature on GR 
acetylation and the effect thereof on GR-mediated transcription, has mainly been due to indirect 
effects such as HSP90 acetylation affecting GR-mediated transcription and not direct GR 











(KXKK/RXKK) in the GR that corresponds to amino acids 492-495 has been identified and 
recently dex-dependent acetylation of the endogenous hGR at K494 and K495 has been shown in 
A549 cells (Fig. 1.8) (Ito et al., 2006b).  Ito et al. also demonstrated that hGR binding to NFB 
and subsequent repression of transcription on a reporter-promoter construct requires 
deacetylation of the hGR by HDAC2.  Furthermore, overexpression of p300, which contains 
HAT activity and has been shown to interact with the GR, results in an increase in rGR mediated 
transactivation on the MMTV (4xGREs) promoter in HeLa cells (Li et al., 2002).  Additionally, 
by using p300 deletion mutants, Li et al. showed that the HAT activity of p300 was required for 
this increase in rGR mediated transactivation on the MMTV promoter in HeLa cells.  However, a 
more recent paper showed that GR acetylation by p300 decreased GR-mediated transactivation 
on a 2xGRE-TATA and SV40-luc promoter in astrocytes, as well as Schwann cells (Fonte et al., 
2007), indicating cell- or promoter-specific differences on the effect of GR acetylation on GR-
mediated transactivation.  Additionally, Faus and Haendler recently showed that the effect of AR 
acetylation on AR-mediated transcription is promoter-specific (Faus and Haendler, 2008), 
indicating that apart from cell-specific differences, the effect of acetylation on AR function can 
also be promoter-specific.  The effects of acetylation on steroid receptor transcription are 
complex and are further complicated by the difficulty in distinguishing between direct acetylation 





In the beginning of the 1980s, it was shown that the GR, PR and ER exist as phosphoproteins in 











1988), suggesting that phosphorylation may be a common feature of all steroid receptors and 
indicating a functional role for phosphorylation. 
 
 
1.8.1 Identification of phosphorylation sites 
 
Several groups showed that the mouse (mGR), rat (rGR) and human (hGR) GR become 
hyperphosphorylated at multiple residues upon hormone treatment and that phosphorylation 
occurs only in the presence of agonists, while the antagonist RU486 does not result in 
phosphorylation of the GR (Dalman et al., 1988;Housley and Pratt, 1983;Singh and Moudgil, 
1985;Hoeck et al., 1989;Orti et al., 1989).  Early speculations that the phosphorylation of the GR 
may play an important role in the transcriptional activation of GR-responsive genes (Hoeck et al., 
1989) encouraged many groups to find the specific sites where the GR is phosphorylated.  By 
using proteases and chemical cleavage reagents, along with an assortment of other techniques 
including immunoprecipitation, [32P] orthophosphate labeling and GR deletion mutants, it was 
demonstrated that dex-dependent phosphorylation of the GR occurs mainly in the amino-terminal 
(Dalman et al., 1988;Hoeck and Groner, 1990).  More specifically, phosphorylation occurs 
mainly on serine and threonine residues in the potent transactivation domain 1 or enh2, of the 
rGR (Hoeck and Groner, 1990).  Identification of the specific serine and threonine residues that 
are phosphorylated, was made possible with solid phase sequencing of the mouse GR (Bodwell et 
al., 1991).  Bodwell et al. were able to identify the location of seven in vivo phosphorylation sites 
on the mouse GR (S122, S150, S212, S220, S234, S315 and Thr159) and found that all seven 
phosphorylation sites were situated in the amino terminal of the mGR (Fig. 1.8).  These seven 
phosphorylation sites are all conserved in the rat GR, whereas 6 are conserved in the human GR 











and Garabedian, 2004).  More recently, another phosphorylation site at S404 on the hGR was 
identified (Galliher-Beckley et al., 2008). 
 
Table 1.  Residues phosphorylated on the GR.  The phosphorylation sites identified in the mouse GR 
(mGR) and their equivalent positions in the rat (rGR) and human (hGR) glucocorticoid receptor* (Bodwell 
et al., 1991;Ismaili and Garabedian, 2004;Webster et al., 1997;Galliher-Beckley et al., 2008).  
 
 
In addition to the phosphorylation sites being situated in the AF-1 transactivation domain, three 
of the serine residues (S212, S220 and S234, in mouse numbering) are situated in a highly acidic 
region on the mouse GR, which has been shown to be necessary for transactivation (Bodwell et 
al., 1991).  An more in-depth investigation of the seven phosphorylation sites in the mouse GR, 
revealed that hyperphosphorylation in response to dex treatment, occurred mostly at S212, S220 
and S234 (Bodwell et al., 1995).  The development of phospho-specific antibodies that are 
capable of recognizing individual phosphorylated serine residues (P-S203, P-S211 and P-S226), 
greatly enhanced the in vivo analysis of the individual phosphorylation sites (Wang et al., 
2002b;Chen et al., 2008).  Using a panel of ligands consisting of three agonists (dex, predn and 
fluocinolone) and two antagonists (RU486 and ZK299), Wang et al. were able to show that 
agonists phosphorylated the hGR at S211, while antagonists caused only minimal 
phosphorylation (Wang et al., 2002b). More recently it was shown that GR agonists (dex and 
cort), as well as prog and ald phosphorylate the hGR at S226 (Chen et al., 2008).  Furthermore, 
phosphorylation was found to be a dynamic process wherein the phosphorylation status on one 
serine residue influences the phosphorylation of another (Wang et al., 2007b).  Phosphorylation 
                                                  











at S211 is only slightly influenced by phosphorylation at S203 and/or S226, while the extent of 
phosphorylation at S226 depends on the phosphorylation status of S203 (Wang et al., 2007b). 
S226 has a greater tendency to become phosphorylated when S203 is not phosphorylated, and 
vice versa.  These authors concluded that phosphorylation on all three residues is a dynamic 
process in which the final steady-state phosphorylation status is determined by a combination of 
kinases and phosphatases (Wang et al., 2007b).  
 
 
1.8.2 Both kinases and phosphatases involved in GR phosphorylation  
 
Endogenous protein kinases were implicated in the phosphorylation of the GR (Kaul et al., 2002) 
and subsequent sequence analysis of the mouse, rat and human GR demonstrated that the 
phosphorylation sites are all followed by a proline residue (reviewed in (Ismaili and Garabedian, 
2004)), making it the favoured context for cyclin-dependent kinases (CDKs) and mitogen-
activated protein kinases (MAPKs), as shown in table 2.  A subsequent in vitro study with the rat 
GR, showed that these two kinase families were indeed able to phosphorylate the rat GR, with 
CDKs phosphorylating S224 and S232 (human S203 and S211), and MAPKs phosphorylating 
S246, human S226 (Krstic et al., 1997).                  
 
Table 2.  Kinases capable of phosphorylating the GR. The kinase families capable of phosphorylating 
the hGR, as well as their consensus binding sequence and the residues they phosphorylate (in human 













A more in-depth study, using in vitro kinase overexpression assays, showed that c-Jun N-terminal 
kinase (JNK), a member of the MAPK family, is responsible for the in vitro phosphorylation of 
the overexpressed rGR at the rat equivalent to S226 (Rogatsky et al., 1998b).  The study also 
demonstrated that activation of JNK via UV treatment led to the inhibition of transcriptional 
activation from a GTCO-CAT promoter (2x GREs) construct in HeLa cells.  A similar study on 
the hGR (Itoh et al., 2002) confirmed that JNK phosphorylates the GR at S226 in vitro and that 
transcriptional activation is inhibited in COS-7 cells on a TK-luc promoter when JNK is activated 
with UV treatment. They also demonstrated that S226 phosphorylation, by JNK, was 
accompanied by enhanced nuclear export of the GR after dex withdrawal and proposed that this 
most likely leads to the down-regulation of GR transcriptional activity.  Additionally, using in 
vitro kinase assays, it was shown that CDK and JNK phosphorylate the rGR in vitro at the rat 
equivalent of S211 and S226, respectively and that yeast strains devoid of CDK and JNK reduced 
and enhanced GR mediated transcription, respectively (Krstic et al., 1997).  However, in the 
above studies, whether the activation of JNK by UV treatment directly increased GR 
phosphorylation at S226 in mammalian cells was not investigated. Thereafter, Miller et al. 
showed in CV-1 cells, that mutation of the hGR S211 to alanine reduced transactivation on a 
pGRE-SEAP promoter and showed in vitro with purified kinases that p38 phosphorylates the 
hGR at S211 (Miller et al., 2005).  In the same study, inhibition of p38 by means of a specific 
p38 inhibitor, slightly decreased GR phosphorylation on S211.  However, the total amount of GR 
was also decreased with the p38 inhibitor, which could account for the slight decrease in S211 
phosphorylation (Miller et al., 2005). More recently, the phosphorylation status of overexpressed 
hGR at S211 and S203 was increased by overexpressing CDK5 in HCT116 cells (Kino et al., 
2007).  Furthermore, inhibition of CDK, by means of an inhibitor, resulted in increased or 
decreased transactivation, depending on the specific gene (Kino et al., 2007). Taken together, in 











phosphorylate the GR on S211.  However, there is no conclusive data directly linking an 
endogenous kinase, by means of kinase inhibition, with site specific phosphorylation of the GR 
on S211 and/or S226 in mammalian cells.   
 
Interestingly, very little is known about the phosphatases involved in GR de-phosphorylation.  
However, it has recently been shown that inhibition of general serine/threonine protein 
phosphatases, as well as a reduction in protein phosphatase 5 (PP5) protein levels (by siRNA 
knock-down of PP5), enhanced GR phosphorylation at S203 and S226, but not S211 (Wang et 
al., 2007b).  These results suggest that PP5 plays an important role in de-phosphorylating the GR 
at S203 and S226. More recently, PP5 has also been implicated in de-phosphorylating the GR at 
S211 (Zhang et al., 2009).  
 
 
1.8.3 Transcriptional regulation by phosphorylation  
 
In an attempt to clarify the role of these three serine residues in transcriptional transactivation, 
expression vectors for mutated mGR incapable of being phosphorylated on those specific 
residues, where the serine residues were replaced with an alanine (S212A, S220A and S234A in 
mouse numbering), were constructed (Mason and Housley, 1993).  These mutated proteins were 
compared to wild type (wt) mGR in their ability to activate transcription of the complex MMTV 
promoter upstream of the chloramphenicol acetyltransferase (CAT) gene (MMTV-CAT) in COS-
1 cells.  The mutated proteins showed similar transactivation efficiency as the wt GR, suggesting 
that phosphorylation at those three residues is not necessary to activate transcription on this 
complex promoter.  A similar study, where the hGR signaling system was reconstructed in yeast, 











efficiency as the wt hGR on a complex thymidine kinase promoter linked to two GREs (Almlof 
et al., 1995).  However, this study also indicated that the S226 mutant (S226A) had a 
transactivation efficiency higher than that of the wt, suggesting that S226 phosphorylation caused 
an inhibitory effect on transcriptional activation of this promoter.  Webster et al., looked at the 
ability of the three phosphorylation mutants to activate the complex MMTV-CAT promoter, as 
well as a simple tyrosine aminotransferase (TAT) promoter containing a minimal adenovirus E1b 
TATA sequence with two GREs (GRE2-TATA-CAT) in COS-1 cells (Webster et al., 1997).  
Consistent with the study of Mason and Housley, the phosphoryation mutants did not show a 
significant difference from the wt mGR in activating the complex MMTV-CAT promoter.  
However, two of the mutants (S212A and S220A in mouse numbering) demonstrated only 50-
75% transactivation efficiency, compared to wt mGR, on the simple GRE2-TATA-CAT promoter 
construct, suggesting that phosphorylation on those two sites are necessary for maximal 
transactivation on the simple promoter.  The S234 mutant (mGR) did however not show any 
difference as compared to the wt receptor, even on the simple promoter.  Additionally, the 
combined mutation of all three phosphorylation sites (S212A/S220A/S234A or 3A) of the mGR 
did not show any difference on the MMTV-CAT promoter, but led to an almost complete loss of 
dex-mediated transactivation on a simple GRE promoter in COS-1 cells (Webster et al., 1997).  
In contrast, Kino et al. recently demonstrated that mutation of S203 (S203A) resulted in a 3-fold 
increase in efficacy (above wt hGR), upon dex stimulation, whereas mutation of either S211 
(S211A) or S226 (S226A) resulted in a 2-fold increase and mutation of all three sites 
simultaneously (3A) led to a 4-fold increase in transactivation on the MMTV promoter in human 
colon carcinoma, HCT116 cells (Kino et al., 2007).  A possible explanation for some of the 
apparent inconsistencies in the above mentioned studies came when the effects of the two single 
mutants, S211A and S226A, were studied on endogenous genes in human bone cancer, U2OS 











dex, Chen et al. demonstrated that phosphorylation at S226 of the hGR inhibits transactivation in 
a dose-dependent manner on the GILZ, LAD1, IGFBP1 and IRF8 genes, whereas 
phosphorylation at S211 was required for maximal transactivation efficacy and potency on the 
GILZ and LAD1 genes at low concentrations of dex, and on the IGFBP1 and IRF8 genes at low 
and high concentrations of dex (Chen et al., 2008).  Interestingly, at high concentrations of dex, 
phosphorylation at S211 inhibited transactivation on the GILZ and LAD1 genes.  Furthermore, 
Chen et al. showed that phosphorylation at S211 or S226 is required for maximal GR-mediated 
repression on six different genes, including c-Jun and SMAD7. However on the PAC1 gene, both 
the S211A and S226A mutants increased transcription, whereas wt GR repressed the gene.  
Taken together, these results indicate that the effect of GR phosphorylation on transcription is 
cell-, gene-, as well as GC concentration-dependent (Chen et al., 2008).    Nevertheless, the 
underlying mechanisms whereby phosphorylation of the GR regulates GR-mediated transcription 
are still unclear.  
 
 
1.8.4 Role of GR phosphorylation 
 
In attempts to determine the mechanism whereby GR phosphorylation influences transcription, 
several steps in the GR signalling pathway have been implicated, including nuclear trafficking, 
protein stability and protein-protein interactions (recently reviewed in (Weigel and Moore, 2007).  
Wang et al. demonstrated that dex stimulation leads to the accumulation of GR phosphorylated at 
S211 in the nucleus, whereas GR phosphorylated at S203 remained cytoplasmic, suggesting a 
role for phosphorylation at S211 in nuclear import in U2OS cells (Wang et al., 2002b).  
However, mutation of the mGR residue equivalent to the hGR S211, as well as the simultaneous 











the GR in COS-1 cells (Webster et al., 1997). Furthermore, it has been shown that 
phosphorylation of the progesterone and estrogen receptors (PR and ER, respectively) influences 
receptor localisation in the absence of ligand and that phosphorylation of the liganded AR is 
required for nuclear export (Weigel and Moore, 2007;Pierson-Mullany and Lange, 2004).  
Similarly, phosphorylation of the hGR at S226 has been shown to play a role in nuclear export of 
the GR after dex withdrawal in COS-7 cells (Itoh et al., 2002). However, nuclear import does not 
appear to be affected by agonist-induced phosphorylation of either the PR, AR or ER.  Taken 
together these results suggest that the role of agonist-induced phosphorylation in steroid receptor 
subcellular trafficking may be receptor-, and cell-specific or depend on which particular serine 
residue(s) within a particular receptor is phosphorylated.  
 
Several lines of evidence implicate receptor phosphorylation as playing a role in receptor protein 
degradation both in the absence and presence of ligand.  Webster et al. showed that the combined 
mutation of the mGR residues equivalent to the hGR S203, S211 and S226 residues, resulted in a 
decrease in dex-mediated mGR degradation (Webster et al., 1997).  Furthermore, Webster et al. 
also showed that the simultaneous mutation of 7 or 8 phosphorylation sites completely abolished 
dex-mediated mGR degradation and slightly stabilized the unliganded GR protein, resulting in its 
slower degradation in COS-1 cells. More recently, Galliher-Beckley et al. showed that the 
mutation of a single phosphorylation site (S404) resulted in a complete loss of dex-mediated GR 
degradation (Galliher-Beckley et al., 2008).  Thus GR phosphorylation is strongly implicated in 
playing a role in stability of the unliganded and liganded receptor, where the effect on liganded 
receptor may be a mechanism to regulate transcription efficacy.  
 
The concept of modulation of steroid receptor degradation via phosphorylation is not limited to 











However, phosphorylation of the PR at S400 enhances degradation of the unliganded PR 
(Pierson-Mullany and Lange, 2004), whereas phosphorylation at S294 enhances degradation of 
the liganded PR (Lange et al., 2000), indicating a complex mechanism involving serine-specific 
phosphorylation on the stability of the unliganded or liganded PR. In contrast to the GR, agonist 
binding to the AR leads to increased stability of the receptor, which is believed to be mediated 
via agonist-induced AR phosphorylation (Chen et al., 2006). Thus steroid receptor 
phosphorylation is implicated in playing a role in stability of the unliganded and liganded 
receptor, where the effect on liganded receptor may be a mechanism to regulate transcriptional 
efficacy. However, as for the effect of receptor phosphorylation on subcellular trafficking, these 
effects may be receptor-and cell-specific or also depend on which particular serine residue(s) 
within a particular receptor is phosphorylated.  
 
Aside from the above mentioned nuclear translocation and degradation of the GR, recent studies 
demonstrate that differences in the phosphorylation status of the GR also influence the interaction 
of the GR with other proteins, including tumor suppressor gene protein (TSG101), components of 
the mediator complex and CBP/p300 (Ismaili et al., 2005;Chen et al., 2008;Kino et al., 
2007;Galliher-Beckley et al., 2008).  In U2OS cells, TSG101 binds preferentially to the 
unphosphorylated form of the unliganded GR and thereby stabilizes the unliganded GR against 
degradation (Ismaili et al., 2005).  Using a yeast two-hybrid screening, it was found that the 
vitamin D receptor-interacting protein 150 (DRIP150 or MED14), that forms part of the mediator 
complex, binds to the GR AF-1 domain and that this interaction enhances GR transactivation 
(Hittelman et al., 1999).  It was later shown that mutation of S211 resulted in a 50% decrease in 
MED14 binding to the GR (Chen et al., 2008), indicating a possible role for GR phosphorylation 
at S211 in the recruitment of the mediator complex in U2OS cells.  Chen et al. proposed a model 











interaction between the hGR and MED14, since mutation of S211 resulted in a 50% decrease in 
transcriptional activity on two MED14-dependent genes, IGFBP1 and IRF8, as well as inhibited 
the interaction between GR and MED14 to a similar degree (Chen et al., 2008). However, this 
model does not account for differences seen on MED14-independent genes and indeed when two 
such genes, GILZ and LAD1, were investigated, they found that mutation of S211 resulted in a 
reduced transcriptional activity at low GC concentration, but an increased transcriptional activity 
at high GC concentrations. Furthermore, mutation of S226 did not change the interaction between 
the GR and MED14, but still resulted in an increased transcriptional activity on MED14-
dependent and MED14-independent genes.  Taken together these results indicate that GR 
phosphorylation affects GR interaction with additional factors, other than MED14, to modulate 
GR transcriptional activity in U20S cells. Additionally, over-expression of CDK5, known to 
hyperphosphorylate the GR in vitro, resulted in a decrease in dex-induced recruitment of the 
histone acetyltransferase co-activator, p300 to the GR bound on a MMTV-luciferase promoter in 
COS-1 and HCT116 cells (Kino et al., 2007). In contrast, phosphorylation of the hGR at S404, 
by glycogen synthase kinase 3 (GSK3), was shown to be required for the recruitment of p300 
in U2OS cells (Galliher-Beckley et al., 2008). Studies on the ER demonstrated that 
phosphorylation of the receptor is important for the recruitment of co-factors, wherein the 
phosphorylation status of one specific serine residue determines the recruitment of co-activator, 
SRC3, versus co-repressor, stromelysin-1 platelet-derived growth factor-responsive element-
binding protein (Likhite et al., 2006;Endoh et al., 1999;Gburcik et al., 2005;Weigel and Moore, 
2007).  
 
Taken together, these studies suggest that the mechanisms by which dex-induced phosphorylation 
of the GR modulates GR-mediated transcription may occur at multiple levels and be promoter- 











results about whether phosphorylation plays a role in GR nuclear import, but some evidence that 
GR phosphorylation plays a role in stabilizing the unliganded and liganded GR protein.  
Additionally, phosphorylation of the GR has been linked to the binding of MED14, which forms 
part of the mediator complex, and hyperphosphorylation of the GR at S203, S211 and S226 has 
been shown to restrict the dex-dependent binding of p300, whereas dex-mediated 











Chapter 2 Thesis rationale, Aims and Hypotheses:  
 
 
2.1 Thesis Rationale  
 
The GR plays a role in most inflammatory processes and GCs are currently used 
pharmacologically to treat a variety of diseases, including autoimmune diseases and pulmonary 
diseases (Moutsatsou P, 2008).  However, long-term treatment with steroids results in a variety of 
side-effects including osteoporosis (Luengo et al., 2001;Reid and Ibbertson, 1987;Robson et al., 
2002).  A better understanding of how steroid receptors function, is therefore needed in order to 
design more effective drugs with fewer side-effects, for many different pharmacological 
applications.   
 
A wide range of GCs bind to the GR resulting in an array of different biological responses in a 
ligand-, promoter- and cell-specific manner (Ronacher et al., 2009). A central question in SR 
research is what determines the basis of ligand-selective biological responses. For example why 
do different ligands, all acting through the GR in the same cell, on the same promoter, display 
different potencies (the concentration of ligand needed for half the maximal response) and 
efficacies (maximal response)?  This is in addition to cell-specific differences, i.e. differences 
obtained with the same ligand, on the same promoter in different cells, as well as promoter-
specific differences, i.e. differences obtained with the same ligand, in the same cells, on different 
promoters (Ronacher et al., 2009). In the GR transcriptional pathway, there are 8 different steps 











important steps in determining ligand-selectivity, namely (1) ligand-binding to the receptor 
(affinity and kinetics) (Koubovec et al., 2005;Lind et al., 2000;Selman et al., 1996;Attardi et al., 
2004),  (2) conformational changes induced by ligand-binding (Bledsoe et al., 2002;Kauppi et al., 
2003), (3) phosphorylation of the liganded GR (Stubsrud, 2005;Wang et al., 2002b;Chen et al., 
2008),  (4) dimerisation (Savory et al., 2001;Dewint et al., 2008) and (5) nuclear translocation of 
the liganded GR (Schaaf and Cidlowski, 2003;Vicent et al., 2002), (6) binding of the liganded 
GR to DNA (Garside et al., 2004;Pandit et al., 2002), (7) interaction with other transcription 
factors (Coghlan et al., 2003;Garside et al., 2004;Wang et al., 2004;Cho et al., 2005;Wang and 
Simons, Jr., 2005;Kroe et al., 2007;Wang et al., 2007a;Miner et al., 2007;Tao et al., 2008) and 
(9) degradation of the liganded GR (Cidlowski and Cidlowski, 1981;Dong et al., 1988) (Fig. 2.1).  
However, most studies published to date that have attempted to investigate the basis of ligand-
selective responses were performed with too few ligands to accurately determine the role of a 












Figure 2.1 Steps in the GR transcriptional pathway potentially determining GR ligand-selectivity.  
Taken and modified from (Gross and Cidlowski 2008). 
 
Reports in the literature have shown different relative binding affinities (RBAs) and binding 
constants for different ligands for the GR (Koubovec et al., 2005;Lind et al., 2000;Selman et al., 
1996;Attardi et al., 2004). However, most of these studies were done in different cells and only 
focussed on a few GR ligands.  Ronacher et al. 2009 showed for the first time in a systematic 
approach with binding affinities and efficacy and potency for transactivation and transrepression, 











transactivation and transrepression, is not related to its relative affinity for the receptor 
((Ronacher et al., 2009;Koubovec et al., 2005).  In other words, ligand-selective efficacy is not 
determined by the different affinity of the ligands for the GR. In contrast, however, relative 
affinity for the receptor correlated to ligand-selective potency for transactivation, but not for 
transrepression. 
 
It is generally accepted that different ligands induce different conformational changes of the GR 
upon binding.  The crystal structure of the LBD of the GR in the presence of the agonist dex and 
antagonist RU486 revealed that the final position of helix 12 is very different in the presence of 
agonist vs. antagonist (Bledsoe et al., 2002;Kauppi et al., 2003).  More recently, 
hydrogen/deuterium exchange measured by mass spectrometry experiments with dex-bound GR 
in complex with the co-activator TIF-2 and RU486-bound GR in complex with the co-repressor 
NCoR, has confirmed the crystal structure results (Frego and Davidson, 2006). These ligand-
induced conformational changes are accompanied by GR phosphorylation and exposure of the 
nuclear localisation signals.  Furthermore, these ligand-induced conformational changes are 
though to form different interacting surfaces and form the basis of differential co-factor 
recruitment (Kroe et al., 2007).  However, a direct link between different conformations and 
ligand-selective GR transcription with a large panel of ligands has not been established.   
 
Ligand-selective GR phosphorylation at S211, with a panel of ligands consisting of three agonists 
(dex, predn and Fluocinolone) and two antagonists (RU486 and ZK299), showed that agonists, 
but not antagonists phosphorylated the hGR at S211 (Wang et al., 2002b).  Ligand-selective 
phosphorylation at S211 with a large panel of GR ligands was found to correlate with ligand-
selective GR transactivation potency and efficacy ((Stubsrud, 2005); Table E3 in addendum E). 











direct role for GR phosphorylation in transcription ((Stubsrud, 2005); Table E2 in addendum E).  
However, ligand-selective GR phosphorylation at S211 did not determine the rank order of 
ligand-selective GR transactivation, as a S211 phosphorylation deficient GR mutant still showed 
the same rank order of ligand-selective GR transactivation.  More recently it was shown that GR 
agonists (dex and cort), and to a lesser extent prog and ald result in phosphorylation the hGR at 
S226 (Chen et al., 2008).  However, whether ligand-selective GR phosphorylation at S226 is 
required for ligand-selective GR transcription is yet to be determined. 
 
The liganded, but not the unliganded GR, has been shown to form dimers in solution, in the 
absence of DNA (Savory et al., 2001).  Recently it was demonstrated that a dissociated GC, 
CpdA, does not lead to GR dimerisation, but still allows nuclear translocation and GR-mediated 
transrepression, but not transactivation (Dewint et al., 2008).  Taken together, these results 
indicate that GR dimerisation could be ligand-specific and possibly contribute to ligand-selective 
GR-mediated transcription.  However, a direct link between ligand-selective GR dimerisation and 
transcription with a large panel of ligands has not been established.  
 
The GR continuously shuttles between the cytoplasm and the nucleus and data in the literature 
suggest that the pathways of receptor trafficking and processing within the nucleus influence GR 
mediated transcription (DeFranco, 2002).  Additionally, it has been shown that nuclear import of 
the receptor is influenced by ligand affinity and that differences in nuclear retention 
characteristics of agonist-activated GR may determine ligand-specific responses (Schaaf and 
Cidlowski, 2003;Vicent et al., 2002).  Taken together, these results indicate that GR nuclear 
import could be ligand-specific and possibly contribute to ligand-selective GR mediated 
transcription. However, a direct connection between ligand-selective GR nuclear import and 











There is some evidence in the literature that the dissociation rate of liganded-GR from DNA is a 
measure of ligand potency (Pandit et al., 2002).   More recently, chromatin immunoprecipitation 
experiments in HeLa cells, showed ligand-selective recruitment of the GR to the IL-8 promoter, 
wherein more GR was recruited in the presence with dex, than in the presence of the antagonist 
RU486 (Garside et al., 2004).  Furthermore, these differences were not due to differential nuclear 
import (Garside et al., 2004). Taken together, these results indicate that GR binding to DNA 
could be ligand-selective and contribute to ligand-selective GR-mediated transcription.   
 
Different ligands have been shown to result in differential co-activator and co-repressor 
recruitment to the GR (Coghlan et al., 2003;Garside et al., 2004;Wang et al., 2004;Cho et al., 
2005;Wang and Simons, Jr., 2005;Kroe et al., 2007;Wang et al., 2007a;Miner et al., 2007;Tao et 
al., 2008).  Furthermore, there is evidence for a co-factor binding model, whereby the 
transcriptional response of the GR to agonists, partial agonists and antagonists are linked to the 
recruitment of co-activator, mixed co-activator/co-repressor and co-repressor complexes, 
respectively (Cho et al., 2005).  However, there is also substantial evidence refuting this model.  
For example, the GR agonist dex recruits the co-repressors NCoR and SMRT (Wang and Simons, 
Jr., 2005;Wang et al., 2007a;Wang et al., 2004).  A critical evaluation of the literature reveals 
that there is little quantitative evidence for the model with no studies showing a direct correlation 
between the extent of recruitment of co-regulators by the liganded GR and the potency or 
efficacy for transactivation.  In addition, most of the above mentioned studies used too few 
ligands to establish a general conclusion.  Since most researchers have investigated the model in 
the context of transactivation, very little is known about the effects of ligand on differential co-
factor recruitment in the context of transrepression.  Ronacher et al. 2009 for the first time 
provided strong quantitative biochemical support for a model in which GR-mediated ligand-











promoter-specific differences in potency and efficacy, for both transactivation and 
transrepression (Ronacher et al., 2009).  
 
Many researchers have shown that the unliganded GR is degraded slowly over time, and that 
stimulation with dex significant enhances the rate at which the GR is degraded (Cidlowski and 
Cidlowski, 1981;Dong et al., 1988).  However, most studies have been conducted with only one 
or two ligands, most commonly with dex and RU486.  Taken together, these results indicate that 
the rate of GR degradation is possibly ligand-specific and could determine the basis of ligand-
selective GR mediated transcription. However, a direct link between ligand-selective GR 
degradation and transcription with a large panel of ligands, has not been shown.   
 
This study forms part of a larger investigation which aims to investigate the role of each of the 
steps depicted in figure 2.1 in ligand-selective responses. The biological response of a large panel 
of ligands in transactivation and transrepression was previously determined by other researchers 
in the candidate’s laboratory (E. Stubsrud and K. Ronacher; Table E4 in addendum E). The 
biological responses were measured as potency and efficacy derived from the dose-response 
curves for transactivation and transrepression.  For the transactivation model, reporter assays 
were performed on a TAT-GRE promoter in COS-1 cells with the hGR ((Stubsrud, 2005); Table 
E5 Addendum E).  For the transrepression model, reporter assays on were performed with two 
different promoters, the AP-1- and NFB-luc promoters, in COS-1 cells with the hGR (K. 
Ronacher; Table E5 in addendum E).   
 
The biological response of a particular ligand can be correlated with the behaviour of the 
liganded GR at any particular step in the GR transcriptional pathway.  These correlations do not 











modulate ligand-selectivity.  These steps can then be investigated further to establish which step 
in the GR transcriptional pathway determines ligand-selectivity.   
  
A broad panel of GR ligands including the available endogenous and synthetic steroidal and non-
steroidal agonists, full/partial agonists, partial agonists, dissociative glucocorticoids and 
antagonists will be used. This should provide a good basis for correlating ligand-selective effects 
at a specific step with transcriptional response.  The panel of ligands used, as well as their relative 
efficacy for transcription on the three different promoters and their classification is shown in 
table 2.1.  More detailed discussion of each individual ligand is given in addendum A (“Panel of 
GR ligands”).  For the purposes of this study, for the particular gene and system being 
investigated, a ligand was classified as a full agonist if it induces the maximal possible response 
(efficacy ≥ 85% as compared to dex) and as partial agonist if it induces a response less than 
maximal (efficacy ≤ 85% as compared to dex). An antagonist was defined as a compound that 
binds to the receptor, induces no response of its own and has been shown to antagonize the 
transcriptional effects of dex. Furthermore, compounds that show full agonist activity on one 
promoter and partial activity on another promoter were classified as full/partial agonists, whereas 
ligands which show no activity on one promoter with partial of full activity on at least one other 



















Table 2.1 Relative efficacy for transactivation and transrepression via the GR and ligand 
classification. Relative efficacy for transactivation via the TAT-GRE ((Stubsrud, 2005); Addendum E) 
and for transrepression via the NFB-luc and AP-1-luc were determined in transiently transfected COS-1 




2.2 Aims and Hypotheses 
 
1. Does hGR phosphorylation at S226 and/or GR degradation occurs in a ligand-selective 
manner? 
 
The hypothesis is that different ligands result in different extents of hGR phosphorylation at 
S226, wherein the agonists result in the most and the antagonists result in the least amount of GR 
phosphorylation at S226. This hypothesis will be tested by comparing the ability of a chosen 
panel of ligands, to phosphorylate the expressed hGR at S226, using an antibody that specifically 
recognises GR phosphorylated at S226 (P-S226), in COS-1 cells. Furthermore, it is hypothesised 
that hGR phosphorylation at S226 occurs in a GC-dose-dependent manner.  Therefore, ligand-
selective GR phosphorylation at S226 in response to saturating ligand concentrations (10 M), as 
                                                  











well as sub-saturating ligand concentrations for some ligands (100 nM), will be determined. 
Additionally, since results in the literature suggest that there are cell-specific differences in GR 
phosphorylation, it was also hypothesised that ligand-selective hGR phosphorylation at S226 
occurs in a cell-specific manner.  This will be investigated by examining ligand-selective hGR 
phosphorylation in two different, COS-1 and U2OS, cell lines.    
 
Similarly, it is hypothesised that GR degradation occurs in a ligand-selective manner, wherein the 
rate of degradation is faster with agonists than with antagonists. In order to determine if GR 
degradation occurs in a ligand-selective manner, the ability of different ligands to induce hGR 
protein degradation will be tested by inhibiting de novo protein synthesis, stimulating with the 
different ligands and examining the GR protein levels over time.   
 
2. Does the extent of hGR phosphorylation at S226 and/or hGR degradation determine 
ligand-selective efficacy and/or potency for transactivation and/or transrepression? 
 
The hypothesis is that the relative amount of GR phosphorylation at S226, induced by the 
different ligands, will determine the ‘rank order’ of ligand-mediated transactivation and 
transrepression.  Firstly, correlation analyses between the potency and efficacy of the ligands in 
transactivation and transrepression, in the same cell system (E. Stubsrud and K. Ronacher; 
Addendum D), and the extent of ligand-selective phosphorylation at S226 will be performed to 
test the hypothesis that ligand-selective hGR phosphorylation at S226 could possibly determine 
the rank order of ligand-selective GR mediated transcription.  Thereafter, if a positive correlation 
is obtained, the ability of a S226 phosphorylation-deficient, transiently transfected hGR mutant 
(S226A), to cause ligand-selective GR transactivation and transrepression, will be tested in COS-











mediated transactivation or transrepression, the phosphorylation mutant should not show ligand-
selective transactivation or transrepression.   
 
Similarly, the alternative hypothesis that ligand-selective GR degradation determines the ‘rank 
order’ of ligand-induced transactivation and transrepression will be tested. In other words, the 
rate at which the GR is degraded in response to a particular ligand may determine the 
transcriptional response of the particular ligand. First correlation analyses between the potency 
and efficacy of the ligands in transactivation and transrepression, in the same cell system (E. 
Stubsrud and K. Ronacher; Addendum E), and the extent of ligand-selective GR degradation will 
be performed to test the hypothesis that ligand-selective GR degradation could possibly 
determine the rank order of ligand-selective GR mediated transcription. The hypothesis will be 
further investigated by inhibiting hGR degradation with a proteasome inhibitor and examining 
the effect thereof on ligand-selective hGR transactivation of a TAT-GRE-luc reporter using 
transiently expressed hGR in COS-1 cells.   If ligand-selective GR degradation determines 
ligand-selective transactivation, then when GR degradation is inhibited such that the GR levels 
are similar in the presence of all the ligands, they should all result in the same efficacy for 
transactivation.  Furthermore, the alternative hypothesis that ligand-selective GR transactivation 
determines ligand-selective GR degradation will also be investigated.  In other words, the 
transcriptional response with a particular ligand may determine the rate at which the GR is 
degraded with that particular ligand.  This will be investigated by inhibiting GR-mediated 
transcription with an RNA polymerase inhibitor, and examining the effect thereof on ligand-
selective GR degradation.  If ligand-selective GR transactivation is required for ligand-selective 
GR degradation, then inhibition of GR-mediated transcription should result in a similar 












3. Which kinases phosphorylate the hGR at S211 and S226 in intact cells? 
 
According to results in the literature with in vitro kinase assays, JNK and p38 are responsible for 
hGR phosphorylation at S226 and S211 in COS-1 cells, respectively.  Therefore, it is 
hypothesised that JNK and p38 are responsible for phosphorylation of the transiently expressed 
hGR at S226 and S211, respectively in COS-1 cells.  This will be tested by examining the effect 
of specific JNK and p38 inhibitors on hGR phosphorylation at S226 and S211.  If JNK and p38 
are responsible for phosphorylation of the GR at S226 and S211, respectively, then the relative 
amount of hGR phosphorylation should be inhibited or reduced in response to the specific 
inhibitors.  
 
4. What are the molecular mechanisms whereby agonist-induced hGR phosphorylation 
modulates transcription efficacy? 
   
In the literature there are conflicting results on the role of GR phosphorylation on GR 
degradation, and the effect thereof on GR-mediated transcription. The hypothesis that agonist-
induced hGR phosphorylation at S211 and S226 modulates transcription via modulation of hGR 
degradation rate will be investigated in more detail.  This will be done by directly comparing the 
degradation rate of transiently expressed wt hGR with phosphorylation hGR mutants, which can 
no longer be phosphorylated at S211 (S211A) or S226 (S226A), in the absence and presence of 
the agonist dex, in COS-1 cells.  If agonist-induced hGR phosphorylation at S211 or S226 is 
required for enhanced GR degradation, then the phosphorylation mutants should have a slower 












Furthermore, acetylation and phosphorylation of the androgen receptor (AR) have been 
functionally linked (Fu et al., 2004).  Additionally, direct acetylation of the AR by p300 has been 
shown to be important for AR-mediated transactivation (Fu et al., 2000;Fu et al., 2004).  
Therefore the hypothesis that GR phosphorylation at S211 and S226 is important for the 
recruitment of p300 and acetylation of the GR will be investigated.  By comparing the ability of 
transiently expressed wt and phosphorylation mutant hGR to recruit p300 in in vitro pull down 
assays using COS-1 cell extracts, it will be determined if GR phosphorylation is required for the 
recruitment of p300.  Furthermore, using an antibody raised against acetylated lysine, the 
acetylation status of expressed wt and phosphorylation mutant hGR will be determined.  If hGR 
phosphorylation is required for hGR acetylation via p300, then the phosphorylation mutant 
should show reduced acetylation and should not be able to recruit p300. 
 
In addition, GR phosphorylation has been shown to play a role in the recruitment of the 
secondary co-factor, p300 (Kino et al., 2007;Galliher-Beckley et al., 2008).  However, the 
requirement of GR phosphorylation at S226 and/or S211 for recruitment of a primary co-factor, 
has not previously been shown. The hypothesis that hGR phosphorylation at S226 and/or S211 is 
required for the recruitment of the primary co-factor, GRIP-1, will thus be investigated. This will 
be done by examining the interaction between GRIP-1 and wt hGR, as well as the S211A and 
S226A phosphorylation mutants by immunoprecipitation assays (in the presence and absence of a 
GRE), as well as chromatin immunoprecipitation assays in COS-1 cells.  If GR phosphorylation 
is required for GRIP-1 recruitment, then the mutants would not be able to recruit GRIP-1.   
 
Understanding what determines ligand-selective potency and efficacy will further our 























Chapter 3 Materials and Methods 
 
 
3.1 Cell Lines 
 
Monkey kidney fibroblast cells (COS-1 and COS-7), human endocervical cells (END-1/E6E7) 
and human osteosarcoma cells (U2OS) were purchased from American Type Culture Collection 
(ATCC, USA) and mouse pituitary gonadotrope cells (LT2) were kindly provided by Dr. 
Pamela Mellon from the University of California, San Diego, USA.  COS-1, COS-7, U2OS cells 
and LT2 cells were cultured in 75 cm2 culture flasks (Greiner Bio-One International, Austria) in 
high glucose (1 g/ml) Dulbecco’s Modified Eagles Medium (DMEM, Sigma-Aldrich, South 
Africa) supplemented with 10% (v/v) fetal calf serum (Delta Bioproducts, South Africa), 100 
IU/ml penicillin and 100 g/ml streptomycin (Gibco Invitrogen, Paisley, UK) at 37°C in a 5% 
CO2 incubator.  Human osteosarcoma U2OS cells stably transfected with HA-tagged human GR 
using FuGENE 6 (Roche, South Africa) were obtained from Dr. MJ Garabedian and were 
cultured under the same conditions as described above, however in the presence of 300 g/ml 
Geneticin (Sigma-Aldrich, South Africa). END-1 cells were cultured in Keratinocyte serum free 
medium (Gibco Invitrogen, Paisley, UK) supplemented with 0.1 ng/ml EGF (Gibco Invitrogen, 
Paisley, UK), 50 g/ml bovine pituitary extract (Gibco Invitrogen, Paisley, UK), 0.4 mM CaCl2 
(Gibco Invitrogen, Paisley, UK), 100 IU/ml penicillin and 100 g/ml streptomycin (Gibco 
Invitrogen, Paisley, UK) at 37C in a 5% CO2 incubator.   
 
The COS-1, COS-7 and U2OS cells stock cultures, in 75 cm2 culture flasks (Greiner Bio-One 











incubator, before the addition of 8 ml DMEM, containing 10% fetal calf serum and antibiotics as 
described above. The COS-1, COS-7 and U2OS cells were maintained by regular splitting twice 
a week at a 1/10 dilution. The LT2 cell stock cultures, in 175 cm2 culture flasks (Greiner Bio-
One International, Austria), were trypsinized in 2 ml trypsin for 3 minutes at 37°C in a 5% CO2 
incubator, before the addition of 8 ml DMEM, containing 10% fetal calf serum and antibiotics as 
described above. These cells were maintained by splitting at a 1/4 dilution only once a week. The 
END-1 cells, in 75 cm2 culture flasks (Greiner Bio-One International, Austria), were trypsinized 
in 2 ml trypsin for 10 minutes at 37°C in a 5% CO2 incubator, before the addition of 8 ml 
keratinocyte serum free medium (Gibco Invitrogen, Paisley, UK) supplemented with 0.1 ng/ml 
EGF (Gibco Invitrogen, Paisley, UK), 50 g/ml bovine pituitary extract (Gibco Invitrogen, 
Paisley, UK), 0.4 mM CaCl2 (Gibco Invitrogen, Paisley, UK), 100 IU/ml penicillin and 100 
g/ml streptomycin (Gibco Invitrogen, Paisley, UK). These cells grow very slowly and were 
maintained by splitting at a 1/4 dilution every second week.    
 
 
3.2 Compounds and antibodies   
 
Dexamethasone, cortisol (hydrocortisone), prednisolone, aldosterone, MPA (6-Methyl-
17hydroxyprogesterone acetate), progesterone, NET (norethindrone acetate), RU486 
(mifepristone) and UDCA (ursodeoxycholic acid) were purchased from Sigma-Aldrich, South 
Africa and made up in 100% ethanol.  Compound A (2,4-acetoxyphenyl)-2-chloro-N-methyl-
ethylammonium chloride) was synthesized in Stellenbosch as previously described (Louw et al., 
1997).  All the above mentioned compounds were dissolved in EtOH. DO6 and AL438 were a 











100% DMSO and a 50% DMSO, 50% EtOH mixture, respectively.  The test compounds were 
added to the cells such that the final concentration of EtOH was less than 0.1%.   
 
Tumor Necrosis Factor- (TNF-), 4-Phorbol 12-myristate 13-acetate (PMA), Z-Leu-Leu-Leu-
al (MG132), -amanitin and cycloheximide (CHX) was purchased from Sigma-Aldrich, South 
Africa. The p38 inhibitor (SB203580), JNK inhibitor (SP600125) and CDK inhibitor 
(roscovitine) were purchased from Merck chemicals South Africa.   
   
The anti-phospho-serine 226 (P-S226) hGR and anti-phospho-serine 211 (P-S211) hGR specific 
antibodies was a generous gift from Dr M.J. Garabedian (New York University, School of 
Medicine, USA).  The GR (H300; sc-8992), MKP-1 (sc-370) and P300 (sc-32244) antibodies 
were purchased from Santa Cruz Biotechnology (USA).  The -actin (#4967), phospho-
SAPK/JNK (Thr183/Thr185) (#9251), SAPK/JNK (#9252), p53 (#2524), phospho-p44/42 MAP 
kinase (Thr202/Tyr204) (#9101), p44/42 MAPK (#9102), phospho-p38 MAPK (Thr180/Tyr182) 
(#9211), p38 MAPK (#9212), GAPDH (#14C10) and acetylated lysine (#9441) antibodies were 
purchased from Cell Signaling Technology.  The HA (12CA5) and histone H3 (#ab1791) 
antibodies were from Roche (South Africa) and Abcam (UK), respectively.  The secondary anti-
rabbit HRP conjugate (NA934VS) and anti-mouse HRP conjugate (NA931) antibodies were 
purchased from AEC Amersham (South Africa).  The dilutions used for each specific primary 
antibody, as well as the corresponding secondary antibody and dilution thereof can be obtained 
















HA-tagged human GR wt (HA-hGRwt), as well as the S211A (HA-hGRS211A) and S226A 
(HA-hGRS226A) mutant expression vectors were obtained from Prof. M. J. Garabedian at New 
York University, School of Medicine, USA (Wang et al., 2002b).  The pTAT-GRE-E1b-luc (or 
TAT-GRE containing an E1b promoter and 2 copies of rat TAT-GRE) and the MMTV-luc 
(containing 4 GREs; MMTV) plasmids were gifts from Dr. G. Jenster at Erasmus University of 
Rotterdam, Rotterdam, the Netherlands (Sui et al., 1999) and Gordon L Hager (National Cancer 
Institute, USA), respectively. The pRS human GR (pRS-hGRwt), pRS S203/211/226A (pRS-
hGR3A), pRS S211A (pRS-hGRS211A) and pRS S226A (pRS-hGRS226A), as well as the wt 
and dominant negative CDK5 plasmids were a gift from Tomoshige Kino (NIH, Bethesda, USA). 
The 7x AP-1-luc (AP-1) and 5x NFB-luc (NFB) plasmids were obtained from Stratagene 
(Houston, Texas, USA), whereas the pcDNA3.1 (empty vector) plasmid was obtained from 
Invitrogen (UK). The pCMV--galactosidase plasmid (-gal) was a gift from Dr G. Hageman 
(University of Gent, Belgium).  HA-GRIP-1 plasmid was a gift from M.R. Stallcup (University 
of California, USA), while wt and dominant negative JNK and p38 plasmids were generously 
given by Prof. A. Moon (Duksung Women’s University, Seoul, Korea). 
 
 
3.4 Plasmid transformation and preparation 
 
The pRS human GR constructs were transformed into HB101 competent cells and all the other 
plasmids were transformed into DH5 competent cells.  The transformations were done by heat-











with 100 l competent cells and left on ice for 30 minutes.  Thereafter the mixture was placed at 
42°C for 2 minutes and back on ice for an additional 2 minutes before 900 l SOC medium (2% 
(w/v) tryptone, 0.5% (w/v) yeast extract, 0.05% (w/v) NaCl, 2.5 mM KCl, 10 mM MgCl2 and 20 
mM glucose) (Sambrook et al., 1989) was added and incubated for 1 hour at 37°C with shaking.  
The cells were plated on LB-AMP plates (1% (w/v) tryptone, 0.5% yeast extract, 1% NaCl and  
agarose containing 50 g/ml ampicillin) (Sambrook et al., 1989) and left overnight at 37°C.  The 
next day, a positive colony was picked and grown in 50 ml LB medium (1% (w/v) tryptone, 0.5% 
yeast extract and 1% NaCl) (Sambrook et al., 1989) containing 50 µg/mL ampicillin (Sigma-
Aldrich, St. Louis, MO, USA) for at least 8 hours at 37°C with shaking.  For glycerol stocks 
equal amounts (1 ml) of 80% (v/v) glycerol and cell suspension were mixed and stored at -80°C.  
For plasmid purification, LB medium containing 50 g/ml ampicillin was inoculated and allowed 
to grow overnight at 37°C with shaking.  The next day the plasmid DNA was purified with the 
Promega PUREYIELD plasmid maxiprep (Promega, Madison, WI, USA), according to the 
manufacturers’ protocol.  The integrity and purity of the plasmids were assessed by restriction 
enzyme digestion and agarose gel electrophoresis.    
 
 
3.5 Transactivation  
 
COS-1 cells were seeded into 10-cm dishes (NUNC, AEC Amersham) at a density of 2x106 
cells/dish in DMEM, containing 10% fetal calf serum and antibiotics as described above.  The 
next day the cells were transfected with 10 g of either HA-hGRwt, HA-hGRS226A, pRS–
hGRwt, pRS-hGR3A, pRS-hGRS211A or pRS-hGRS226A and 3.75 g TAT-GRE or MMTV 











ratio of 1 g DNA : 2 l FuGENE 6, and incubated for 24 hours.  On the morning of day three, 
the cells were washed with PBS (Sambrook et al., 1989) and incubated with trypsin (Highveld 
Biologicals, South Africa) at 37C before being re-plated into 24-well plates (NUNC, AEC 
Amersham) at a density of 5x104 cells/well in DMEM, containing 10% fetal calf serum and 
antibiotics as described above.  After a 24 hour incubation, the cells were washed in PBS and 
serum-free DMEM was added before the cells were treated with vehicle (EtOH) or the respective 
compounds for 24 hours.  The cells were harvested by washing twice with PBS and lysed in 50 l 
Reporter lysis buffer (Promega, Madison, WI, USA).  Luciferase activity was measured using the 
Luciferase Assay System (Promega, Madison, WI, USA) and a Modulus microplate reader 
(Turner Biosystems, Sunnyvale CA, USA).  The luciferase values obtained were normalized to 
protein content per well as determined by standard Bradford assay (Bradford, 1976).  If the COS-
1 cells were plated directly into 24-well plates, the cells were transfected with proportionally less 
DNA, keeping the ratio of 10 µg GR/ 2 X 106  cells, as well as 0.025 g -gal.  In this case the 
expression of -galactosidase, which was measured using the GalactoStar Assay Kit (Tropix, 
Bedford MA, USA), was used to normalize for transfection efficiency in each well.  If so, it is 
stated in the figure legend of the appropriate experiment. The normalised transactivation value 
for 10 µM dex with wt GR was set as 100 % and values for all the other samples were calculated 
relative to the maximal induction by 10 µM dex with wt GR. The relative efficacy is given as the 
maximal induction point and the EC50 (nM) was obtained from fitting the dose-response curve in 

















COS-1 cells were seeded into 24-well plates at a density of 5x104 cells/well in DMEM, 
containing 10% fetal calf serum and antibiotics as described above.  The following day, the cells 
were transfected with 0.125 g HA-hGRwt, HA-hGRS211A, HA-hGRS226A, pRS-hGRwt, 
pRS-hGRS211A or pRS-hGRS226A and 0.25 g of NFB or AP-1 plasmids, as well as 0.025 g 
-gal using FuGENE 6 according to the manufacturer’s instructions, using a ratio of 1 g DNA : 
2 l FuGENE 6, and incubated for 24 hours.  On day three the cells were washed with PBS and 
incubated with serum-free DMEM containing 20 ng/ml PMA and vehicle (EtOH) or the 
appropriate compounds for 24 hours.  The following day the luciferase activity was measured 
using the Luciferase Assay System (Promega, Madison, WI, USA) and a Modulus microplate 
reader (Turner Biosystems, Sunnyvale CA, USA).  The luciferase values obtained were 
normalized to the expression of -galactosidase, which was measured using the GalactoStar 
Assay Kit (Tropix, Bedford MA, USA).  Induction with PMA only was set to 100% and other 
conditions expressed as relative % thereof.   
 
 
3.7 Western Blotting 
 
3.7.1 Western blotting for ligand-selective phosphorylation (Chapter 3.1) 
 
For the phosphorylation assays COS-1 were plated into 6-cm tissue culture dishes (NUNC, AEC 
Amersham) at a density of 7x105 cells/dish and U2OS cells were plated into 12-well plates 











serum and antibiotics as described above.  COS-1 cells were transiently transfected with 3.5 g 
HA-hGRwt DNA per dish, using FuGENE 6 (Roche, South Africa) according to manufacturer’s 
instructions, using a ratio of 1 g DNA : 2 l FuGENE 6.  The U2OS cells were not transfected, 
since they contain stably transfected HA-hGRwt (obtained from Dr M.J. Garabedian (New York 
University, School of Medicine, USA).  After 24 hours, the COS-1 cells were washed with PBS, 
trypsinised and re-plated into 12-well plates (NUNC, AEC Amersham) at a density of 2x105 
cells/well in DMEM, containing 10% fetal calf serum and antibiotics as described above. Twenty 
four hours after re-plating, the COS-1 and the U2OS cells were washed with PBS and incubated 
with serum-free DMEM containing vehicle (EtOH), 100 nM or 10 M of the appropriate 
compounds for 1 hour.  Subsequently the cells were washed with PBS and lysed in 400 l lysis 
buffer (20 mM Tris, 150 mM NaCL, 1 mM EDTA, 1 mM EGTA, 1% (v/v) TritonX-100, 2.5 mM 
sodium pyrophosphate, 1 mM -glycerolphosphate, 1 mM sodium orthovanadate, 1 mM PMSF, 
1 mM sodium fluoride) containing protease inhibitors (1 complete mini protease inhibitor 
cocktail tablet/10 ml, Roche, South Africa).  The protein content of each sample was determined 
by Bradford assay before loading equal amounts of protein, typically 20 g, in 1x SDS sample 
buffer (5x SDS sample buffer: 100 mM Tris-CL pH 6.8, 5% (v/v) SDS, 20% (v/v) glycerol, 5% 
-mercaptoethanol and 0.1% (w/v) bromophenolblue) onto an 8% SDS-polyacrylamide gel.  
Rainbow marker (1.5 µl) (Amersham, South Africa) was also loaded on the gel.  The separated 
proteins were transferred onto a Hybond-ECL Nitrocellulose membrane (Amersham, South 
Africa) for 1 hour at 180 mA, using the Mini Protean III blotting system (BioRad, South Africa) 
in Tris/Glycine transfer buffer (25 mM Tris, 250 mM glycine and 10% (w/w) methanol).  The 
membranes were blocked overnight at 4°C in 4% blocking solution (4% (w/v) ECL Advance 
blocking powder (Amersham, South Africa) and Tris-buffered saline (TBS, 50 mM Tris, 150 mM 











blocking solution containing an anti-P-S226 specific antibody (previously described in (Chen et 
al., 2008)) at a dilution of 1:10 000 for 1 hour at RT.  Thereafter the blots were washed 1x 10 
minutes and 2x 5 minutes in TBST at RT. As secondary antibody an anti-rabbit HRP conjugate 
antibody (NA934VS, Amersham, South Africa) was used at a dilution of 1:10 000 in a 5% 
milkpowder solution (5% (w/v) milkpowder, 1x TBST) for 1 hour at RT. The blots were washed 
1x 10 minutes and 2x 5 minutes in TBST at RT and autoradiography was performed.  Thereafter, 
the membranes were stripped for 30 minutes at 60 °C in stripping buffer (100 mM 2-
mercaptoethanol, 2% (w/v) SDS, 62.4 mM Tris-Cl, pH 6.7). The blots were washed twice with 
TBST for 10 minutes, blocked overnight, as previously described, and quantification of total GR 
levels were performed on the same blot by reprobing with an antibody to total GR (H300, Santa 
Cruz Biotechnology, USA), followed by secondary antibody probing and autoradiography. 
 
 
3.7.2 Western blotting for other applications (Chapter 3.3 – 5.4) 
 
COS-1 cells transiently transfected with hGR, as well as U2OS, LT2 or END-1 cells, containing 
endogenous GR were plated into 12- or 6-well plates at different amounts of cells/well, as 
indicated in the figure legends and treated with inducing compound or inhibitor and vehicle 
(EtOH) or test compound, as indicated in the figure legends.  After ligand stimulation the cells 
were washed twice with PBS and harvested in 50 or 100 l 2x SDS sample buffer, for 12- or 6-
well plates respectively, and boiled for 5 minutes.  Thereafter equal amounts were separated on a 
SDS-PAGE gel and transferred to membrane, as described above.  The membranes were blocked 
in 4% blocking solution for 1 hour at RT and incubated with primary antibody, in 4% blocking 











2x 5 minutes at RT with TBST and incubated with secondary antibody, in 5% milkpowder 
solution for 1 hour at RT.  Thereafter the blots were washed 1x 10 minutes and 2x 5 minutes in 
TBST at RT and autoradiography was performed.  The dilutions used for each specific primary 
antibody, as well as the corresponding secondary antibody and dilution thereof can be obtained 
from addendum B (Antibodies).  
 
3.7.3 Autoradiography and quantification 
 
The proteins were visualized by the ECL advance Western blotting detection kit (Amersham, 
South Africa) or ECL normal Western blotting detection kit (Amersham, South Africa), 
according to the manufacturer’s protocol, and Hyperfilm MP high performance autoradiography 
film (Amersham, South Africa).  Bands on the X-ray film were scanned or the film was 
photographed, before quantification using AlphaEaseFC FluorChem 5500 (Alpha Innotech).   
 
 
3.8 GR Half-life 
 
COS-1 cells were plated into 10-cm dishes (NUNC, AEC Amersham) at a density of 2x106 
cells/dish in DMEM, containing 10% fetal calf serum and antibiotics as described above.  The 
next day the cells were transfected with 10 g HA-hGRwt, HA-hGRS211A, HA-hGRS226A, 
pRS-hGRwt or pRS-hGR3A.  On day three the cells were washed with PBS  and incubated with 
trypsin at 37C before being re-plated into 6-well plates (NUNC, AEC Amersham) at a density of 
4x105 cells/well in DMEM, containing 10% fetal calf serum and antibiotics.  After 24 hour 











M cycloheximide for 1 hour.  The cells were then treated with vehicle (EtOH) or 10 M 
compound and harvested at various time points, before Western blot analysis was performed as 
described above, using an antibody to total GR and -Actin as loading control.  The amount of 
GR at the zero hour time point was set to 100% and the amount of GR at the other time points 
was calculated as percentage of the zero hour time point.      
 
 
3.9 Inhibition of transcription  
 
COS-1 cells were seeded into 24-well plates (NUNC, AEC Amersham) at a density of 5x104 
cells/well in DMEM, containing 10% fetal calf serum and antibiotics as described above, and 
incubated for 24 hours.  The following day the cells were transfected with 0.047 g TAT-GRE 
and 0.125 g HA-hGRwt per well, using FuGENE 6 (Roche, South Africa) according to the 
manufacturer’s instructions, using a ratio of 1 g DNA : 2 l FuGENE 6.  After 24 hour 
incubation, the cells were pre-treated with either 1 g/ml or 2.5 g/ml of the RNA polymerase II 
inhibitor, -amanitin (Sigma-Aldrich, South Africa), for 2 hours and subsequently stimulated 
with vehicle (EtOH) or 100 nM dex or MPA for 24 hours.  The cells were harvested by washing 
twice with PBS and lyses in 50 l Reporter lysis buffer (Promega, Madison, WI, USA).  
Luciferase activity was measured using the Luciferase Assay System (Promega, Madison, WI, 
USA) and a Modulus microplate reader (Turner Biosystems, Sunnyvale CA, USA).  The 
luciferase values obtained were normalized to protein content per well as determined by standard 
Bradford assay.  After the luciferase and Bradford assays were performed, equal amount of 











described above, probing for total GR with anti-GR antibody (H300, Santa Cruz) and for -actin 
with anti--actin antibody (Cell Signaling) as loading control. 
 
 
3.10 Inhibition of degradation  
 
COS-1 cells were seeded into 24-well plates (NUNC, AEC Amersham) at a density of 5x104 
cells/well in DMEM, containing 10% fetal calf serum and antibiotics as described above, and 
incubated for 24 hours.  The following day the cells were transfected with 0.047 g TAT-GRE 
and 0.125 g HA-hGRwt per well, using FuGENE 6 (Roche, South Africa) according to the 
manufacturer’s instructions, using a ratio of 1 g DNA : 2 l FuGENE 6.  After 24 hour 
incubation, the cells were pre-treated with either 5 M or 10 M of the proteasome inhibitor, 
MG132 (Sigma-Aldrich, South Africa), for 2 hours and subsequently stimulated with vehicle 
(EtOH) or 100 nM dex or MPA for 24 hours.  The cells were harvested by washing twice with 
PBS and lysed in 50 l Reporter lysis buffer (Promega, Madison, WI, USA).  Luciferase activity 
was measured using the Luciferase Assay System (Promega, Madison, WI, USA) and a Modulus 
microplate reader (Turner Biosystems, Sunnyvale CA, USA).  The luciferase values obtained 
were normalized to protein content per well as determined by standard Bradford assay.  After the 
luciferase and Bradford assays were performed, equal amount of proteins were loaded onto a 8% 
SDS-PAGE and Western blot analysis were performed, as described above, probing for total GR 
with anti-GR antibody (H300, Santa Cruz) and for -actin with anti--actin antibody (Cell 













3.11 JNK CASE assay 
 
COS-1 cells were plated into 96-well plates (NUNC, AEC Amersham) at a density of 5x103 
cells/well in DMEM, containing 10% fetal calf serum and antibiotics as described above, and 
incubated for 24 hours.  The following day, the cells were washed with PBS and serum-free 
DMEM was added to the cells, before being transfected with 0.05 g HA-hGRwt.  On day three 
the cells were pretreated with 0.02 g/ml TNF- for 1 hour before being stimulated with vehicle 
(EtOH) or 100 nM compound for an additional 1 hour.  Subsequently the cells were fixed to the 
96-well plate in a 4% cell fixing buffer (89% (v/v) PBS and 11% (v/v) 37% formaldehyde) for 20 
minutes at RT.  In order to determine the amount of phosphorylated JNK and total JNK in each 
well, the Superarray CASE JNK (T183/Y185) assay (FE-004, Super Array Bioscience 
Corporation) was performed according to manufacturers’ protocol.  Briefly, the amount of 
phosphorylated JNK (P-JNK) and total JNK, in each well, were determined by the use of 
phospho-JNK and total JNK specific antibodies (Super Array Bioscience Corporation).  
Furthermore the relative cell number in each well was determined and used to normalize the 
amount of phosphorylated and total JNK.  Thereafter the ratio of P-JNK / total JNK was 
calculated for each compound. 
 
 
3.12 Kinase and GR phosphorylation timecourse 
 
COS-1 cells were seeded into 6-well plates (NUNC, AEC Amersham) at a density of 3x105 
cells/well in DMEM, containing 10% fetal calf serum and antibiotics as described above, and 











well and incubated for an additional 24 hours before being pretreated with 0.02 g/ml TNF- for 
15 minutes.  Subsequently, the cells were treated with vehicle (EtOH) or 100 nM dex and 
incubated for various times.  At the appropriate time, the cells were harvested and equal amounts 
of cell extract were separated on an 8% SDS-PAGE.  The Western blots were cut in half and the 
top part of the Western blots were probed with either an anti-P-S226 GR-specific or an anti-P-
S211 GR-specific antibody (previously described in (Wang et al., 2002b;Chen et al., 2008)), 
whereas the bottom half of the Western blots were probed with either an anti-phospho-
SAPK/JNK antibody (P-JNK; Cell Signaling Technology) or an anti-phospho-p38 (P-p38; Cell 
Signaling Technology) antibody.  After developing, the blots were stripped, as described above, 
and re-probed for either total GR with anti-GR antibody (H300, Santa Cruz), total JNK with anti-
JNK antibody (Cell signaling Technology) or for total p38 with anti-p38 antibody (Cell Signaling 
Technology).                
 
 
3.13 Kinase inhibition 
 
3.13.1 MAPK inhibition  
 
COS-1 cells were seeded into 6-well plates (NUNC, AEC Amersham) at a density of 3x105 
cells/well in DMEM, containing 10% fetal calf serum and antibiotics as described above, and 
incubated for 24 hours.  The following day, the cells were transfected with 3 g HA-hGRwt per 
well and incubated for an additional 24 hours before being pre-treated with either 10 M p38 
inhibitor (SB203580), 50M JNK inhibitor (SP600125) or no inhibitor for 16 hours in serum-free 











harvested.  Equal amounts of protein were separated on an 8% SDS-PAGE and probed either for 
anti-P-S226 GR, anti-P-S211 GR, anti-P-JNK or anti-P-p38.  After developing, the blots were 
stripped as described above and re-probed for either total GR with anti-GR antibody (H300, 
Santa Cruz), total JNK with anti-JNK antibody (Cell signaling Technology) or for total p38 with 
anti-p38 antibody (Cell Signaling Technology).   
 
3.13.2 CDK inhibition  
 
LT2, END-1 cells and COS-1 cells were plated into 12-well plates at a density of 5x105 
cells/well, 5x105 cells/well and 1.5x105 cells/well, respectively.  The following day, the COS-1 
cells were transiently transfected with 1 g HA-hGRwt and incubated for 24 hours.  Thereafter 
the LT2, END-1 cells and COS-1 cells were pretreated with 20 M of the general CDK 
inhibitor, roscovitine, for 1 hour in serum-free DMEM, before stimulation with 100 nM dex or 
vehicle (EtOH). The cells were harvested and equal amounts of cell extract were separated on 
SDS-PAGE. Western blot analysis was performed using either an anti-P-S211 or an anti-P-S226 
GR-specific antibody. Thereafter the membrane was stripped and reprobed with anti-GR 






















LT2, END-1 cells and COS-1 cells were plated into 12-well plates at a density of 2x105 
cells/well, 5x105 cells/well and 1.5x105 cells/well, respectively.  The following day, the cells 
were transiently transfected with 1 g p35 (to activate CDK) and 1 g wt plasmid expressing 
CDK5 or DN- CDK5 (Kino et al., 2007).  The COS-1 cells were also transiently transfected with 
1 g HA-hGRwt.  After a 24 hour incubation, the cells were stimulated with 100 nM dex or 
vehicle (EtOH) for 1 hour in serum-free DMEM. The cells were harvested and equal amounts of 
cell extract were separated on SDS-PAGE. Western blot analysis was performed using either an 
anti-P-S211 or an anti-P-S226 GR-specific antibody. Thereafter the membrane was stripped and 
reprobed with anti-GR antibody (H300, Santa Cruz) for total GR. 
 
3.14.2 JNK and p38 
 
LT2 and COS-1 cells were plated into 12-well plates at a density of 2x105 cells/well and 
1.5x105 cells/well, respectively.  The following day, the cells were transiently transfected with 1 
g plasmid expressing wt or DN- JNK, or DN- p38 (Kang et al., 2003). The COS-1 cells were 
also transiently transfected with 1 g HA-hGRwt.  After a 24 hour incubation, the cells were 
stimulated with 100 nM dex or vehicle (EtOH) for 1 hour in serum-free DMEM. The cells were 
harvested and equal amounts of cell extract were separated on SDS-PAGE. Western blot analysis 
was performed using either an anti-P-S211 or an anti-P-S226 GR-specific antibody. Thereafter 











3.15 Effect of -amanitin and MG132 on GR and kinase phosphorylation 
 
COS-1 cells were seeded into 6-well plates (NUNC, AEC Amersham) at a density of 3x105 
cells/well in DMEM, containing 10% fetal calf serum and antibiotics as described above, and 
incubated for 24 hours.  The following day, the cells were transfected with 3 g HA-hGRwt per 
well and incubated for 24 hours, before being pre-treated with either 2.5 g/ml -amanitin or 10 
M MG132 for 2 hours in serum-free DMEM.  The cells were subsequently stimulated with 100 
nM dex or vehicle (EtOH) and harvested.  Western blot analysis were performed as described 
above, using either an anti-P-S226 GR, anti-P-S211 GR, anti-P-JNK or anti-P-p38 specific 
antibody.  After developing, the blots were stripped as previously described, and re-probed with 
antibodies to either total GR (H300, Santa Cruz), total JNK (Cell signaling Technology), or total 





COS-1 cells were seeded into 10-cm dishes (NUNC, AEC Amersham) at a density of 1.5x106 
cells/dish in DMEM containing 10% fetal calf serum and antibiotics, as described above.  After a 
24 hour incubation, the cells were transfected with 3 g HA-GRIP-1 and 3 g of either pRS-
hGRwt, pRS-hGR3A or pcDNA3.1 (empty vector) using FuGENE 6 (Roche, South Africa) 
according to the manufacturer’s instructions.  The following day, the cells were treated with 1 
M dex or vehicle (EtOH) for 1 hour in serum-free DMEM, washed once with PBS and lysed 
with 500 l cytobuster (Novagene) containing protease inhibitors (1 complete mini protease 











1.6 g GR (H300, Santa Cruz) antibody was added to the remaining supernatant and incubated at 
4°C rotating over night.  The following day the antibodies were precipitated by addition of 28 l 
of a 25% slurry pre-blocked protein A/G PLUS-Agarose beads (Santa Cruz) for 2 hours at 4°C 
while rotating, followed by 2x washes with PBS. The GR-bound proteins were released from the 
beads by boiling in 2x SDS-sample treatment buffer.  The samples were separated on 6% SDS-
PAGE and Western blotted as described above, probing with anti-GR (H300, Santa Cruz) and 
anti-HA (12CA5, Roche) antibodies. 
 
 
3.17 Avidin Biotin Complex DNA (ABCD) assay 
 
The ABCD assay was performed as previously described in Cho et al. with minor modifications 
(Cho et al., 2005). This assay is a multistep assay, wherein seperate cytosols for the GR and the 
co-factor of interest are prepared.  Thereafter, the GR cytosol is incubated with vehicle or 
hormone, before being incubated with beads containing GRE oligonucleotides, allowing the GR 
to bind to its GREs.  Subsequently, the second cytosol (containing the co-factor of choice) is 
incubated with the GR-GRE-bead mixture, thereby allowing the co-factor of choice to bind to the 
GR.  This complex on the beads is then pelleted by centrifugation, washed, eluted with SDS 
sample buffer and analysed by SDS-PAGE and Western blotting, probing with antibodies for the 
GR and the co-factor of choice is performed.  After autoradiography, the relative amount of co-
factor bound to the GR can then be measured.     
 
COS-7 cells were seeded into 15-cm dishes (NUNC, AEC Amersham) at a density of 2x106 











Twenty four hours later, the cells were transfected with 5 g of either pRS-hGRwt, pRS-hGR3A, 
HA-GRIP-1 or pcDNA3.1 (empty vector) using FuGENE 6 (Roche, South Africa) according to 
the manufacturer’s instructions and incubated for 48 hours.  The cells were then harvested using 
either the TAPS method (GR and TAPS mock cytosols) or the cytobuster method (GRIP-1 and 
cytobuster mock cytosols).   
 
For cytosol preparation using the “TAPS” method (Cho et al., 2005), the cells were washed twice 
with ice cold PBS and incubated with 2 ml trypsin for 5 minutes at 37°C before the addition of 9 
ml DMEM containing 10% fetal calf serum and antibiotics per dish.  After scraping loose all the 
cells, they were transferred into a 50 ml tube and pelleted at 500 x g for 5 minutes at 4°C.  After 
two PBS washes, the pellet was snap-frozen in an ethanol-dry ice bath and weighed.  One pellet 
volume TAPS buffer (0.1 M TAPS pH 9.5) was added to the pellet (1 ml TAPS per 1 g pellet) 
and incubated on ice for 1 hour with vortexing every 10 minutes.  The cellular debris was 
pelleted at 15 000 x g for 15 minutes at 4°C and aliquots of the supernatant were snap-frozen in 
an ethanol-dry ice bath and stored at -80°C.   
 
For cytosol preparation using the “cytobuster” method (Cho et al., 2005), the cells were washed 
twice with PBS and incubated with 2 ml cytobuster (Novagene) containing protease inhibitors (1 
complete mini protease inhibitor cocktail tablet/10 ml, Roche, South Africa) per dish for 5 
minutes at room temperature.  Subsequently the cells were scraped and pelleted at 15 000 x g for 
15 minutes at 4°C and aliquots of the supernatant were snap-frozen in an ethanol-dry ice bath and 
stored at -80°C.         
 
To prepare the annealed GRE oligonucleotides, consensus GRE oligonucleotides (sense: 5’-











TAG AAC ATT CCT GTA CAG GATC-3’, Invitrogen) that are 5’ biotinylated were annealed 
by mixing equimolar amounts (1.74 g/l) of each oligonucleotide, heating to 100°C for  5 
minutes, then allowing to cool overnight.  In order to determine whether annealing had occurred, 
the mixture and input single stranded oligonucleotides was electrophoresed on a 20% 
polyacrylamide-TAE gel at 120 V and the DNA was visualised by ethidium bromide staining. 
 
On day one of the ABCD assay, 20 l TAPS cytosol containing either hGRwt, hGR3A or TAPS 
mock cytosol were diluted to 100 l with HEPES wash buffer (10 mM Hepes pH 7.5, 1 mM 
EDTA, 10% (v/v) glycerol) and stimulated with 1 M dex or vehicle (EtOH) for 2.5 hours on ice 
before being heat activated for 30 minutes at 20°C.  During that time, 5 l of the annealed GRE 
oligonucleotides were immobilized on 100 l of a 50% slurry Streptavidin affinity matrix 
(EZview Red Streptavivdin Affinity Gel (E5529) Sigma-Aldrich, South Africa) for 2 hours 
rotating at 4 °C.  The activated GR cytosol (20 l cytosol diluted to 100 l with HEPES wash 
buffer) was incubated in the presence of 40 l of the GRE/bead complex O/N at 4 C with 
rotating, to allow DNA binding. The following day, the samples were centrifuged at 8 200 x g for 
1 minute at 4 °C and supernatants were removed. To determine co-factor recruitment, the GR-
DNA-bead complex pellet (20 l actual beads) was incubated at 4 °C for 4 hours on the rotator 
with 200 l GRIP-1 cytosol diluted 1:1.8 with mock (untransfected) cytobuster cytosol. 
Thereafter the beads were pelleted by centrifugation at 8 200 x g for 1 minute, washed with 1 ml 
HEPES buffer and vortexed for 10 seconds, before centrifugation (as above). The beads were 
washed three times with 1 ml HEPES buffer, as described above, and the protein complexes were 
eluted off the beads by boiling in 30 l 2 x SDS sample buffer, vortexing and centrifugation at 











by 6% SDS-PAGE and Western blotted, probing with anti-GR (H300, Santa Cruz) and anti-HA 
(12CA5, Roche) antibodies, as described above. 
 
 
3.18 Chromatin Immunoprecipitation (ChIP) assay 
 
The ChIP assay was performed as previously described (Ma H, 2003;Shang et al., 2000), with 
some minor modifications.  This is a multistep assay, wherein DNA binding proteins in living 
cells are crosslinked to the DNA. Thereafter, the cells are harvested and the chromatin is 
sonicated to break it up into smaller pieces, before immunoprecipitation with an antibody of 
choice (i.e. the specific protein being investigated). The crosslinking is then reversed and the 
specific DNA to which the protein was bound is amplified by PCR, using primers specific for the 
DNA sequence of interest.  Thereby the relative recruitment of the protein of choice to the 
specific DNA sequence can be determined. 
 
COS-1 cells were plated into 15-cm dishes (NUNC, AEC Amersham, South Africa) at a density 
of 2x106 cells/well, in DMEM containing 10% fetal calf serum and antibiotics, as described 
above.  After a 24 hour incubation the cells were transfected with 5 g HA-GRIP-1, 5 g MMTV 
and 9 g of either pRS-hGRwt, pRS-hGR3A or pcDNA3.1 (empty vector) using FuGENE 6 
(Roche, South Africa) according to the manufacturer’s instructions.  The following day the cells 
were washed with PBS and serum starved for 2 hours in serum-free DMEM, before stimulation 
with vehicle (EtOH) or 1 M dex for 1 hour.  After stimulation, the proteins were cross-linked 
with 1% formaldehyde for 10 minutes at 37°C, before the reaction was stopped with 0.125 M 











PBS, containing protease inhibitors (1 Complete Mini Protease Inhibitor tablet per 20 ml), 
pelleted by centrifugation and resuspended in 500 l nuclear lysis buffer (1% (w/v) SDS, 50 mM 
Tris pH 8.0, 10 mM EDTA, containing protease inhibitor tablet (one tablet per 10 ml nuclear 
lysis buffer)).  The cross-linked DNA was fragmented into 100 – 400 bp fragments, by means of 
sonication (Misonix Sonicator 3000) with a microtip at 20 pulses (power setting 3), each pulse 
being 20 seconds, with resting phases in between each pulse of 40 seconds, on ice.  After 
sonication, the mixture was centrifigated for 10 minutes at 15 000 x g and the supernatant 
(containing the fragmented DNA) was obtained for further analysis.  To confirm the size of the 
DNA fragment in the sonicated chromatin, the DNA was purified, as described below, and 
electrophoresed on a 1% agarose gel and visualisation with ethidium bromide.  The sonicated 
chromatin was either used immediately for further analysis or stored at 80°C. 
 
In order to pre-block the protein A/G PLUS beads (sc-2003 Santa Cruz Biotechnology USA), 
500 l pure beads were incubated with 100 g salmon sperm DNA (Invitrogen) and 1 mg/ml 
BSA (Roche) in 2 ml IP dilution buffer (0.01% (w/v) SDS, 20 mM Tris-HCl pH 8.0, 1.1% (v/v) 
Triton X-100, 167 mM NaCl, 1.2 mM EDTA and 1x protease tablet per 10 ml) for 1 hour at 4°C 
on a rotating wheel.  Thereafter the beads were centrifuged at 5 500 x g for 1 minute at 4°C and 
resuspended as 50% slurry in IP dilution buffer.  
 
DNA quantification of the sonicated chromatin was performed by means of optical density 
readings at 260 nm.  For the input samples, 30 g chromatin was made up to 30 l with nuclear 
lysis buffer and diluted with 90 l IP elution buffer (1% (w/v) SDS and 100 mM NaHCO3).  The 
cross-links were reversed and the input DNA was purified as described below.  For the 











buffer and diluted by adding 950 l IP dilution buffer.  Thereafter the sample chromatin (1 ml) 
was pre-cleared by adding 20 l of a 50% slurry of pre-blocked protein A/G PLUS beads and 
incubated for 1 hour at 4°C on a rotating wheel to reduce non-specific binding.  The pre-cleared 
chromatin was collected by means of centrifugation at 15 000 x g for 10 minutes, and incubated 
with 5 g anti-GR (H300, sc-8992), anti-HA (12CA5) or anti-IgG antibody (sc-2350) overnight 
at 4 °C on a rotating wheel.  The following day, the protein-DNA complexes were incubated with 
40 l of 50% slurry pre-blocked protein A/G PLUS beads for 6 hours at 4°C on a rotating wheel, 
followed by centrifugation at 5 500 x g for 1 minute at 4°C.  The bead pellet, containing the 
protein-DNA complexes, was washed once with 1 ml wash buffer I (0.1% (w/v) SDS, 1% (v/v) 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0 and 150 mM NaCl), followed by washing 
with 1 ml wash buffer II (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl pH 8.0 and 500 mM NaCl) .  Thereafter, it was washed with 1 ml wash buffer III (1% (v/v) 
NP-40, 1% (w/v) sodium deoxycholate, 500 mM LiCl, 1 mM EDTA and 10 mM Tris-HCl pH 
8.0), followed by three washes with 1 ml TE (10 mM Tris pH 8.0 and 0.1 mM EDTA). In order 
to elute the protein-DNA complexes from the beads, containing the protein-DNA complexes, the 
beads were incubated twice with 150 l IP elution buffer for 15 minutes at RT on a rotating 
wheel, followed by centrifugation at 15 000 x g for 10 minutes. 
 
To reverse the cross-links, NaCl (to a final concentration of 300 nM) was added to the input and 
immunoprecipitated DNA, before overnight incubation at 65°C. The following day an 
appropriate volume of 0.5 M EDTA (to a final concentration of 15 nM EDTA) and 1 M Tris pH 
6.5 (final concentration 125 nM Tris), as well as 1 l (thus 10 g) or 2 l (thus 20 g) proteinase 
K (10 g/l stock) (Roche, South Africa) were added to the input and immunoprecipitate, 











QIAquick PCR Purification Kit (Qiagen, USA) according to the manufacturer’s instruction.  
Conventional and quantitative Real-Time PCR was performed using specific primers spanning 
the GRE region of the MMTV promoter (forward 5’-AAC CTT GCG GTT CCC AG-3’; reverse 
5’-GCA TTT ACA TAA GAT TTG G-3’) (Kino et al., 2007).   
 




Each conventional PCR reaction contained the following: 
 
Input DNA / precipitated DNA  1 l / 2 l 
Forward primer    0.2 M 
Reverse primer    0.2 M 
dNTP Mix     0.05 M of each dNTP final 
MgCl2      1 mM 
5x GoTaq buffer (Promega)   1 x 
GoTaq Flexi DNA polymerase (Promega) 1.25U 
PCR H2O     Make up to a final volume of 50 l 
 
After conventional PCR, the amplified DNA was analysed on a 1.5% agarose gel by means of gel 
















Each Real-Time PCR reaction contained the following: 
 
Input DNA / precipitated DNA  0.5 l / 1 l 
Forward primer    0.5 M 
Reverse primer    0.5 M 
SensiMixdT (Quantace)   12.5 l 
PCR H2O     Make up to a final volume of 25 l 
 
In order to assess the relative amount of protein recruitment to the MMTV promoter, the “Fit 
Points” method, described by Pfaffl was used to normalise the inputs in the quantitative Real-
time PCR (Pfaffl, 2001), using the following equation: Response (fold) = [2(Ct EtOH - Ct Dex) IP / 2(Ct 
EtOH – Ct Dex) Input]. Herein the relative amount of specific DNA immunoprecipitated, as measured 
by the crossing points (Ct) from quantitative real-time PCR, of the vehicle sample was subtracted 
from the dex-treated sample.  Similarly, the difference between the vehicle input and dex-treated 
sample was calculated.  Thereafter, the relative ‘fold’ dex-induction in the immunoprecipitate 














3.19 Subcellular fractionation   
 
COS-1 cells were plated into 6-well plates (NUNC, AEC Amersham, South Africa) at a density 
of 3x105 cells/well, in DMEM containing 10% fetal calf serum and antibiotics, as described 
above.  After 24 hour incubation the cells were transfected with 1 g of either pRS-hGRwt, pRS-
hGR3A or pcDNA3.1 (empty vector) using FuGENE 6 (Roche, South Africa) according to the 
manufacturer’s instructions.  The following day the cells were treated with 100 nM dex or vehicle 
(EtOH) for 1 hour, washed once with PBS, resuspended in a low ionic strength buffer (10 mM 
HEPES pH 7.9, 1.5 mM MgCl2, 10 mM DTT and 0.05% NP40) and incubated on ice for 10 
minutes.  For the inputs, 10 l of each sample was removed and boiled in 1x SDS sample 
treatment buffer for 5 minutes.  Thereafter the nuclear pellet and cytoplasmic fractions of the 
remaining cellular fractions were separated by centrifugation at 3000 rpm for 5 minutes and the 
supernatant removed (cytoplasmic fraction).  Typically, 10% of the total volume of the nuclear 
fraction, as well as 10% of the total cytoplasmic fraction, was separated by SDS-PAGE.  Western 
blotting was performed using anti-GR (H300, Santa Cruz Biotechnology, USA), anti-GAPDH 
(14C10, Cell Signaling, South Africa) and anti-histone H3 (ab1791, Abcam, UK) antibodies. 
 
 
3.20 Statistical Analysis 
 
Statistical analyses were carried out using GraphPad Prism software (version 5), using one-way 
ANOVA analysis of variance with either Bonferroni (when comparing all values to each other) or 
Dunnett (when comparing all to values to a single control) post tests.  Correlation analyses were 











indicate P < 0.05, P < 0.01 or P < 0.001, respectively when differences were compared to a single 
control (Dunnett post test).  Statistical significance, when comparing all values to each other 
(Bonferroni), is indicated by different lower-case letters, such that all the conditions with the 
same letter are not statistically significantly different from each other (P > 0.05), while those 
having different letters are statistically significantly different from each other (P < 0.05).  
Fractional occupancy of the GR for each compound was calculated using 
[ligand]/([ligand]+RBA), where the RBA was obtained from Ronacher et al. 2009 ((Ronacher et 
















Upon binding of dex, the GR becomes hyperphosphorylated and the active GR moves into the 
nucleus, where it is able to regulate transcription of GC-responsive genes (Hoeck et al., 
1989;Bodwell et al., 1995;Webster et al., 1997;Wang et al., 2002b;Kino et al., 2007).  Studies 
have shown that dex-dependent phosphorylation occurs mainly at S203, S211 and S226 of the 
hGR and that dex-mediated GR phosphorylation regulates the transcription of GC responsive 
genes (Orti et al., 1989;Bodwell et al., 1995;Blind and Garabedian, 2008).  However, few studies 
have examined the effect of a wide panel of GR ligands on S211 phosphorylation, using at most 
three GR agonists (dex, predn and fluocinolone) and two antagonists (RU468 and ZK299) (Wang 
et al., 2002b), making it difficult to accurately determine whether GR phosphorylation on S211 
correlates with biological activity.  Furthermore, at the time this study was initiated, the effect of 
different ligands on S226 phosphorylation was still undetermined. However, recently a study has 
been published, using two agonists (dex and cort), one full/partial agonist (ald) and one partial 
agonist (prog) (Chen et al., 2008).      
 
The main aims of this section were to determine if GR phosphorylation at S226 occurs in a 
ligand-selective manner and whether ligand-selective phosphorylation at S226 determines the 
rank order of ligand-selective GR-mediated transcription.  Ligand-selective efficacy for 
transactivation in COS-1 cells, with the HA-hGR and the panel of ligands, is shown in table E5 
of addendum E and forms the basis upon which the biological activity of the ligands is defined. 











shown to occur in a ligand-selective pattern, in that agonists phosphorylated the GR the most and 
antagonists phosphorylated the GR the least at S211 ((Stubsrud, 2005); Table E1 in addendum E 
contains data from E. Stubsrud that will be used by the candidate for some analyses).  
Furthermore, phosphorylation at S211 was shown to be required for full transactivational 
efficacy, in that mutation of S211 resulted in a 50% decrease in transactivational efficacy, but 
was found not to determine the rank order of ligand-selective GR-mediated transactivation 
((Stubsrud, 2005); Table E2 in addendum E). In other words, when S211 was mutated and could 
no longer be phosphorylated, the same relative pattern of ligand-selective transactivation efficacy 
was obtained.  This thesis, will therefore not show results on ligand-selective S211 
phosphorylation, and the transactivational response of the S211A mutant with different GR 
ligands and will refer to results obtained by E. Stubsrud.  However, work done by the present 
author on S211 other than that performed by E. Stubsrud will be presented in this thesis.  
 
 
4.1 Ligand-selective hGR phosphorylation 
 
The effect of a wide panel of GR ligands on S211 phosphorylation has been shown ((Stubsrud, 
2005); Table E1 in addendum E).  Additionally, Wang et al. indicated that phosphorylation at 
S203 is only weakly increased upon dex stimulation and therefore this study focussed mainly on 
the effects of a wide panel of GR ligands on S226 phosphorylation (Wang et al., 2002b).   A 
phospho-S226-GR-specific antibody (P-S226) was used in the present study. To show the 
specificity of this antibody, COS-1 cells transiently transfected with hGR wt or S226A mutated 
GR were treated with dex for one hour.  Thereafter the cells were harvested and Western blotting 











phosphorylated at S226 and becomes hyperphosphorylated at S226 upon stimulation with dex 
(Fig. 4.1).  Both the unliganded and dex-stimulated S226A mutant GR did not show any S226 
phosphorylation, indicating that the P-S226 antibody is highly specific and that there is no 
endogenous wt GR in the COS-1 cells detectable by this method.   
 
       
Figure 4.1  Specificity of the P-S226 antibody.  COS-1 cells were plated in a 6-cm dish at a density of 
7x105 cells/dish and transfected with 3.5 g HA-hGRwt or HA-hGRS226A per dish.  After 24 hours, the 
cells were replated into 6-well plates at a density of 4x105 cells/well and treated with 10 M dex or 
vehicle (EtOH) for 1 hour.  Whole cell extracts were prepared and equal amounts of protein (20 g) was 
separated on a 10% SDS-PAGE.  The proteins were transferred onto a nitrocellulose membrane and 
analyzed by immunoblotting with P-S226, stripped and reprobed for total GR.  
 
In order to determine whether S226 phosphorylation is GC dose-dependent, ligand-mediated 
S226 phosphorylation experiments were done using 10 M compound, as well as 100 nM 
compound. The same panel of GR ligands, as part of the larger investigation (see Thesis 
Rationale, Aims and hypotheses table 2.1), was used in this study. Briefly, this panel consists of 
three full agonists (dex, cort and predn), two full/partial agonists (ald and MPA), two partial 
agonists (AL438 and prog), two dissociated ligands (RU486 and CpdA) and three antagonists 
(NET, DO6 and UDCA). Results show that the unliganded GR is basally phosphorylated, but 
becomes hyperphosphorylated upon stimulation with 10 M (Fig. 4.2 A) or 100 nM (Fig. 4.2 B) 
agonist.  Furthermore, it can clearly be seen that different ligands result in ligand-selective 
differences in GR phosphorylation at S226, where the agonists (dex, cort and predn) result in the 
greatest extent of phosphorylation, whereas the antagonists (NET and DO6) results in only 














minimal phosphorylation of the GR.  After quantification and normalisation, the results with 10 
M test compound (Fig. 4.2 C) show that the full agonists dex, cort and predn induced the most 
phosphorylation (100%, 122% and 85%, respectively), followed by the full/partial agonists ald 
and MPA (60% and 44%) and the partial agonists AL438 and prog (34% and 48%).  The 
antagonists NET, DO6 and UDCA (5%, 0% and 8%), as well as the dissociated GC ligand CpdA 
(14%) resulted in little to no increase in S226 phosphorylation.  Interestingly, the dissociated 
compound RU486 resulted in relatively high levels (44%) of S226 phosphorylation, similar to 
that found with the full/partial or partial agonists.  Quantification and normalisation of the results 
obtained with 100 nM test compound also showed that the full-, full/partial- and partial agonists 
resulted in more phosphorylation that the dissociated compounds and the antagonists, however 
this was not as clear as with the 10 M (Fig. 4.2 D).   
 
When comparing figure 4.2 A and figure 4.2 B with the full agonists, it is obvious that the 
amount of S226 phosphorylation with cort (46%) at 100 nM, is significantly less than that 
observed with 10 M test compound (122%).  Additionally, the partial agonist prog did not result 
in any S226 phosphorylation at 100 nM.  The differences between the phosphorylation results 
obtained with 10 M and 100 nM could partly be explained by variations in the fractional 
occupancy or the percentage of GR molecules occupied by ligand.  Due to the RBAs of these 
compounds to the GR (IC50 cort 152 nM; IC50 prog 274 nM; Table E4 in addendum E), the 
fractional occupancy of the GR with cort and prog at 100 nM is 83% and 73%, versus 99.8% and 
99.6%, respectively at 10 M.  Accordingly, ald and NET (IC50 ald 1130 nM and IC50 NET 
1688 nM; Addendum E) which have a fractional occupancy at 100 nM of 42% and 34%, should 
also result in less S226 phosphorylation at 100 nM, as compared to 10 M where they have a 











S226 phosphorylation for ald with 10 M and 100 nM, as well as for NET with 100 nM, it is 
difficult to accurately determine whether the amount of phosphorylation is less with 100 nM than 
with 10 M.   
 
A (10 M) 
 
B (100 nM) 
 


















































   
   
   





























































   
   
   











Figure 4.2  Phosphorylation of the human GR at S226 in COS-1 cells.  COS-1 cells plated a 6-cm 
dishes were transiently transfected with 3.5 g HA-hGRwt. After 24 hour incubation, the cells were 
replated into 12-well plates and incubated an additional 24 hours.  Thereafter the cells were stimulated 
with 10 M (A) or 100 nM (B) test compound, or vehicle (EtOH), for 1 hour.  Whole cell extracts were 











before membranes were stripped and reprobed with an antibody detecting total GR.  After quantification, 
the basal phosphorylation (EtOH control) was subtracted from each test compound, the phosphorylation 
induced by 10 M (C) or 100 nM (D) dex was set as 100 % and the phosphorylation induced by the other 
test compounds was calculated relative to dex.   The Western blots in (A) and (B) are representative 
figures of three independent experiments, whereas data presented in graphs (C) and (D) are presented as 
mean  SD of three independent experiments. Statistical significance is denoted by *, ** or ***, to 
indicate P < 0.05, P < 0.01 or P < 0.001, respectively. 
 
However, differences in fractional occupancy alone, cannot account for the differences seen 
between the 100 nM and 10 M results.  If the amount of S226 phosphorylation at 100 nM and 
10 M for cort and prog is plotted against their respective fractional occupancies, at those ligand 
concentrations, it is clear that the percentage decrease in S226 phosphorylation is much more 
than the decrease in fractional occupancy (Fig. 4.3). With prog the difference in S226 
phosphorylation (52%) is roughly 2x the difference in fractional occupancy (26%), whereas the 
difference in S226 phosphorylation with cort (76%) is roughly 5x the difference in fractional 
occupancy (16%).  This indicates that not only is the “relationship” between fractional occupancy 
and S226 phosphorylation not linear, but that the “relationship” is different for the respective 
ligands. Consequencely, something other than fractional occupancy, which occurs in a ligand-
selective manner, is responsible for the differences between the amount of S226 phosphorylation 
at 100 nM vs. 10 M.  













Figure 4.3 Comparison between the amount of S226 phosphorylation and fractional occupancy with 
cort and prog.  The amount of S226 phosphorylation with cort and prog at 100 nM, as well as 10 M, 
was plotted against the respective fractional occupancy of cort and prog at 100 nM and 10 M.  
 
The results with 10 M compound show the effects on GR phosphorylation at S226 without the 
complicating effect of differential fractional occupancy, as all the ligands saturate the receptor at 
this concentration (except for DO6 with a fractional occupancy of 80.5%; Table E4 in addendum 
E).  There is a general trend that the full agonists result in the most S226 phosphorylation, 
followed by the full/partial agonists, the partial agonists, the dissociated ligands and the 
antagonists.    
 
Reports in the literature suggest that the effect of phosphorylation on GR transactivation could be 
cell-specific (Mason and Housley, 1993;Webster et al., 1997;Chen et al., 2008;Kino et al., 2007).  
In order to determine whether there are cell-specific differences in S226 phosphorylation itself, 
the 10 M S226 phosphorylation experiment was repeated in U2OS cells stably expressing hGR.  
As was found with the S226 phosphorylation results in COS-1 cells, the GR is basally 
phosphorylated in the absence of hormone and becomes hyperphosphorylated upon dex treatment 
(Fig. 4.4 A).  Furthermore, the agonists dex and cort resulted in the highest amount of S226 











phosphorylation, which is consistent with the results obtained in the COS-1 cells.  However, after 
quantification and normalisation, it is evident that there are some differences (Table 4.1) from the 
results obtained in COS-1 cells (Fig. 4.4 B).  For instance, 10 M of the full agonist predn 
resulted in relatively less S226 phosphorylation in the U2OS cells as compared to the COS-1 
cells (31% versus 75% as compared to dex).  Another striking difference is that 10 M of the 
full/partial agonist MPA and the antagonist NET resulted in relatively more S226 
phosphorylation, compared to dex, in U2OS versus COS-1 cells, giving phosphorylation patterns 
expected of a full agonist and a full/partial agonist, respectively.  However, the test compounds 
were classified by their relative efficacy for transactivation in COS-1 cells.  Cell-specific 
differences, other than phosphorylation itself, could influence the ability of a ligand to 
transactivate.  Cell-specific differences, such as GR protein levels, would therefore likely affect 
the relative efficacy of partial agonists for transactivation and in order to further examine the 
relationship between phosphorylation and transactivation in U2OS cells, one would have to 
compare phosphorylation in U2OS cells to the efficacy for transactivation in U2OS cells. For 
instance, the full/partial agonist MPA can switch from a partial agonist to a full agonist, 
depending on the relative amounts of GR (Fig. D1 in addendum D).  In the literature, similar 
results have been obtained for MPA. The dissociated ligand RU486 has also been shown to 
switch to full agonist activity, depending on the amount of GR in the cell (Zhao et al., 
2003;Zhang et al., 2007).  However, a direct comparison between the relative amount of GR in 
the transiently transfected COS-1 cells versus the stably transfected U2OS cells was not done. 
Furthermore, differences in GR levels alone would not account for differences in S226 
phosphorylation with the full agonist, predn.  As mentioned earlier, the ligands were classified 
according to their efficacy for transactivation in COS-1 cells.  Nevertheless, in U2OS cells, predn 











interesting, and suggest cell-specific differences, other than GR levels, such as differential kinase 







Figure 4.4  Phosphorylation of the human GR at S226 in U2OS cells.  U2OS cells stably expressing 
HA-hGRwt were stimulated with 10 M test compound or vehicle (EtOH), for 1 hour.  Whole cell 
extracts were prepared and equal amounts of protein (20 g) were analyzed by Western blotting with P-
S226 antibody, as well as an antibody detecting total GR (A).  After quantification, the basal 
phosphorylation (EtOH control) was subtracted from each test compound, the phosphorylation induced by 
dex was set as 100 % and the phosphorylation induced by the other test compounds was calculated relative 
to dex (B).  The Western blot (A) is one representative of three independent experiments and data in 
histogram (B) is presented as mean  SD of three independent experiments. Statistical significance is 











Table 4.1  Summary of S226 phosphorylation by the panel of ligands compared to dex.  The basal 
phosphorylation (EtOH) control is subtracted and dex was set to 100%.   
 
 
Nevertheless, results show ligand-selective S226 phosphorylation at saturating concentrations for 
all ligands and sub-saturating concentrations for some ligands in COS-1 cells, as well as at 
saturating concentrations in U2OS cells.  Furthermore, there is a general trend that the most 
efficacious ligands resulted in the most S226 phosphorylation and the least efficacious ligands 
resulted in the least amount of S226 phosphorylation in COS-1 cells (Table 4.1).  This trend in 
ligand-selective GR phosphorylation is not simply due to differences in binding affinity of the 
ligand for the GR, since the same trend was observed at saturating concentrations of ligand.  
Additionally, there are some numerical outliers between the COS-1 and U2OS cells, suggesting 
cell-specific differences in S226 phosphorylation. 
 
At the time this work was done, the effect of different ligands on GR phosphorylation at S226 











has recently been published in U2OS cells (Chen et al., 2008). The results presented in this 
section with dex, cort, prog and ald are consistent with those of Chen et al. and also show the 
effect of 8 additional ligands on S226 phosphorylation, where there is a general trend that the 
most efficacious ligands result in the most GR phosphorylation at S226.  Furthermore, the effect 
of increasing amounts of dex on S226 phosphorylation has not previously been shown and this 
thesis shows for the first time, the effect of different ligand concentrations on GR 
phosphorylation at S226, with a whole panel of GR ligands. Results showed numerical 
differences between the different ligand concentrations, which was shown to partially reflect 
different fractional occupancy of the receptor.  However, the same general ligand-selective 
pattern of GR phosphorylation at S226 was found at sub-saturating concentrations for some 
ligands, as well as saturating concentrations for all the ligands, indicating that ligand-selective 
GR phosphorylation at S226 is not only due to differences in receptor binding affinity. It is likely, 
that ligand-binding induces different conformational changes of the GR, with some 
conformations allowing for better interactions between the GR and kinases or phosphatases, 
thereby resulting in ligand-selective GR phosphorylation at saturating ligand concentrations.  
However this remains to be tested.  Nevertheless, these results suggest that with any given GR 
ligand, at any sub-saturating ligand concentration, the amount of GR phosphorylation at S226 
will reflect a combination of fractional occupancy, as well as a ligand-specific contribution to 
phosphorylation (e.g. resulting from a particular GR-ligand conformation).  
 
In addition, although cell-specific differences in the extent of GR phosphorylation have 
previously been proposed (Rogatsky et al., 1998a), this thesis shows for the first time in a 
comprehensive study with a wide panel of GR ligands, that there are cell-specific differences in 
the extent of S226 phosphorylation.  These cell-specific differences are not due to species-











amount of GR protein, as explained above, and therefore likely reflect cell-specific differences in 












4.2  Role of hGR phosphorylation in ligand-selective GR transcriptional      
activity 
 
Having shown ligand-selective S226 phosphorylation in COS-1 cells, it was next determined 
whether ligand-selective S226 phosphorylation correlates with ligand-selective GR 
transcriptional activity in COS-1 cells.  In order to determine this, correlation analysis between 
the 10 M COS-1 phosphorylation results and results on GR transactivation and transrepression 
activity (Table E5 in addendum E) was performed. 
 
 
4.2.1 Correlation analysis between ligand-selective GR phosphorylation at S226 and ligand-
selective GR-mediated transcriptional activity 
 
In order to correlate the S226 phosphorylation results with ligand-selective GR transactivation, 
transactivation data ((Stubsrud, 2005); Table E5 in addendum E), obtained in COS-1 cells using 
the same HA-hGR and TAT-GRE constructs, were used. Correlation analysis between GR 
phosphorylation at S226 and efficacy for transactivation, revealed a good and statistically 
significant correlation (R2 = 0.73, p = 0.0004) for all of the test compounds (Fig. 4.5 A).  The 
antagonists DO6, UDCA and NET do not transactivate, which correlates with no S226 
phosphorylation.  By excluding the antagonists for transactivation (compounds that do not 
transactivate) from the correlation analysis, in order to determine if there is a correlation for the 
compounds that do show transcriptional efficacy, a weaker but still statistically significant 
correlation is observed (R2 = 0.61, p = 0.0135).  This result indicates that there is a correlation 











GR-mediated transactivation.  Correlation analysis of potency for transactivation and S226 
phosphorylation also indicates a statistically significant correlation between potency for 
transactivation and S226 phosphorylation (Fig. 4.5 B).  However, this correlation (R2 = 0.60, p < 
0.0031) is not as strong as between efficacy for transactivation and S226 phosphorylation.  
However, when the antagonists for transactivation (no transactivational potency) are excluded, no 






Figure 4.5  Correlation between S226 phosphorylation with 10 M compound and potency and 











transactivation data obtained in COS-1 cells ((Stubsrud, 2005); Table E5 in addendum E).  
Phosphorylation is correlated with efficacy (A) and potency (B). 
 
In order to accurately determine the role of S226 phosphorylation on hGR mediated 
transrepression, two different transrepression promoters (AP-1 and NFB) were studied.  To 
correlate the S226 phosphorylation results with ligand-selective transrepression via AP-1 and 
NFB proteins, transrepression data from this lab, obtained in COS-1 cells with the same HA-
hGR, as well as either AP-1 or NFB promoter-reporter constructs, were used (K. Ronacher; 
Table E5 in addendum E).  Correlation analysis between GR phosphorylation at S226 and 
efficacy for transrepression via AP-1, revealed a good and statistically significant correlation (R2 
= 0.71, p = 0.0006) for all of the test compounds (Fig. 4.6 A).  Similar to the transactivation 
correlation, exclusion of the antagonists for transrepression (no transrepression) resulted in a 
slightly weaker, but still statistically significant correlation (R2 = 0.51, p = 0.0299) (Table 4.3).  
This correlation shows, that the inclusion of the compounds that do not transrepress or 
phosphorylate the GR at S226 in the correlation with all the ligands, did not give a false positive 
correlation and that there is a correlation between GR phosphorylation at S226 and GR-mediated 
transrepression efficacy, for all the ligands that result in transrepression. Consistent with the 
transactivation correlation, correlation analysis of potency for transrepression on AP-1 and the 
degree of phosphorylation at S226 also indicates a statistically significant correlation (Fig. 4.6 B).  
However, this correlation (R2 = 0.46, p = 0.0159) is not as strong as between efficacy for 
transrepression and S226 phosphorylation. Additionally, when the antagonists for transrepression 
(no transrepression potency) are excluded, no correlation was found, indicating, as was the case 
for transactivation, that for the compounds that do transrepress, there is not a correlation between 











compounds that do not transrepress or phosphorylate the GR at S226 in the correlation with all 






Figure 4.6  Correlation between S226 phosphorylation with 10 M compound and potency and 
efficacy for AP-1 transrepression in COS-1 cells.  Data from the phosphorylation studies was correlated 
with transrepression data obtained in COS-1 cells (K. Ronacher; Table E5 in addendum E). 
Transrepression efficacy (A) and potency (B) values were calculated by plotting dose-response curves 
with the different ligands, subtracting the vehicle background and the potency or efficacy for 
transrepression were calculated as –log EC50 (nM) or relative efficacy with wt dex set to 100%. 
 
Similarly, statistically significant positive correlations between S226 phosphorylation and 











However, when the antagonists were excluded from the correlations, no correlation between GR 
phosphorylation and efficacy or potency for transrepression via NFB was found.  This is 
interesting and indicates that the compounds that do not transrepress via NFB, led to a false 
positive correlation between GR phosphorylation and efficacy or potency for transrepression via 
NFB. In addition, this correlation suggests that for all the compounds that do transrepress via 
NFB, there is no statistically significant correlation between efficacy or potency for 
transrepression via NFB and GR phosphorylation at S226. 
 
Table 4.3 Summary of S226 phosphorylation and transcription correlation analysis (R2 values)‡.  
 
 
Taken together these correlations indicate a positive correlation between GR phosphorylation at 
S226 with efficacy, but not potency for transactivation for all the ligands that result in GR-
mediated transactivation. Similarly positive correlations between GR phosphorylation at S226 
with efficacy, but not potency for transrepression via AP-1 were obtained while no correlation 
between GR phosphorylation at S226 and efficacy or potency for transrepression via NFkB was 
obtained, for all the ligands that result in GR-mediated transrepression.   
 
                                                  
‡ Values were obtained from correlation analysis, with R2 values shown and statistical significance 












One interpretation of these correlations is that ligand-selective GR phosphorylation at S226 
influences or plays a determining role in ligand-selective efficacy, but not potency, for 
transactivation and transrepression (for AP-1, but not NFB).  On the other hand, these 
correlations could indicate that ligand-selective efficacy, but not potency, for transactivation and 
transrepression (for AP-1, but not NFB) influences or plays a determining role in ligand-
selective GR phosphorylation at S226.  In other words, the degree of S226 phosphorylation per se 
could determine the transcriptional response, if phosphorylation occurs before transcription, or 
the transcriptional response could determine the extent of S226 phosphorylation, if 
phosphorylation occurs after transcription.  Additionally, these correlations could simply indicate 
that both ligand-selective GR phosphorylation at S226 and efficacy, but not potency, for 
transactivation and transrepression (for AP-1, but not NFB) are mediated by the same ligand-
selective “determining step” and that ligand-selective GR phosphorylation and efficacy for 
transactivation and transrepression are not functionally linked to each other.  Such a ligand-
selective “determining step” could be a particular ligand-induced GR conformation, wherein, 
ligand-binding causes a particular conformational change in the GR (in agreement with literature 
on crystal structures) and these conformational changes determine both the extent of S226 
phosphorylation and transactivation and transrepression (for AP-1, but not NFB).  Accordingly 
ligand-selective S226 phosphorylation and ligand-selective transcription would both be indicative 
of a particular GR conformation. Nevertheless, all of the above mentioned interpretations suggest 
a different mechanism of ligand-selective GR action on AP-1 vs. NFB. Additionally, 
phosphorylation did not correlate with potency for transactivation or transrepression (minus 
antagonists).  This is very interesting and suggests that another factor, other than 
phosphorylation, influences potency for transactivation and transrepression.  Ronacher et al. 











with the full and full/partial agonists (Ronacher et al., 2009). It is therefore likely that ligand-
selective RBAs are the major contributing factor to potency, but not efficacy, for transactivation 
and transrepression, explaining the lack of a correlation between ligand-selective GR 
phosphorylation and potency for transactivation and transrepression. 
  
 
4.2.2 Role of ligand-selective GR phosphorylation in ligand-selective GR-mediated 
transactivation 
 
In order to determine if ligand-selective GR phosphorylation at S226 determines the rank order of 
ligand-selective efficacy for transactivation, the ability of a S226 GR mutant (S226A), which can 
no longer be phosphorylated on S226, was compared with the ability of wt receptor to 
transactivate a TAT-GRE reporter-promoter construct. COS-1 cells transiently transfected with 
hGR wt or S226A, as well as a TAT-GRE-reporter construct, were stimulated with increasing 
amount of dex.  After 16 hours, luciferase activity was measured and normalised to total amount 
of protein.  Results show typical dex dose-response curves for both wt and S226A mutant (Fig. 
4.7).  When comparing wt and S226A mutant it can clearly be seen that the S226A mutant has a 
much higher efficacy (~ 2.8 fold more than wt), indicating that S226 phosphorylation inhibits 
transactivation efficacy.  Interestingly, the wt and S226A mutant had similar potencies (EC50s of 
6.96e-10 M and 2.8e-9 M), which are not statistically significantly different from each other.  This 
result is consistent with the correlations, wherein GR phosphorylation at S226 influences or plays 
a determining role in efficacy, but not potency, for transactivation.  However, the correlation 
analysis gave a positive correlation, indicating that the more GR phosphorylation at S226, the 
higher the efficacy.  In contrast, results obtained with the mutant receptor indicate that S226 











indicate that ligand-selective phosphorylation per se does not determine ligand-selective efficacy 
for transactivation, but rather reflects a particular conformation that determines ligand-selective 
transactivation.     
 
 
Figure 4.7  Comparison between GR-dependent transactivation with wt receptor and the S226A 
mutant receptor in COS-1 cells.  COS-1 cells were plated in 10-cm dishes at a density of 2x106 
cells/dish and transfected with 10 µg HA-hGRwt or HA-hGRS226A and 3.75 µg TAT-GRE.  After 24 
hours, the cells were replated into 24-well plates and incubated for another 24 hours.  Thereafter the cells 
were treated with vehicle (EtOH) or the indicated concentrations of dex. After 16 hours, luciferase activity 
was assayed.  Bradford protein determination was performed to normalize for equal protein concentrations 
in each well.  Dose-response curves with wt and the mutant receptor were performed three times with each 
value in triplicate plotted as means  SEM, expressed as relative luciferase activity (10 M dex with wt 
GR set as 100 %). 
 
Having shown that S226 phosphorylation influences efficacy, but not potency for transactivation, 
the efficacy for transactivation of wt and the S226A mutant for the different ligands were 
determined.  For wt receptor, results show that the agonists dex, cort and predn are the most 
efficacious (100%, 114% and 96%, respectively), followed closely by the full/partial agonists ald 
(91%) and MPA (89%) (Fig. 4.8). Thereafter it is the partial agonist prog (43%) and the 











not transactivate.  Consistent with the results in figure 4.7, the S226A mutant had a much higher 
efficacy (~ 2.5 fold) than wt when stimulated with dex.  Interestingly, the S226A mutant had an 
efficacy of ~ 2.5 fold higher than wt efficacy for all the compounds that were able to 
transactivate.  This resulted in the ligands having the same “rank order” in efficacy as with wt 
receptor.  Since the S226A mutant cannot be phosphorylated on S226, but still shows the same 
ligand-selective efficacy for transactivation pattern as wt, and since the S226A mutant did not 
influence potency for transactivation, it can be concluded that ligand-selective S226 
phosphorylation does not determine ligand-selective transactivation.  In other words, the 
percentage of GR molecules phosphorylated at S226, with any particular ligand, does not 
determine the transactivational response of the particular ligand.  However, GR phosphorylation 
at S226 does play a role in the maximal efficacy for transactivation, wherein phosphorylation at 
S226 inhibits maximal efficacy for transactivation for all the ligands.     
 
 
Figure 4.8  Comparison between GR-dependent transactivation efficacy with wt receptor and the 
S226A mutant receptor in COS-1 cells.  COS-1 cells were plated in 10-cm dishes at a density of 2x106 
cells/dish and transfected with 3.75 µg TAT-GRE and 10 µg HA-hGRwt or HA-hGRS226A.  After 24 
hours, the cells were replated into 24-well plates and incubated for another 24 hours.  Thereafter, the cells 
were treated with vehicle (EtOH) or 10 M compound. After 16 hours, luciferase activity was assayed.  











graph represents the average of the means of three independent experiments, each performed in triplicate 
with each value plotted as mean  SEM expressed as relative luciferase activity (with wt dex set as 100 
%).  Statistical analyses were carried out using GraphPad Prism software (version 5), using 2-tailed t-test, 
for selected pairs of columns, comparing wt and S226A GR mutant with different ligands. Statistical 
significance is denoted by *, ** or ***, to indicate P < 0.05, P < 0.01 or P < 0.001.  
 
As mentioned earlier, phosphorylation at S211 was found to be required for maximal efficacy for 
transactivation, wherein mutation of S211 resulted in a 50% decrease in efficacy for 
transactivation with all the ligands tested ((Stubsrud, 2005); Table E2 in addendum E).  It is 
therefore interesting to note, that inhibition of p38, the kinase reportedly responsible for 
phosphorylating the GR at S211 (Miller et al., 2005) resulted in a 50% decrease in efficacy for 
transactivation on the same TAT-GRE reporter promoter, in the same cells (K. Ronacher; Figure 
E2 in addendum E).  These results, together with the S211A transactivation results, are consistent 
with a model wherein p38-mediated phosphorylation of the hGR at S211 is required for maximal 
GR-mediated efficacy for transactivation. Furthermore, inhibition of JNK, the kinase reportedly 
responsible for S226 phosphorylation (Rogatsky et al., 1998b) resulted in a ~2 fold increase in 
transactivation efficacy on the same TAT-GRE reporter promoter, in the same cells (K. 
Ronacher; Figure E2 in addendum E).  These results, together with the S226A results, are 
consistent with a model where JNK-mediated phosphorylation of the hGR at S226, is inhibitory 
of maximal GR-mediated efficacy for transactivation.  Therefore, although ligand-selective GR 
phosphorylation does not determine the rank order of ligand-selective transactivation per se, 
phosphorylation on S211 and S226 have opposite effects on efficacy for transactivation and 
modulate the maximal amount of transactivation.  
 
Having shown that phosphorylation at S211 is needed for maximal transactivation efficacy 











transactivational efficacy, as well as the fact that it has previously been suggested that the three 
main GR phosphorylation sites in the LBD can compensate for each other (Wang et al., 2007b), 
the significance of their simultaneous mutation (S226A/S211A/S203A or 3A) on 
transactivational efficacy was next examined. The S203A mutation was included since earlier 
reports in the literature indicated that phosphorylation of S203 is also weakly increased upon dex 
stimulation (Wang et al., 2002b).   The absence of phosphorylation at S211 and S226 in this 
mutant construct was confirmed using GR phospho-serine-specific antibodies (Fig. 4.9).  
  
 
Figure 4.9 Specificities of the P-S211 and P-S226 antibodies.  COS-1 cells transiently transfected with 
either pRS-hGRwt or pRS-hGR3A were treated with vehicle (EtOH) or 100 nM Dex for 1 hour. Western 
blot analysis was performed using either an anti-P-S226 GR-specific antibody (A) or an anti-P-S211 GR-
specific antibody (B). Thereafter the membrane was stripped and reprobed with anti-GR antibody. 
 
COS-1 cells transiently transfected with hGR wt, S211A, S226A, or 3A as well as a MMTV 
reporter-promoter and -gal construct, were stimulated with dex for 16 hours, before luciferase 
and -galactosidase activities were determined.  As can be seen in figure 4.10, mutation of S211 
resulted in a decrease, whereas mutation of S226 resulted in an increase in transcription efficacy 
on the MMTV promoter, which is consistent with the results shown on the TAT-GRE construct 
with S211A ((Stubsrud, 2005); Table E2 in addendum E) and S226A.  Interestingly, the decrease 
seen with the S211 mutant is more prominent on the MMTV promoter, where it shows no 
statistically significant dex-induction, compared to the TAT-GRE construct where it decreased by 











much weaker on the MMTV promoter (Fig. 4.10).  These results show promoter-specific 
differences, between the TAT-GRE construct and the MMTV promoter, on the effect of 
phosphorylation at S211 and S226 on transcriptional efficacy, which is consistent with other 
reports in the literature (Webster et al., 1997).  On the MMTV promoter, the triple 
phosphorylation mutant showed a small, but not statistically significant dex-induction (Fig. 4.10), 
indicating that in this cell system, phosphorylation on S203, S211 and S226 is required for 
transactivation on this promoter.     
 
 
Figure 4.10  Relative transactivation efficacy on the MMTV promoter. COS-1 cells transiently 
transfected with either 0.125 g pRS-hGRwt, pRS-hGR3A, pRS-hGRS211A or pRS-hGRS226A, as well 
as 0.047 g MMTV reporter-promoter and 0.012 g gal constructs, were treated with vehicle (EtOH) or 
100 nM Dex for 24 hours.  Luciferase activity in the cell lysates was normalised to gal activity per well.  
The histogram shows pooled results from two independent experiments, where each condition was 
performed in triplicate, and average values were plotted as means ± SEM, expressed as fold induction 
(relative to EtOH = 1). Statistical significance is indicated by different lower-case letters, such that all the 
conditions with the same letter are not statistically significantly different from each other (P > 0.05), while 
those having different letters are statistically significantly different from each other (P < 0.05).   
 
Furthermore, the result with the S211A mutant is similar to that of the triple phosphorylation 
mutant, indicating that the requirement for S211 phosphorylation on transactivation efficacy is 











this promoter.  Having shown a functional role of GR phosphorylation on transactivation efficacy 
on two different promoters, the role of GR phosphorylation on ligand-selective GR 
transrepression was next examined. 
 
 
4.2.3 Role of ligand-selective GR phosphorylation in ligand-selective GR-mediated 
transrepression 
 
Ligand-selective S211 phosphorylation correlates with efficacy, but not potency for 
transrepression via AP-1 and NFB, for all the ligands that result in GR-mediated transrepression 
(Table E3 in addendum E).  Furthermore, results in this thesis showed that ligand-selective S226 
phosphorylation correlates with efficacy, but not potency for transrepression via AP-1, but not 
via NFB.  In order to shed more light on these correlations and to determine whether ligand-
selective GR phosphorylation at S226 and/or S211 determines ligand-selective GR-mediated 
efficacy for transrepression via AP-1 and/or NFB, COS-1 cells, transiently transfected with 
either hGR wt, S226A or S211A, as well as either an AP-1 or NFB reporter-promoter construct 
were stimulated with 10 ng PMA and increasing concentrations of dex.  After 24 hours, cells 
were harvested and luciferase and -galactosidase activity was measured.  Dose-response curves 
with wt and mutant receptors were plotted and the potencies and efficacies for transrepression 
were calculated.  Results on the AP-1 promoter show that both the S226A and S211A mutant had 
similar potencies to wt GR (EC50 values: 10.15 nM, 10.67 nM and 11.67 nM, respectively) (Fig. 
4.11 A).  Similarly, on the NFB promoter, the S226A and S211A mutants had EC50s of 10.89 
nM and 10.91 nM, which are similar to the value of 10.68 nM found for wt dex (Fig. 4.11 B).  











S211 do not influence potency for transrepression on the AP-1 and NFB promoters.  However, 
on the AP-1 promoter, both the S226A and S211A mutants had relative efficacies higher than 
that of wt (122.5% and 153.25%, as compared to wt) (Fig. 4.11 C).  Similarly, on the NF 
promoter, the S226A mutant had a higher efficacy (155%, as compared to wt), whereas the 
S211A mutant had a slightly lower efficacy (78%, as compared to wt).  Taken together, these 
results show that phosphorylation at S211 and S226 inhibits efficacy for transrepression via AP-
1, whereas phosphorylation at S226, but not S211 inhibits efficacy for transrepression via NFB. 
However, due to the relatively large experimental error, these differences were not statistically 
significant.  These results are not consistent with the positive correlation results between GR 
phosphorylation at S226 and efficacy for transrepression via AP-1 and NFB, which indicated 
that the more phosphorylation, the higher the efficacy for transrepression.  Similarly the positive 
correlation between phosphorylation at S211 and efficacy for transrepression via AP-1 indicated 
that the more S211 phosphorylation, the higher the efficacy for transrepression via AP-1. 
Nevertheless, these results indicate that GR phosphorylation at S211 and/or S226 plays a role in 
efficacy for transrepression on the AP-1 and/or NFB promoter.  
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Figure 4.11 Effect of mutating S211 and S226 on dex stimulated potency and efficacy for 











C           D 
 
Figure 4.11  Effect of mutating S211 and S226 on dex stimulated potency and efficacy for 
transrepression via the GR.  COS-1 cells were plated in 24-well plates at a density of 2.5x104 and 
transfected with 0.125 µg HA-hGRwt, HA-hGRS211A or HA-hGRS226A, 0.25 g AP-1 (A and C) or 
NFB (B and D) reporter-promoter and 0.012 µg -gal constructs per well.  Twenty-four hours post-
transfection the cells were treated with increasing concentrations of dex and 10 ng PMA/well. After 24 
hours, luciferase and -gal activity was assayed. -gal values were used to normalize for transfection 
efficiency.  Dose-response curves with wt and the mutant receptors were fitted, vehicle background was 
subtracted and the potency or efficacy for transrepression were calculated and plotted as –log EC50 (nM) 
(A and B) or relative efficacy with 10 M dex for wt GR set to 100% (C and D).  Graphs represent the 
average of three independent experiments, plotted as mean  SEM.  
 
In order to further investigate these potential differences in efficacy for transrepression, the 
transrepression efficacies for wt and mutant GR, in the presence of the panel of ligands, were 
determined under saturating ligand concentrations.  Results with wt GR on the AP-1 promoter, 
show that RU486 (classified as a dissociated compound) is a full agonist for transrepression and 
resulted in the most transrepression of about ~ 60% (Figs. 4.12 A and B).  The full/partial agonist 
MPA, as well as the full agonists dex, cort and predn also resulted in transrepression (~ 40%, 
40%, 30% and 30% repression, respectively).  The full/partial agonist ald and the partial agonist 
prog repressed very little (~ 20% and 10% repression), while the dissociated ligand CpdA and the 
antagonists NET and UDCA did not result in any transrepression.  Furthermore, there is a general 
trend that both the S226A and S211A mutants repressed more than wt in a statistically significant 











4.12 A and B, respectively). However, a similar ligand-selective pattern as wt was found with 
both the mutants.  Therefore, ligand-selective GR phosphorylation at S211 or S226, does not 
determine the rank order of ligand-selective GR transrepression via AP-1. Interestingly, with the 
dissociated ligand CpdA and the antagonists NET and UDCA, which do not cause 
transrepression by wt GR, the S226A mutant increased transcription in a statistically significant 
manner, while the S211A mutant did not. These results are not due to differential expression 
levels between wt and mutant GR, as expression levels were monitored throughout the thesis by 
means of Western blotting and were found to be similar (data not shown). The increase in 
transcription with the S226 mutant with CpdA, UDCA and NET is difficult to interpret, but 
suggests that there are some mechanistic differences in ligand-mediated GR transrepression via 
AP-1 between the agonists and partial agonists as compared to the dissociated ligand CpdA, as 
well as the antagonists NET and UDCA. Nevertheless, ligand-selective GR phosphorylation at 
S211A or S226A, plays an important role in mediating the efficacy for transrepression via AP-1, 
but does not determine the rank order of ligand-selective transrepression via AP-1.  
 
On the NFB promoter, very little repression with wt GR was obtained, e.g. with dex only 20% 
repression (Figs. 4.12 C and D).  Nevertheless, RU486 resulted in the most repression (~ 40% 
repression), followed by dex, ald, predn and MPA (~ 20%, 15%, 16% and 10%), whereas cort, 
prog, NET, CpdA and UDCA did not result in any transrepression.  Similar to the results 
obtained on the AP-1 promoter, results indicate a general trend wherein S226A and S211A 
repressed more than wt GR in a statistically significant manner for the full- and full/partial 
agonists, e.g. dex, predn, ald and MPA. Additionally on the NFB promoter, with prog and 
RU486, S226A, but not S211A repressed more than wt GR. Contrary to results obtained on AP-











some promoter-specific differences in the mechanism of GR-mediated transrepression on AP-1 
versus NFB for these specific ligands.  Taken together, these results indicate, that ligand-
selective GR phosphorylation at S211 or S226 does not determine the rank order of ligand-
selective transrepression via NFB.  Furthermore, these results with S226 are not consistent with 
the correlations, wherein no correlation between GR phosphorylation at S226 and efficacy for 
transrepression via NFB, for the ligands capable of transrepression, was found.  However, these 
results are consistent with the correlation between ligand-selective S211 phosphorylation and 





Figure 4.12  GR-dependent AP-1 and NFB efficacy for transrepression in COS-1 cells (continues 
























Figure 4.12  GR-dependent AP-1 and NFB efficacy for transrepression in COS-1 cells.  COS-1 cells 











hGRS211A or HA-hGRS226A, 0.25 g AP-1 or NFB reporter promoter and 0.012 µg -gal construct 
per well.  Twenty-four hours post-transfection the cells were treated with 10 ng PMA/well and either 10 
M of the indicated compounds or vehicle (EtOH). After 24 hours, luciferase and -gal activity was 
assayed. -gal values were used to normalize for transfection efficiency.  The AP-1 (S226A and S211A, 
A and B, respectively) and NFB (S226A and S211A, C and D, respectively) efficacies for 
transrepression were calculated and plotted as relative efficacy, with vehicle wt set to 100%.  Graphs 
represent the average of three independent experiments and are plotted as means  SEM. Statistical 
analyses were carried out using GraphPad Prism software (version 5), using a two-tailed t-test, with 
selected pairs of columns, comparing wt and phosphorylation mutant GR with different ligands. Statistical 
significance is denoted by *, ** or ***, to indicate P < 0.05, P < 0.01 or P < 0.001. 
 
Interestingly, inhibition of JNK, the kinase reportedly responsible for S226 phosphorylation, 
resulted in a statistically significant increase in dex-mediated efficacy for transrepression on the 
NFB promoter (K. Ronacher; Figure E2 in addendum E).  Inhibition of p38, the kinase 
reportedly responsible for S211 phosphorylation, resulted in a small but not statistically 
significant increase in dex-mediated efficacy for transrepression on the NFB promoter (K. 
Ronacher; Figure E2 in addendum E).    However, on the AP-1 reporter-promoter construct, 
inhibition of neither JNK nor p38 had any effect on dex-mediated efficacy for transrepression (K. 
Ronacher; Figure E2 in addendum E).  These results are consistent with a model, wherein p38- 
and JNK-mediated GR phosphorylation on S211 and S226, respectively, inhibits maximal 
efficacy for transrepression via NFB, but not AP-1.  The result with the inhibitors are in 
agreement with the results for NFB in figures 4.12 C and D, i.e. increased efficacy for 
transrepression with the phosphorylation mutants and is consistent with a model wherein p38- 
and JNK-mediated phosphorylation at S211 and S226 inhibits maximal efficacy for 
transrepression.  However, the inhibitor results are not in agreement with the results for AP-1 in 
figures 4.12 A and B, since an increased efficacy for transrepression was also found with the 











phosphorylation mutants vs. the kinases inhibitors on AP-1-mediated transrepression, could 
indicate that the kinases inhibitors are not completely inhibiting GR phosphorylation at S211 and 
S226 and that a complete loss of GR phosphorylation is needed to influence efficacy for 
transrepression via AP-1.  However, this is not the case on NFB-mediated transrepression, 
indicating slight differences between these two promoters, for example different proteins and 
pathways involved. On the other hand, these differences could indicate that the effect of the 
kinase inhibitors on NFB is not directly mediated by a loss in GR phosphorylation, but rather by 
an indirect effect of the kinase inhibitors.   
 
Having shown that phosphorylation at S211 and S226 inhibits maximal efficacy for 
transrepression via AP-1 and NFB, and in light of a report suggesting that the GR 
phosphorylation sites can compensate for each other (Wang et al., 2007b), the significance of 
their simultaneous mutation (3A) on transrepression efficacy was next examined. Due to the fact 
that very little transrepression was found with wt dex, only 20%, on the NFB reporter-promoter 
versus 40% on the AP-1 promoter, the effect of GR phosphorylation on S226, S211 and S203 
was only examined on the AP-1 reporter-promoter. Results show ligand-induced transrepression 
with wt, as well as the triple phosphorylation mutant GR, with the agonist dex giving the most 
transrepression (Fig. 4.13).  Interestingly, for wt and 3A receptor, the partial agonist prog 
appeared to result in similar or even more repression than the full/partial agonist MPA, although 
these differences were not statistically significant.  This is contrary to the previous findings on 
the AP-1 promoter (see figures 4.12 A and B, as well as Table E3 in addendum E), where MPA 
resulted in more transrepression than prog and could indicate methodological differences between 
these experiments.  However, the only difference between these experiments is the specific hGR 











relative expression levels of these two hGR constructs can account for these differences, however 
a direct comparison of the relative GR levels should first be performed.  Nevertheless, contrary to 
the transactivation efficacy with the triple phosphorylation mutant (Fig. 4.10), as well as efficacy 
for transrepression via AP-1 with the single phosphorylation mutants (Figs. 4.12 A and B), no 
statistically significant differences between wt and triple mutant receptor in efficacy for 
transrepression on AP-1 were found when comparing all the ligands.  However, there was a 
general trend with all the ligands investigated, that the triple phosphorylation mutant resulted in 
slightly more repression than wt receptor, and when only dex-mediated transrepression of wt and 
3A mutant GR was compared to each other, a small but statistically significant difference was 
found (Fig. 4.13).     
 
 
Figure 4.13  GR-dependent AP-1 efficacy for transrepression in COS-1 cells.  COS-1 cells were 
plated in 24-well plates at a density of 2.5x104 and transfected with 0.125 µg pRS-hGRwt or pRS-hGR3A, 
0.25 g AP-1 reporter-promoter and 0.012 µg -gal construct per well.  Twenty-four hours post-
transfection the cells were treated with vehicle (EtOH) or 10 M of the indicated compounds and 10 ng 
PMA/well. After 24 hours, luciferase and -gal activity was assayed. -gal values were used to normalize 
for transfection efficiency.  The efficacy for transcription were calculated and plotted as relative efficacy 
(EtOH +PMA set to 100%).  Values shown are from three independent experiments, plotted as means  
SEM. Statistical significance is indicated by different lower-case letters, such that all the conditions with 











different letters are statistically significantly different from each other (P < 0.05). Additional statistical 
analyses were carried out using GraphPad Prism software (version 5), using a two-tailed t-test, with 
selected pairs of columns, comparing wt and phosphorylation mutant GR with different ligands. Statistical 
significance is denoted by * , to indicate P < 0.05. 
 
These results were unexpected and difficult to interpret.  Since both the single phosphorylation 
mutants resulted in more transrepression than wt receptor, a bigger difference in 3A versus wt 
repression was expected.  One interpretation of this data is that phosphorylation on either S211 or 
S226 already inhibits efficacy for transrepression to a “maximal” extent and that their combined 
phosphorylation cannot further inhibit efficacy for transrepression via AP-1. Additionally, in this 
experiment dex in the presence of wt GR resulted in more relative repression (~75%) as 
compared to the results for dex in the presence of wt GR shown in figures 4.12 A and B (~40%).  
This indicates that the hGR expression constructs used in figure 3.13 (pRS-hGR) expresses more 
GR than that in figure 4.12 (HA-hGR). The higher GR levels could also result in “maximal” 
transrepression with wt GR, preventing further repression with the triple phosphorylation mutant 
and repeat experiments with lower amounts of GR, could possibly result in a bigger difference 
between wt and triple phosphorylation mutant.  However, this remains to be tested.  On the other 
hand, since the triple phosphorylation mutant includes S203, it is possible that phosphorylation at 
S203 is required for maximal efficacy for transrepression.  Therefore, the result obtained with the 
triple phosphorylation mutant could be the combination of inhibitory and enhanced effects on 
efficacy for transrepression with the individual phosphorylation sites.  However, the role of S203 
phosphorylation on efficacy for transrepression has not been investigated, herein or in the 
literature, and further experiments are needed to confirm a role for S203 phosphorylation in 












Taken together, results suggest that GR phosphorylation at S211 and/or S226 inhibits efficacy for 
transrepression, but that the rank order of ligand-selective GR-mediated transrepression is not 
dependent on ligand-selective GR phosphorylation per se, as ligand-selective differences in 
efficacy for transrepression was still observed with the single phosphorylation mutants.  
Unfortunately, the results obtained with combined mutation of S226, S211 and S203 did not 
show any statistically significant differences and should be repeated with lower amounts of GR in 
order to determine whether ligand-selective transrepression is still obtained with the combined 
mutation of S226, S211 and S203. 
 
Results presented in this section, represent for the first time a comprehensive study with a wide 
panel of GR ligands, on the role of ligand-selective GR phosphorylation at S226 and/or S211 on 
ligand-selective GR mediated transactivation and/or transrepression on different GR-regulated 
promoters.  Ligand-selective GR phosphorylation at S226 and S211 correlates with ligand-
selective efficacy, but not potency, for transactivation and transrepression. However, 
transactivation and transrepression with GR phosphorylation mutants, still showed ligand-
selective transactivation and transrepression.  This shows that ligand-selective GR 
phosphorylation at S226 or S211 does not determine the rank order of ligand-selective GR-
mediated transactivation or transrepression. This leaves unanswered the question as to what 
determines ligand-selectivity, as well as why positive correlations between GR phosphorylation 
and efficacy for transactivation and transrepression were obtained.  It is likely that both ligand-
selective GR phosphorylation and ligand-selective transcription are mediated by the same ligand-
selective “determining” step.  Thereby, ligand-selective GR phosphorylation is an indirect 
consequence and only “mimics” ligand-selectivity.  This would explain why the positive 
correlations were obtained between GR phosphorylation and transcription.  In addition, the 











transactivation and transrepression, indicating that the same ligand-selective “determining” step 
is maintained in the phosphorylation mutants. This further indicates that ligand-selective GR 
phosphorylation is an indirect effect and only reflects ligand-selectivity, since the mutants cannot 
be phosphorylated but still resulted in ligand-selective transactivation and transrepression. For 
more detailed discussion on this, see Chapter 8 (Conclusions and future perspectives).       
 
At the time this work was done, the effect of GR phosphorylation at S226 with different ligands 
on GR-mediated transactivation was not known, but recently GR phosphorylation at S226 with 
dex and prog has been shown to inhibit efficacy for transactivation on a MMTV reporter-
promoter in U2OS cells (Chen et al., 2008).  Results presented in this section are consistent with 
those of Chen et al., which showed that phosphorylation at S211 is required for, while 
phosphorylation at S226 inhibits maximal efficacy for transactivation and additionally show the 
effect of GR phosphorylation at S226 on efficacy for transactivation with 8 additional ligands.    
The results in this thesis are consistent with a model wherein dex-mediated GR phosphorylation 
at S211 is required for the recruitment of a co-activator (e.g. “X”), whereas dex-mediated 
phosphorylation at S226 is required for the recruitment of a co-repressor (e.g. “Y”) (Fig. 4.14).  
This is consistent with a recent report in the literature, where the co-repressors NCoR and SMRT 
were shown to be recruited to an endogenous GC-regulated gene in response to dex (Hong et al., 
2009). According to the model shown below, wt GR bound with dex, that is phosphorylated at 
both S226 and S211, will recruit both co-activator (X) and co-repressor (Y).  When S211 is not 
phosphorylated (i.e. with the S211A mutant), dex-bound GR would not be able to recruit the co-
activator (X), but would still be able to recruit the co-repressor (Y) through phosphorylated S226.  
This combination would result in the S211A mutant having a reduced efficacy for transactivation, 
compared to wt, as was found on the MMTV promoter (Fig. 4.10).  In contrast, when S226 is not 











repressor (Y), but would still be able to recruit the co-activator (X) through S211, resulting in the 
increased maximal efficacy seen on the MMTV promoter in figure 4.10. This is consistent with 
the recruitment of NCoR and SMRT to an endogenous human metallothionein IIa (hMTIIa) gene 
in COS-7 and HeLa cells, where knock-down of NCoR or SMRT, by siRNA, resulted in a 
increase in dex-mediated transactivation on the hMTIIa gene (Hong et al., 2009).  
 
 
Figure 4.14 Phosphorylation site-specific GR phosphorylation mediates co-activator vs. co-repressor 
recruitment. Light blue square illustrates the GR bound with dex (small red triangle). While X = co-
activator; Y = co-repressor; GRE = glucocorticoid response element; BTM = basic transcription 
machinery. 
 
Furthermore, the inhibitory effect of phosphorylation at S226 on efficacy for transactivation, was 
much weaker on the MMTV- versus the TAT-GRE promoter.  In contrast, the requirement of 
S211 phosphorylation for efficacy for transactivation on the MMTV promoter, as shown in this 
thesis, was greater than observed in results previously obtained on the TAT-GRE promoter 
((Stubsrud, 2005); Table E2 in addendum E).  These results indicate promoter-specific 
differences in the role of GR phosphorylation at S226 and S211 on transactivation efficacy, 
which is consistent with a previous report in the literature (Webster et al., 1997).  However, there 
are some inconsistencies between the promoter-specific differences obtained by Webster et al. 
and those obtained in this thesis.  On a MMTV promoter, Webster et al. did not see any effect of 
phosphorylation of the mGR at the mouse equivalents to S211 or S226 on transactivation efficacy 











equivalent to S211 was required for maximal transactivation efficacy and phosphorylation at the 
mouse equivalent to S226 had no effect on a TAT-GRE promoter in COS-1 cells.  In contrast, 
results in this thesis show that phosphorylation of the hGR at S226 inhibited transcription 
efficacy on both the MMTV- and TAT-GRE promoters, albeit to different extents, while 
phosphorylation of the hGR at S211 is required for maximal transactivation efficacy on the 
MMTV promoter. Furthermore, on the MMTV promoter Webster et al. did not see any 
difference in transactivation efficacy between wt and the triple phosphorylation mutant, whereas 
a complete loss in transactivation efficacy with the triple phosphorylation mutant on the MMTV 
promoter was shown in this thesis. Other than methodological differences, possibly resulting in 
different GR expression levels, the different results obtained in this thesis as compared to those of 
Webster et al. could be due to species-specific differences (rat vs. human GR).  To this extent 
Rogatsky et al. examined the role of phosphorylation of the rat GR at threonine 171, the only 
know phosphorylation site that is not conserved in humans, on GR-mediated transactivation and 
came to the conclusion that there are species-specific differences in the role of GR 
phosphorylation on transactivation (Rogatsky et al., 1998a).  Whether there are species-specific 
differences in the role of GR phosphorylation, can only be determined by a direct comparison of 
mGR vs. hGR and requires further investigation.  Furthermore, the results obtained with the triple 
phosphorylation mutant on the MMTV promoter in this study, as well as by Webster et al., 
appears to be inconsistent with a recent report where a 4 fold increase, compared to wt, in hGR-
mediated transactivation efficacy on the MMTV promoter was observed in HCT116 cells (Kino 
et al., 2007).  In the same study, Kino et al. also showed a 2 fold increase, compared to wt, in 
hGR-mediated transactivation efficacy on the MMTV promoter with the S211A or S226A 
mutant.  The inconsistencies between the results obtained by Kino et al. and results presented in 
this thesis, both with the hGR, are most likely due to cell-specific differences in downstream 











Interestingly, with the dissociated ligand CpdA, no transrepression on AP-1 or NFB was found 
for wt receptor.  This is in agreement with recently published data on CpdA on the same AP-1 
and NFB reporter-promoter constructs in COS-1 cells (Ronacher et al., 2009), but in contrast to 
another report in the literature, which showed GR-mediated transrepression via NFB with CpdA 
(De Bosscher et al., 2005).  In the study by De Bosscher et al. CpdA was shown to repress TNF-
 induced expression of the NFB-regulated IL6 and E-selectin promoters in L929 and 
HEK293T cells.  Apart from possible cell- and promoter-specific differences between the study 
of De Bosscher et al. and results represented in this thesis, as well as in Ronacher et al. 2009, 
there are also some methodological differences, including induction with TNF- versus PMA.  
Furthermore, De Bosscher et al. stimulated with test compound first, before induction with TNF-
, whereas results presented in this thesis, as well as in Ronacher et al. 2009 was obtained by 
first inducing with PMA and then stimulated with test compound.  Whether the above mentioned 
differences could account for the differences on the CpdA mediated transrepression via NFB is 
very interesting, but remains to be tested.    
 
At the time this work was done, the effect of GR phosphorylation on GR-mediated 
transrepression was not known.  However, recently phosphorylation at S211 and S226 has been 
shown to be required for maximal dex-mediated efficacy for transrepression on 6 different GC-
regulated endogenous genes, including c-Jun and SMAD17 in U2OS cells (Chen et al., 2008).  
These results are in contrast to the results obtained in this thesis in COS-1 cells, where 
phosphorylation at S211 and S226 inhibited maximal efficacy for transrepression on both the AP-
1 and NFB promoter and indicate possible cell- and/or promoter specific differences.  One 
possible explanation is that phosphorylation at S211 and S226 interferes with the ability of the 











GR is required for transrepression (Ito et al., 2006b), suggesting that post-translational 
modifications play an important role in GR-mediated transrepression. However, whether GR 
phosphorylation inhibits GR-mediated transrepression via interference with GR binding to AP-1 
and NFB remains to be tested.   On the other hand, these results could indicate that GR 
phosphorylation at S211 and S226 is required for the recruitment of a co-activator to the AP-1 
and NFB promoters. Interestingly, on the collagenase 3 promoter, agonist induced GR recruits 
the co-activator GRIP-1 to an AP-1 promoter. However, in this study, GRIP-1 behaved more like 
a co-repressor and not as a co-activator (Rogatsky I, 2001). Whether GR phosphorylation at S211 
and S226 is required for the recruitment of another co-activator, which behaves as a co-activator 
on the AP-1 and NFB promoters, remains to be tested. However, in the literature there is no 
evidence that supports this hypothesis.   
 
Furthermore, Chen et al. showed that wt GR repressed the PAC1 gene with dex in the absence of 
inducing compound (i.e. no TNF- or PMA).  However, the S211A mutant resulted in a 5 fold 
increase in transcription, whereas the S226A mutant increased transcription by 2 fold, in response 
to dex, in the absence of inducing compound (Chen et al., 2008).  These results are interesting 
and also indicate promoter-specific differences on the effect of GR phosphorylation at S211 and 
S226 on GR-mediated transrepression in the same cell.  Additionally, these results by Chen et al. 
for dex are similar to results in this thesis showing an increase in transcription with the S226A 
mutant on the AP-1 promoter with the dissociated ligand CpdA and the antagonists NET and 
UDCA.  This result is novel as it indicates that not only is the effect of GR phosphorylation on 
transrepression promoter-specific, but also ligand-specific.  In other words, GR phosphorylation 
at S226, with different ligands, results in different transrepression responses in the same cells, on 











To summarise, ligand-selective phosphorylation at S226 was shown to inhibit efficacy, but not 
potency for transactivation. Furthermore, ligand-selective phosphorylation at S226, as well as 
S211 was shown to inhibit efficacy, but not potency, for transrepression on AP-1 and NFB.  
However, ligand-selective phosphorylation at neither S211 nor S226 determines the rank order of 
ligand-selective transactivation or transrepression via AP-1 or NFB.  This leaves the question of 
what determines ligand-selective GR transcription unanswered, and other possibilities will be 











Chapter 5 Investigation into the kinases involved in GR 
phosphorylation (Results and Discussion) 
 
According to the literature, S226 is predominantly phosphorylated by JNK, whereas S211 is 
primarily phosphorylated by p38 or CDKs (Rogatsky et al., 1998b;Krstic et al., 1997;Miller et 
al., 2005;Itoh et al., 2002;Kino et al., 2008). However, to date there is not one study that 
convincingly shows in vivo, which kinases phosphorylate the hGR at S226 and/or S211 in 
mammalian cells by inhibiting kinase activity.  Most studies involved in vitro kinase assays, or 
were performed in yeast cells devoid of specific kinases.  
 
 
5.1 The use of specific MAPK inhibitors on GR phosphorylation  
 
Transactivation and transrepression data with GR phosphorylation deficient mutants presented in 
figures 4.8 and 4.12, as well as with JNK and p38 kinase inhibitors (Fig. E2 in addendum E), are 
consistent with a role for JNK and p38 in mediating phosphorylation of the GR at S226 and 
S211, respectively.  In order to determine whether JNK and p38 phosphorylates the GR at S226 
and S211, respectively, in COS-1 cells, these cells were transiently transfected with hGR and pre-
treated with either a JNK or p38 inhibitor, before stimulation with dex and determination of the 
amount of S226 or S211 phosphorylation (Fig 5.1 A and B, respectively).  Results show that 
inhibition of JNK results in a small decrease in the amount of basal, as well as dex induced S226 
phosphorylation, whereas inhibition of p38 reduces the amount of basal and dex induced S226 
phosphorylation even more (Fig. 5.1 C). Additionally, the combination of JNK and p38 inhibitors 











phosphorylation (Fig. 5.1 C). Inhibition of JNK did not significantly reduce the total amount of 
dex-induced S211 phosphorylation, whereas inhibition of p38 and the combined inhibition of p38 
and JNK significantly reduced the total amount of basal and dex-induced S211 phosphorylation 
(Fig. 5.1 D).  However, results show that inhibition of JNK and p38 slightly decreased the total 
amount of GR, whereas the simultaneous inhibition of JNK and p38 decreased the total amount 
of GR even more (Figs. 5.1 E and F).  After quantification and normalisation to the total GR 
levels, results show that the fold dex-induced S226 phosphorylation was not reduced upon 
inhibition of JNK or p38, or the combination thereof (Fig. 5.1 G).  Furthermore, inhibition of 
JNK alone or p38 alone did not reduce the fold dex-induced S211 phosphorylation, whereas the 
combination of JNK and p38 inhibitors slightly decreased the fold dex-induced S211 







Figure 5.1  Effect of JNK and p38 inhibitors on the phosphorylation status of the GR at S226 (A) 
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Figure 5.1  Effect of JNK and p38 inhibitors on the phosphorylation status of the GR at S226 (A) 
S211 (B). COS-1 cells were plated in 6-well plates at a density of 3x105cells/dish and transfected with 3.5 
g HA-hGRwt per well. After 24 hour incubation, cells were pre-treated with 50  JNK (JNKi) or 10 
 p38 inhibitor (p38i), or a combination of them (JNKi & p38i) for 24 hours and then treated with 











extracts (10 l) were analyzed by Western blotting with either an anti-P-S226 (A) or anti-P-S211 antibody 
(B).  After developing, the blots were stripped and re-probed with total GR (A and B). After quantification 
the amount of P-S226 (C), P-S211 (D) and total GR (E) and (F) was determined. Thereafter, the amount of 
phosphorylated/total protein was calculated and plotted relative to the EtOH no inhibitor sample set as one 
(G and H).  The histograms (C-H) are the average of three independent experiments, plotted as the ave ± 
SEM, whereas the Western blots (A) and (B) is one representative blots of three independent experiments. 
Statistical significance, relative to EtOH no inhibitor, is denoted by *, ** or ***, to indicate P < 0.05, P < 
0.01 or P < 0.001.  
 
These results show that inhibition of JNK, which reportedly phosphorylates the GR at S226, does 
not inhibit or even reduce the fold dex-induced S226 phosphorylation.  Similarly, S211 is 
reportedly phosphorylated by p38, but inhibition of p38 does not inhibit or even reduce the fold 
dex-induced S211 phosphorylation.  The combination of the two inhibitors, did however reduce 
the fold dex-induced phosphorylation at S211, but not S226.  Similar results on dex-mediated  
phosphorylation of the mGR with the JNK and p38 inhibitors was found in mouse LT2 cells at 
the equivalent residues in the mGR (Kotitschke, 2009).     
 
Due to apparent inconsistency between these results and reports in the literature that used in vitro 
kinases assays to show that JNK phosphorylates S226, while p38 phosphorylates S211, it was 
next determined whether the JNK and p38 inhibitors were active under the experimental 
conditions. Reports in the literature suggest that JNK and p38 have to be phosphorylated 
themselves in order to be active (Miller et al., 2005;Rogatsky et al., 1998b).  The 
phosphorylation status of JNK and p38 was therefore used as a measurement of their activity.  In 
the absence of any inducing compound (such as TNF), JNK1 and JNK2/3 are only weakly 
phosphorylated (Fig. 5.2 A).  Inhibition of JNK resulted in a small decrease in the amount of 
JNK1 and JNK2/3 phosphorylation, whereas inhibition of p38 did not reduce the amount of 











phosphorylated JNK is very small (without prior stimulation with TNF), the decrease seen is 
very small.  Additionally, the combined inhibition of JNK and p38, also slightly decreased the 
amount of phosphorylated JNK1 and JNK2/3. On the other hand, whereas very low levels of 
phosphorylated p38 were visible in the control or with the JNK inhibitor, inhibition of p38 
increased, rather than decreased the amount of phosphorylated p38 (Fig. 5.2 B).  Similarly, the 
combined inhibition of JNK and p38 also increased the amount of phosphorylated p38.  
Furthermore, as with the total GR levels, after quantification it can be seen that the total amount 
of JNK and p38 decreased in response to the kinase inhibitors (Figs. 5.2 C, D and E).  After 
quantification and normalisation to total amount of JNK or p38, it can be seen that inhibition of 
JNK slightly reduced phosphorylated JNK1 and reduced phosphorylated JNK2/3 (Figs. 5.2 F and 
G), while it increased the amount of phosphorylated p38 (Fig. 5.2 H). In contrast, inhibition of 
p38 increased the amount of phosphorylated JNK1, JNK2/3 and p38 (Figs. 5.2 F-H).  Similarly, 
the combined inhibition of JNK and p38, also increased the amount of phosphorylated JNK1, 
JNK2/3 and p38. The results with the p38 inhibitor on p38 activity are very difficult to interpret, 
since the data suggest that the p38 inhibitor activated rather than de-activated p38.  However, the 
p38 inhibitor was shown to inhibit p38 in mouse LT2 cells, under similar conditions as 
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Figure 5.2  Effect of JNK and p38 inhibitors on the phosphorylation status of JNK and p38 
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Figure 5.2  Effect of JNK and p38 inhibitors on the phosphorylation status of JNK (A) and (B) and 
p38 (C). COS-1 cells were plated in 6-well plates at a density of 3x105cells/dish and transfected with 3.5 
g HA-hGRwt. After 24 hour incubation, cells were pre-treated with 50  JNK or 10  p38 inhibitor, 
or a combination of them for 24 hours and then treated with vehicle (EtOH) or 10n dex for 1 hour.  
Whole cell extracts were prepared and equal amounts of protein (10 l) were analyzed by Western 
blotting with either an anti-P-JNK (A) or anti-P-p38 antibody (B).  After developing, the blots were 
stripped and re-probed with total JNK (A) or p38 (B). After quantification the amount of total JNK (C and 
D) and p38 (E) was plotted with the EtOH no inhibitor sample set to 100%. Thereafter, the amount of 
phosphorylated/total JNK (F and G) and p38 (H) was calculated and plotted with the EtOH no inhibitor 
sample was set to one.  The amount of total JNK (C) and (D) and total p38 (E), as well as histograms (F), 
(G) and (H) is representative of the average of three independent experiments, plotted as the ave ± SEM, 












Nevertheless, these results indicate that these kinase inhibitors cross-react and that the use of 
these kinase inhibitors in order to determine which kinase phosphorylates the GR in vivo, is not 
possible.  The decrease in total protein levels for GR, JNK and p38 indicate that there is cell 
death or apoptosis occurring.  This is in agreement with published data showing that the 
inhibition of JNK enhances apoptosis, but in contrast to data showing that the inhibition of p38 
protects against apoptosis (Miller et al., 2005).  Interestingly, the use of the same p38 inhibitor, 
as in this study, by Miller et al. also resulted in a decrease in total GR levels in CEM-C7-14 cells.  
However, the authors did not comment on the decreased GR levels and further concluded that 
inhibition of p38 protected against apoptosis. It therefore seems that the concentrations of 
inhibitors and the time of incubation needed to see a decrease in GR phosphorylation, would 
result in cell death due to a requirement of these kinases for cell survival. 
 
 
5.2 Modulation of GR phosphorylation using MAPK expression constructs 
 
The use of JNK and p38 MAPK inhibitors to investigate GR phosphorylation at S226 and/or 
S211 in COS-1 cells was unsuccessful.  Therefore overexpression of wt and/or dominant negative 
(DN-) JNK and p38 protein to modulate GR phosphorylation at S226 and/or S211, was attempted 
as an alternative strategy.  In order to investigate whether this strategy would be successful for 
both expressed GR in COS-1 cells and on endogenous GR, the effect of MAPK expression 
constructs on GR phosphorylation was determined in COS-1 cells transiently transfected with 
hGR, as well as in LT2 cells expressing endogenous mGR. Results show that expression of DN- 
p38 (Fig. 5.3 A), as well as wt JNK (Fig. 5.3 B), resulted in increased total p38 and JNK1 protein 
levels, respectively.  Both expressed and endogenous GR exhibited dex-induced phosphorylation 











fold dex-induced phosphorylation in the LT2 cells was not as high as in COS-1 cells.  
Furthermore, overexpression of wt and DN- JNK and DN- p38, did not influence the total GR 
levels, as was observed when the kinases were inhibited (Figs. 5.3 E and F). This could indicate 
that overexpression of the DN- kinases does not completely block the effect of the endogenous 
kinases, and that enough endogenous kinases are still available to perform crucial functions 
required for cell survival.  On the other hand, this could indicate that it is not the inhibition of the 
MAPKs that result in cell death per se, but rather that the inhibitors themselves are toxic to the 
cells by inhibiting or enhancing some other factors that are crucial for cell survival. After 
quantification and normalisation, it was found that expression of DN- p38 did not reduce the level 
of dex-induced GR phosphorylation of the human or mouse equivalent to S226 or S211 (Fig. 5.3 
E and F, respectively).  Furthermore, expression of wt and DN- JNK did not increase or decrease, 
respectively, GR phosphorylation on the human or mouse equivalent to S226 or S211 (Fig. 5.3 G 
and H, respectively). In retrospect, it would have been a good idea to determine if the total 
amount of phosphorylated p38 and/or JNK was decreased, i.e. to determine if the DN- constructs 


































Fig. 5.3 The effect of expression of wt and DN- JNK and/or p38 on S226 and S211, or mouse 


















Fig. 5.3 The effect of expression of wt and DN- JNK and/or p38 on S226 and S211, or mouse 
equivalent, hGR or mGR phosphorylation.  LT2 or COS-1 cells transiently transfected with 1 g HA-
hGRwt were transfected with 1 g DN- p38 (A and C), wt JNK or DN- JNK (B and D) and incubated for 
24 hours.  Thereafter the cells were treated with vehicle (EtOH) or 100 nM dex for 1 hour and cell lysates 











S211 GR-specific antibody or an anti-P-S226 GR-specific antibody. Thereafter the membrane was 
stripped and reprobed with anti-GR antibody. After quantification and normalisation to total GR, the 
amount of phosphorylated/total protein in the EtOH sample was set to one (E – H). The Western blots (A - 
D) and the graphs (E – H) are from a single experiment. 
 
These results are similar to the inhibitor results, in that expression of wt and DN- JNK does not 
change the fold dex-induced S226 phosphorylation.  Similarly, expression of DN- p38 does not 
change the fold dex-induced S211 phosphorylation. It should be noted that these expression 
experiments were only performed once and more repeats will have to be done to show this result 
in a statistically significant manner.  However, due to the fact that the same result was obtained in 
both cell lines and that these results are in agreement with the inhibitor results, it was concluded 
that reports in the literature with in vitro assays, wherein JNK and p38 phosphorylates the GR at 
S226 and S211, respectively, may be misleading and that different kinases are likely to 
phosphorylate the GR in vivo in these cells.  Alternatively, it is possible that these kinases can 
compensate for one another, wherein inhibition of one kinase results in activation of another 
kinase (as shown in Fig. 3.16), which in turn could phosphorylate the GR.     
 
In the literature, there are two studies that indicate that CDKs can phosphorylate the GR at S211 
in yeast and HCT116 cells (Krstic et al., 1997;Kino et al., 2007).  In a last attempt to identify the 
kinases that phosphorylate the GR at S211 and/or S226 in mammalian cells in vivo, the effect of a 
general CDK inhibitor on S211 and S226 phosphorylation was examined. Human END-1 and 
mouse LT2 cells, containing endogenous GR, as well as COS-1 cells transiently transfected 
with hGR were treated with a CDK inhibitor and dex, before determining GR phosphorylation at 
the human and mouse equivalents of S211 and S226.   Similar to the results obtained with the 
MAPK expression constructs, all three cell lines showed dex-induced GR phosphorylation on the 











cells showed a smaller fold dex-induced GR phosphorylation, than the expressed GR in COS-1 
cells (Fig. 5.4 A). In contrast to the results obtained with the MAPK inhibitors, inhibition of 
CDKs did not decrease the total amount of GR.  This could indicate that CDKs are not crucial for 
the survival of these cells, or that the inhibitor did not completely inhibit all the CDKs and that 
enough CDKs are still active to mediate crucial functions required for cell survival.  After 
quantification and normalisation to total GR levels, it can be seen that inhibition of CDK did not 
inhibit GR phosphorylation of the human and mouse equivalents to S226 or S211 (Fig. 5.4 B and 
C, respectively) in any of the cell lines investigated.  Furthermore, expression of wt and DN- 
CDK5 on GR phosphorylation at the human and mouse equivalents of S211 and S226 were also 
investigated in all three cell lines (Fig. 5.4 D) and similarly to the CDK inhibitor results, 
expression of DN- CDK5 did not change dex-induced GR phosphorylation at the human or 




































Figure 5.4  Effect of an CDK inhibitor and expression constructs on GR phosphorylation (continues 


















Figure 5.4  Effect of a CDK inhibitor and expression constructs on GR phosphorylation. LT2 and 
END-1 cells or COS-1 cells transiently transfected with 1 g HA-hGRwt were either pre-treated with 20 











incubated for 24 hours, before stimulation with 100 nM dex or vehicle (EtOH). Thereafter the cells were 
harvested and equal amounts of cell extract were separated on SDS-PAGE. Western blot analysis was 
performed using either an anti-P-S211 GR-specific antibody or an anti-P-S226 GR-specific antibody (A 
and D). Thereafter the membrane was stripped and reprobed with anti-GR antibody.  After quantification 
and normalisation to total GR, the amount of phosphorylated/total protein in the EtOH sample was set to 
one (B, C, E and F). The Western blots (A and D) and the graphs (B, C, E and F) are from a single 
experiment. 
 
These inhibitor and expression experiments were only performed once and more repeats will 
have to be done to show these results in a statistically significant manner.  However, due to the 
fact that the same result was obtained in all three cell lines and that inhibitor and expression 
results are in agreement with each other, it was concluded that CDKs do not play a major role in 
GR phosphorylation at S226 or S211 in these cells in vivo.   
 
Having been unable to determine the kinases responsible for GR phosphorylation in COS-1, 
LT2 and END-1 cells at the human or mouse equivalent to S211 and S226 by the above 
mentioned strategies, an alternative strategy was investigated.   
 
 
5.3 Kinetics of GR, JNK and p38 phosphorylation 
 
As an alternative strategy to investigate the kinases responsible for the in vivo phosphorylation at 
S226 and S211 in COS-1 cells, the kinetics of JNK and p38 phosphorylation, as well as GR 
phosphorylation at S226 and S211, was further examined.  This was done in order to correlate an 
increase or decrease in kinase activity with an increase or decrease in GR phosphorylation.  
Reports in the literature suggest that JNK and p38 have to be phosphorylated themselves in order 











their activity (Miller et al., 2005;Rogatsky et al., 1998b). Additionally, earlier very low levels of 
phosphorylated JNK (Fig 5.2) were shown in the absence of inducing compound (e.g. TNF-).  
In order to obtain a more detectable JNK phosphorylation signal, the following experiments were 
conducted in the presence of TNF-.  COS-1 cells, transiently transfected with hGR were 
pretreated with TNF- for 15 minutes, before treatment with 100 nM dex.  At various time 
points, cells were harvested and equal amounts of protein were separated on SDS-PAGE.  
Phosphorylated JNK and GR phosphorylated at S226 were detected by Western blotting with 
anti-P-JNK or anti-P-S226 antibodies, respectively.  Thereafter the membranes were stripped and 
reprobed for total JNK or GR (Figs. 5.5 A and B).  Results show that in the unliganded form the 
GR is basally phosphorylated at S226, while dex stimulation results in hyperphosphorylation 
(Fig. 5.5 A).  GR phosphorylation at S226 is rapid, with high levels of dex-mediated 
phosphorylation already visible at 15 minutes and peaks at around 30 to 60 minutes.  However 
due to experimental error no statistically significant differences were detected (Fig. 5.5 C).  In the 
absence of TNF-, very little phosphorylated JNK is observed (Fig. 5.2 A), while stimulation 
with TNF- results in phosphorylation of JNK1 and JNK2/3 (Fig. 5.5 B).  The amount of 
phosphorylated JNK1 and JNK2/3 is already maximal with TNF- stimulation and 15 minutes to 
30 minutes after addition of dex.  There after the amount of phosphorylated JNK1 and JNK2/3 
decreases rapidly over time and at 60 minutes no phosphorylated JNK1 or JNK2/3 was detected 
(Figs. 5.5 D and E).  Total GR (Fig. 5.5 F) and total JNK (Figs. 5.5 G and H) were not affected 
by TNF- induction and did not change significantly over the time examined.  These results 
indicate that JNK is rapidly activated/phosphorylated by TNF- (within 15 minutes), which 
correlates with GR phosphorylation at S226 (also within 15 minutes, but not max at 15 minutes).  
However after 15 to 30 minutes, the amount of phosphorylated JNK decreases rapidly in a dex-











Furthermore, dex-stimulation does not result in JNK phosphorylation, but does result in GR 
phosphorylation at S226 (in the absence of TNF-). Taken together, these results are not 
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Figure 5.5  Time-dependent phosphorylation status of the GR at S226 and JNK (continues on next 
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Figure 5.5  Time-dependent phosphorylation status of the GR at S226 (A) and JNK (B).  COS-1 cells 
were plated in 6-well plates at a density of 3x105cells/dish and transfected with 3.5 g HA-hGRwt. After 
24 hour incubation, cells were pre-treated with 0.02 g/ml TNF- for 15 minutes and then treated with 
vehicle (EtOH) or 10n compound.  At the appropriate time, whole cell extracts were prepared and 
equal amounts of protein (10 l) were analyzed by Western blotting with either an anti-P-S226 (A) or 
anti-P-JNK antibody (B).  After developing, the blots were stripped and re-probed with total GR or total 
JNK antibody, respectively. After quantification and normalisation to total GR or JNK, the amount of P-
S226 (C) and P-JNK (D and E) were plotted with EtOH –TNF set to one. The total amount of GR (F) or 
JNK (G and H) is shown with EtOH –TNF set to one. The histograms (C - H) are representative of the 
average of four independent experiments, plotted as the ave ± SEM, whereas the Western blots (A) and 
(B) is one representative blot of four independent experiments. Statistical significance is indicated by 
different lower-case letters, such that all the conditions with the same letter are not statistically 
significantly different from each other (P > 0.05), while those having different letters are statistically 












As mentioned earlier, phosphorylated/active p38 reportedly phosphorylates the GR on S211 
(Miller et al., 2005).  Additionally, in the literature there is conflicting data on the role of GCs in 
p38 phosphorylation, with some results indicating that dex stimulation leads to phosphorylation 
of p38 in CEM-C7-14 cells (Miller et al., 2005;Zhang et al., 2000a), whereas others show that 
dex stimulation leads to de-phosphorylation of p38 in the presence of TNF- in human 
pulmonary endothelial and A549 cells (Pelaia et al., 2001;Jang et al., 2007).  In an attempt to 
determine what happens in COS-1 cells, the kinetics of p38 and GR S211 phosphorylation was 
examined (Figs. 5.6 A and B).  Results show that the unliganded GR is basally phosphorylated on 
S211 and that stimulation with TNF- did not lead to induction of S211 phosphorylation (Fig. 
5.6 A).  Stimulation with dex results in rapid S211 phosphorylation, which is apparent at 15 
minutes and reaches maximum phosphorylation around 60 minutes (Fig. 5.6 C).  Phosphorylation 
of p38 was not significantly induced by TNF-, and did not increase or decrease significantly 
over time in the presence of TNF- or in the presence of dex (Figs. 5.6 B and D).  Similarly to 
the results shown for S226 and JNK, induction with TNF- did not change the levels of total GR 
or p38 over the time investigated (Figs. 5.6 E and F).  The results obtained with p38 are difficult 
to interpret, as it is neither phosphorylated nor de-phosphorylated in response to dex or TNF-. 
These differences, with respect to the literature (Pelaia et al., 2001;Jang et al., 2007), could 
possibly be due to cell-specific or methodological differences, since the above mentioned studies 
were performed in human pulmonary endothelial or A549 cells.  Furthermore, in the studies by 
both Pelaia et al. and Jang et al. the cells were first stimulated with dex and then treated with 
TNF-, wherein results presented in this thesis were obtained by pre-treatment with TNF- first 
and then stimulation with dex (Pelaia et al., 2001).  However, whether the effect of dex and/or 











to the above mentioned methodological differences remains to be tested and warrants further 
investigation.   
 
Taken together, S211 phosphorylation is rapid, being already visible at 15 minutes after hormone 
addition and reaches a max at about 60 minutes, whereas the phosphorylation status of p38 does 
not change in response to TNF-, dex or within the time period investigated.  The 
phosphorylation status of p38 does not correlate with an increase in GR phosphorylation at S211, 
which is consistent with a model wherein p38 does not phosphorylate the GR at S211. However, 
these results were all obtained in the presence of TNF- and the possibility that dex stimulation 
results in an increase in p38 phosphorylation in the absence of TNF-, as has previously been 
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Figure 5.6  Time-dependent phosphorylation status of the GR at S211 (A) and p38 (B). COS-1 cells 











24 hour incubation, cells were pre-treated with 0.02 g/ml TNF- for 15minutes and then treated with 
vehicle (EtOH) or 10n compound.  At the appropriate time, whole cell extracts were prepared and 
equal amounts of protein (10 l) were analyzed by Western blotting with either an anti-P-S211 (A) or 
anti-P-p38 antibody (B).  After developing, the blots were stripped and re-probed with total GR or total 
p38 antibody, respectively. After quantification and normalisation to total GR (C) or p38 (D), the amount 
of phosphorylated/total protein in the –TNF sample was set to one.  The amount of total GR (E) and p38 
(F), as well as histograms (C) and (D) is representative of four independent experiments, plotted as the ave 
± SEM, whereas the Western blots (A) and (B) is one representative of four independent experiments. 
Statistical significance is indicated by different lower-case letters, such that all the conditions with the 
same letter are not statistically significantly different from each other (P > 0.05), while those having 
different letters are statistically significantly different from each other (P < 0.05).   
 
Taken together, the kinetics of all the above results are not consistent with a role for JNK- or p38-
mediated GR phosphorylation at S226 or S211.  
 
In order to determine if JNK is phosphorylated/de-phosphorylated in this system, as well as 
whether this happens in a ligand-selective manner, a JNK CASE assay was performed.  This 
assay is an ELISA based assay, which determines the amount of phosphorylated and total JNK as 
a percentage of total protein and is more sensitive than the JNK phosphorylation Western blots 
(as above).  The JNK CASE assay was first performed in the absence of TNF-, but no 
difference in the amount of phosphorylated JNK was observed in the absence or presence of dex 
(data not shown).  This supports the Western blot results wherein dex stimulation did not activate 
JNK (Fig. 5.7).  COS-1 cells transiently transfected with hGR, were pre-treated with TNF- for 
15 minutes, before treatment with 100 nM test compound for 30 minutes.  Thereafter the CASE 
assay was performed, determining phosphorylated and total JNK, as well as the relative cell 
number.  After normalisation to relative cell number, the amount of phosphorylated JNK over 
total JNK was determined and plotted.  Results in figure 5.7 show that stimulation with TNF- 











5.5), as well as other reports in the literature (Pelaia et al., 2001).  Furthermore, stimulation with 
dex statistically significantly decreases the amount of phosphorylated JNK by 60%, which is also 
consistent with reports in the literature (Pelaia et al., 2001;Jang et al., 2007), but not with results 
obtained in the JNK kinetics assay, where no statistically significant decrease was seen.  
However, as mentioned above, the CASE assay is more sensitive than the JNK phosphorylation 
Western blots.  Furthermore, stimulation with the full/partial agonist MPA also resulted in a 
statistically significant decrease of 58% in phosphorylated JNK, whereas the partial agonist prog, 
the dissociated ligand RU486 and the antagonist NET also decreased the amount of 
phosphorylated JNK.  However, due to relatively large experimental error, these decreases were 
not statistically significantly different.            
 



















Figure 5.7  Ligand-dependent de-phosphorylation of JNK.  COS-1 was seeded in a 96-well plate at a 
density of 5x103 cells/well.  The following day the cells were transfected with 0.05 g HA-hGRwt per 
well and incubated for 24 hours. After 24 hour incubation, cells were pre-treated with 0.02 g/ml TNF- 
for 15 minutes and then treated with vehicle (EtOH) or 10n compound for 1 hour.  Thereafter the cells 
were fixed to the wells and probed with an anti-P-JNK or total JNK antibody, as well as a cell staining 
buffer to determine the relative cell number in each well.  After normalization to relative cell number, the 
amount of phosphorylated JNK over total JNK was determined and plotted.  Values were determined in 
duplicate and plotted as an average of four independent experiments. Statistical significance, relative to 











Taken together, these results are consistent with a model whereby full agonists and full/partial 
agonists result in de-phosphorylation/de-activation of JNK, whereas partial agonists, dissociated 
GCs and antagonists only slightly (if at all) de-phosphorylate/de-activate JNK.   
 
A careful look at the literature reveals that there are only four papers showing manipulations of 
GR phosphorylation in intact cells. In a key paper by Garabedian’s group (Chen et al., 2008),  the 
authors tried to inhibit overexpressed hGR phosphorylation in U2OS cells at S211 and S226 
using a variety of 19 different kinase inhibitors, including CDK, cAMP, tyrosine kinase, MEK1 
and MEK2 and general kinase inhibitors, to no avail. This is consistent with results presented in 
this thesis, where inhibition of JNK, p38 and CDK did not reduce GR phosphorylation at S211 or 
S226.  In the study by Chen et al., the only compound that significantly reduced GR 
phosphorylation at these residues was curcumin or turmeric, the yellow colouring agent found in 
curry powder.  Miller et al. showed a decrease in S211 phosphorylation of endogenous hGR in 
the presence of p38 inhibitors in CEM-C7-14 cells, however they did not normalise to their 
decreasing total GR levels and did not show whether the p38 inhibitor is active which makes 
interpretation of the data difficult (Miller et al., 2005).  Since results in this thesis show that the 
p38 inhibitor did not inhibit GR phosphorylation on S211 or of p38 itself, the effect of expressing 
a dominant negative p38 on GR phosphorylation on S211 and S226 in COS-1 cells 
overexpressing hGR, as well as mouse LT2 cells containing endogenous mGR, was examined.  
However, as with the p38 inhibitor, transfection of the dominant negative p38 construct where 
the protein was shown to be expressed, did not significantly reduce the amount of GR 
phosphorylation on S211 or S226.    Similarly, overexpression of wt and dominant negative JNK 
in COS-1 cells overexpressing hGR, as well as mouse LT2 cells containing endogenous mGR, 











S211 or S226.  In another study the phosphorylation status of the overexpressed hGR at S211 and 
S203 was manipulated by overexpressing wt and dominant negative CDK5 in HCT116 cells 
(Kino et al., 2007).  However, the same wt and dominant negative CDK5 expression constructs 
did not cause a significant increase or decrease in GR phosphorylation on S211 or S226 in COS-1 
cells overexpressing hGR, or human endocervical END-1 and mouse LT2 cells containing 
endogenous hGR or mGR, respectively.  Additionally, a general CDK inhibitor (roscovitine) did 
not significantly reduce S211 or S226 phosphorylation in COS-1, END-1 or LT2 cells.  The 4th 
paper used a GSK inhibitor to block endogenous and expressed hGR S404 phosphorylation in 
A549 and U2OS cells, stably expressing wt hGR (Galliher-Beckley et al., 2008). These authors 
showed that some inhibitors can be used successfully, but that GSK is not substantially involved 
in S211 or S226 phosphorylation. This inhibitor would therefore not have been appropriate in this 
study.  
 
Taken together, it seems that manipulating GR phosphorylation at S211 and S226 in vivo, is 
difficult.  It is possible that an combination of kinases are involved in this process or that the 
kinases can compensate for each other, e.g. inhibition of one kinase leads to hyper activation of 
another kinase (as shown in figure 5.2), which in turn phosphorylates the GR at S211 and/or 
S226.  However, transactivation and transrepression results with wt and S211A and S226A, as 
well as p38 and JNK inhibitors, are consistent with a role of p38 and JNK in phosphorylating the 
GR at S211 and S226, respectively.  Furthermore, kinetics data of phosphorylated JNK, p38 and 
GR at S211 and S226, are not consistent with a role for JNK or p38, in mediating GR 
phosphorylation on S226 and/or S211. Additionally, JNK is de-activated/de-phosphorylated in a 
ligand-selective manner in a timeframe that correlates to increased ligand-selective GR 











S211, also results in the most JNK dephosphorylation.  Taken together, results in this thesis are 
not consistent with a direct role for JNK in phosphorylating the GR at S226 and/or S211 in vivo. 
It would be tempting to hypothesis that active JNK and p38 can indirectly modulate GR-mediated 
transcription (given the kinase inhibitor transcription results) in a process that does not involve 
direct GR phosphorylation at S226 or S211.  The GR in turn, could result in ligand-selective 
deactivation of JNK as a means to prevent over-stimulation. However, further studies are 


















Chapter 6 Ligand-selective GR degradation (Results and Discussion) 
 
 
Although there are some inconsistencies in the literature, as discussed in the literature review, 
previous studies are consistent with the hypothesis that after dissociating from the DNA, the 
liganded-GR is exported to the cytoplasm, where it is degraded through the 
ubiquitin/proteasome-dependent protein degradation pathway (Bellingham et al., 1992;Liu and 
DeFranco, 2000;Wallace and Cidlowski, 2001).  Furthermore, degradation of the GR has been 
shown to restrict GR-mediated transactivation and it is hypothesised to occur after transcription 
and act as a “shut-down mechanism” to prevent over-stimulation (Deroo et al., 2002;Wallace and 
Cidlowski, 2001;Kinyamu et al., 2008).  The down-regulation of GR protein levels in the absence 
of ligand, as well as in the presence of the GR agonist dex or antagonist RU486, has previously 
been shown (Cidlowski and Cidlowski, 1981;Hoeck et al., 1989;Wallace and Cidlowski, 
2001;Webster et al., 1997).  However, these studies used one or two GR ligands only, and the 
effect of a wide panel of GR ligands on GR mediated down-regulation remains unclear.  
Additionally, some of these studies did not inhibit transcription, which further complicates the 
interpretation of the data, since the results measured is most likely the combination of protein 
degradation, as well as new protein synthesis.   
 
 
6.1 Ligand-selective GR degradation 
 
To test the hypothesis that ligand-selective GR degradation determines the rank order of ligand-











differential ligand-dependent GR degradation.  Therefore, the half-life of the GR in response to a 
wide panel of ligands was investigated.  In order to accurately determine the half-life of the GR, 
de novo protein synthesis needs to be inhibited.  This was done by pre-treatment with 
cycloheximide (CHX), which acts specifically on the 60S subunit of eukaryotic ribosomes, 
thereby inhibiting protein translation (Clotworthy and Traynor, 2006), followed by measuring the 
amount of GR protein at various time points, in the absence and presence of ligand.  It should be 
noted that this method is not considered to be the most accurate method in determining the exact 
half-life of the GR, where pulse-chase experiments are considered to be more accurate.  
However, in the present work the aim was determine relative GR degradation with a large panel 
of ligands, rather than the exact half-life of one ligand, which would have been very difficult and 
costly. In order to determine the optimal concentration of CHX, COS-1 cells were treated with 
increasing amounts of CHX. It was established that using amounts higher than 1 M CHX caused 
cell death (data not shown).  To determine if 1 M CHX was sufficient to inhibit de novo protein 
synthesis, the levels of endogenous tumor suppressor protein 53 (p53), in the presence and 
absence of CHX, were examined over a period of 72 hours.  p53 has a short half-life of 45-60 
minutes and is usually expressed at low levels in cells (Utama et al., 2006).  COS-1 cells were 
treated with 1 M CHX for up to 72 hours.  Thereafter, equal amounts of cell extract were 
separated by SDS-PAGE and Western blotting with anti-p53 was performed.  Figure 4.1 shows 
that in the absence of CHX, the levels of p53 gradually increase over time, whereas in the 
presence of CHX, no p53 was detectible (Fig. 6.1).  The zero hour time point (0h) already 
included a one hour pre-treatment with CHX. It should be mentioned that ideally a protein 
loading control should have been included.  Nevertheless, this result shows that in the presence of 











CHX) and there after no new p53 protein was made, indicating that 1 M CHX is sufficient to 







Figure 6.1  p53 protein levels in the presence and absence of CHX.   COS-1 cells were treated with 1 
M CHX for up to 72 hours.  Thereafter, equal amounts of cell extract were separated on SDS-PAGE and 
Western blotting with anti-p53 was performed.  
 
In order to determine the half-life of the GR in response to the selected panel of ligands (as 
shown in figure 2.1 in Thesis Rationale, Aims and Hypothesis), COS-1 cells transiently 
transfected with hGR were pretreated with 1 M CHX for 1 hour, before stimulation with 10 M 
test compound for different times.  Results show that the unliganded GR degrades slowly over 
time and that stimulation with dex dramatically increases the rate of degradation (Fig. 6.2 A).  
Moreover, all the ligands caused the GR to degrade at different rates.  If it is assumed that 
eventually all the ligands will lead to the total degradation of all the GR proteins (0% GR 
remaining), the half-life of the GR or the time it takes to degrade 50% of the initial amount of 
GR, for all the different ligands can be determined (Fig. 6.2 B).  In general the full agonists dex, 
cort and predn had the shortest half-life of 10, 12 and 9 hours, respectively, followed by the full 
agonists/partial agonists (ald and MPA) and the partial agonist (prog) (Fig. 6.2 C and Table 6.1). 
Note that the classification of the biological activity of the ligands is based on their efficacy for 
transcription in COS-1 cells with HA-hGR (see table E5 in addendum E). The dissociated ligand 
CpdA and the antagonist NET had a half-life of 42 and 37 hours, respectively, which is similar to 
44 hours for the unliganded GR.  However, within the partial agonist, dissociated and antagonist 
groups, several outliers were found.  For instance, RU486, a dissociated glucocorticoid in this 











respectively).  Similarly, the antagonist NET had a shorter half-life than the dissociated ligand 
CpdA (37 versus 42 hours, respectively). Furthermore, a similar trend was observed for all the 






















Figure 6.2  Ligand-dependent GR degradation (half-life).  COS-1 cells were plated in 10-cm dish at a 
density of 2x106cells/dish and transfected with 10 g HA-hGRwt. After 24 hour incubation, cells were 
replated into 6-well plates at a density of 4x105 cells/well. The next day the cells were pre-treated with 1 
M cycloheximide for 1 hour and then treated with vehicle (EtOH) or 10 M compound.  The zero hour 
time points (0h1 and 0h2) were taken at the time of stimulation (i.e. after the 1 hour pre-treatment with 
CHX). At the appropriate time, whole cell extracts were prepared and equal amounts of protein (7 l) 
were analyzed by Western blotting with anti-GR and -actin antibody (A).  After quantification and 
normalization to -actin, the amount of GR present at the two 0 hour time points (0h1 and 0h2) were 
averaged and was set to 100%. Thereafter the amount of GR present at the other time points was 
calculated as a percentage of the amount of GR at 0 hour (B).  Thereafter the half-life (C) and the amount 
of GR remaining at 72 hours (D) were calculated and plotted.  The data shown in graphs (B), (C) and (D) 
is representative of four independent experiments, plotted as ave ± SEM, and the Western blots (A) is one 
representative from four independent experiments.  Statistical significance, relative to EtOH, is denoted by 













Table 6.1  GR half-life values in response to different compounds, as calculated from figure 4.2. 
 
 
As mentioned above, there was a general trend that the more potent ligands for transactivation, 
had the shortest half-life.  In an attempt to investigate the relationship between ligand-selective 
GR degradation and ligand-selective GR transcription, correlation analysis on the results obtained 
from the half-life studies, as well as transcription data from this lab (E. Stubsrud, K. Ronacher, 
table in E5 Addendum E) was performed.   
 
In order to correlate the half-life results with GR transactivation, efficacy and potency for 
transactivation results obtained in the same cells (COS-1) and with the same GR construct, on the 
TAT-GRE, were used ((Stubsrud, 2005); Table E5 in addendum E).  A very good and statistically 
significant correlation was obtained for both potency (R2 = 0.72, p < 0.01) and efficacy (R2 = 
0.78, p < 0.001) (Fig. 6.3 A and B, respectively).  When the antagonists for transactivation 
(showing no transactivation) were excluded from the correlation, an even better correlation for 
both potency and efficacy was obtained (R2 > 0.93, p < 0.001). This is done to exclude the 
possibility that the ligands that do not lead to GR transactivation and/or degradation will give a 
false positive correlation and suggests that for the ligands that give a transcriptional response, 
there is a good correlation between GR degradation and transactivation.  The correlation analysis 
indicates a potential relationship between transactivation and degradation of the GR.   
 
In order to determine whether this correlation also holds for transrepression, correlation analysis 
between half-life and transrepression was also performed. Data obtained from two different 











Table in E5 in addendum E). As for transactivation, a good and statistically significant 
correlation between GR half-life and AP-1 potency (R2 = 0.69, p < 0.01), as well as efficacy (R2 
= 0.87, p < 0.001) was observed (Fig. 6.3 C and D, respectively).  Furthermore, when the 
antagonists for transrepression (showing no transrepression) were removed, to prevent a false 
positive correlation with ligands that do not transrepress, a good and statistically significant 
correlation between GR half-life and AP-1 potency (R2 = 0.62, p < 0.001), as well as efficacy (R2 
= 0.72, p < 0.001) was still observed.  This result indicates that for those ligands that do cause 
GR-mediated transrepression, there is a good correlation with GR degradation.  Additionally, on 
the NFB promoter, an even better correlation was found for both transrepression efficacy (R2 = 
0.96, p < 0.0001) and potency (R2 = 0.87, p < 0.0001) (Fig. 6.3 E and F, respectively) for all the 
ligands, as well as for efficacy (R2 = 0.94, p < 0.0001) and potency (R2 = 0.83, p < 0.001) when 



































A            B 
 
 
C            D 
 
 
E       F 
 
Figure 6.3  Correlation analysis between half-life and transcription.  Transactivation potency (A) and 
efficacy (B) was measured using a TAT-GRE reporter-promoter in the same cells and with the same GR 
construct (HA-hGR) with which the half-life experiments was performed ((Stubsrud, 2005); Table E5 in 
addendum E).  Transrepression potency (C) and efficacy (B) was measured using an AP-1-, as well as an 











half-life experiments were performed (K. Ronacher; Table E5 in addendum E). The efficacies and 
potencies were calculated as a percentage of dex.  
 
These correlations can be interpreted in different ways.  Firstly, ligand-selective GR degradation 
determines the rank order of ligand-selective transcription, wherein the rate at which the GR is 
degraded, with any given ligand, will determine the extent of GR-mediated transcription of that 
particular ligand. Secondly, they can suggest the inverse of the above mentioned scenario, 
wherein ligand-mediated transcription of the GR, with any given ligand, determines the rate at 
which the GR is degraded in response to that particular ligand. Additionally, they can imply that 
both ligand-selective GR degradation rates and transcription activity, are simply a consequence of 
another ligand-selective “determining step” (e.g. different conformational changes) and that 
ligand-selective GR transcription and GR degradation are not directly functionally linked, i.e. do 
not have a direct cause and effect relationship. 
 
Interestingly, when ligand-selective GR degradation was correlated with ligand-selective GR 
phosphorylation at S226 (R2 =  0.78, p = 0.0008) and S211 (R2 = 0.89, p < 0.0001), very good 
statistically significant correlations were found (Fig. 6.4 A and B, respectively).  These 
correlations could simply imply a direct relationship between GR phosphorylation at S211 and/or 
S226 and GR degradation, wherein the amount of ligand-selective GR phosphorylation will 
determine the rate at which the GR is degraded, or vice versa.  However, this remains to be tested 
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Figure 6.4 Correlation between ligand-selective GR phosphorylation and half-life. Ligand-selective 
GR phosphorylation at S226 (A) and S211 (B) was obtained from Chapter 3 and E. Stubsrud ((Stubsrud, 
2005); Table E1 in addendum E) and correlated to ligand-selective GR half-life. 
  
To summarize, results presented in this thesis shows ligand-selective GR degradation in response 
to a wide panel of GR ligands for the first time, wherein the more potent ligands results in the 
most rapid GR degradation.  Furthermore, correlation analysis showed a strong correlation 
between GR half-life and GR phosphorylation, as well as ligand-selective transcription on three 
different promoters. These results indicate a possible relationship between GR ligand-mediated 
biological response (as measured by transactivation and transrepression on the three different 
promoters) and GR ligand-mediated protein degradation for both direct DNA binding (GRE) and 
tethering (AP-1 and NFB) models.  In order to further investigate this possible relationship, 













6.2 Relationship between GR half-life and transcription 
 
In order to further investigate the relationship between transcription and GR degradation, the 
effect of MG132 (which blocks proteasomal degradation) and -amanitin (which blocks RNA 
polymerase II transcription) on GR transcription and degradation, respectively, was determined. 
 
 
6.2.1  Inhibition of degradation  
 
Proteasomal inhibition has been shown to increase GR mediated transcription on stable or 
transiently transfected MMTV promoters in human breast cancer cells (Deroo et al., 
2002;Wallace and Cidlowski, 2001).  Additionally, it has recently been shown with microarray 
analysis that proteasomal inhibition results in simultaneous up- and down-regulation of GR target 
genes, depending on the specific gene (Kinyamu et al., 2008).  In order to investigate what 
happens in this system, MG132 was used to block proteasomal degradation of the GR and the 
effect thereof on transcription was determined.  In the absence of MG132, the GR is degraded in 
a dex-dependent manner, whereas using increasing amounts of MG132, blocks dex-mediated GR 
degradation (Fig. 6.5 A).  After quantification and normalization of several experiments, it was 
determined that after 24 hours without MG132, dex resulted in a 70% decrease in GR protein 
levels relative to EtOH (Fig. 6.5 B).  This result is consistent with GR half-life experiments that 
showed that the half-life of dex-bound GR is 9 hours.  In the presence of MG132, even at the 
lower 5 M MG132 concentration, no statistically significant dex-mediated GR degradation was 
detected, showing that GR degradation was inhibited (Fig. 6.5 B) and that GR degradation is 











After verifying that GR degradation was inhibited, the effect of MG132 on GR-mediated 
transcription was investigated.  With increasing amounts of MG132, ligand-selective GR 
transactivation efficacy on the TAT-GRE reporter-promoter increased in a dose-dependent 
manner (Fig. 6.5 C).  Unfortunately, the error in this experiment was large and no statistical 
significance could therefore be established.  It is interesting that the transactivation efficacy of 
MPA did not increase as much as that of dex, indicating that the relationship between GR 
degradation and transcription is possibly ligand-selective.  This is in agreement with results 
obtained on the MMTV promoter, where proteasomal inhibition increased dex-mediated 
transactivation, but decreased corticosterone-mediated transactivation (Stavreva et al., 2004). 
 
When looking at the effect of MG132 on a gal reporter-construct, a constitutively expressed 
promoter-reporter construct, inhibition of proteasomal degradation did not have any effect (Fig. 
6.5 D).  This is possibly due to the gal protein having a long half-life and that it is not 
degraded during the time of this experiment. Nevertheless, this result indicates that the increase 
in GR transactivation is not due to MG132 increasing transcription in general, e.g. resulting in 
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Figure 6.5  The effect of blocking degradation on dex-mediated GR transactivation. COS-1 cells 
were plated in 24-well plates at a density of 2.5x104 and transfected with 0.125 µg HA-hGRwt and 0.047 
µg TAT-GRE reporter-promoter and 0.012 g -gal construct per well.  After 24 hours, the cells were pre-
treated with MG132 for 4 hours before stimulation with vehicle (EtOH) or 100 nM Dex for an additional 











normalize for equal protein concentrations in each well and set to 100% for dex in the absence of MG132 
(C) and -gal activity was measured (D).  Equal amounts of samples were loaded onto an 8% SDS-PAGE 
and Western blotting was performed probing with an antibody detecting total amounts of GR and a -actin 
antibody as loading control (A). After quantification and normalisation to -actin, the amount of GR 
present in the EtOH 0 M MG132 was set to 100% and the other samples plotted as percentage thereof 
(B).  Graphs in (B), (C) and (D) are the average of four independent experiments with each value in 
triplicates plotted as means  SEM, while the Western blot (A) shows one representative of four 
independent experiments. Statistical significance is indicated by different lower-case letters, such that all 
the conditions with the same letter are not statistically significantly different from each other (P > 0.05), 
while those having different letters are statistically significantly different from each other (P < 0.05).   
 
Taken together, these results show that the inhibition of GR degradation results in an increase in 
ligand-mediated GR transactivation on the TAT-GRE reporter-promoter in COS-1 cells.  This is 
consistent with other reports in the literature, showing that inhibiting degradation results in 
increased GR-mediated transactivation (Deroo et al., 2002;Wallace and Cidlowski, 2001;Garside 
et al., 2006), which suggests that GR degradation happens after GR mediated transcription (since 
blocking degradation still allows transactivation) and acts as a “shut-down” mechanism to 
prevent over stimulation.  However this study, as well as the above mentioned studies, only 
looked at the effect of inhibiting proteasomal degradation on transactivation, but did not look at 
transrepression.  It would be interesting to determine the effect of proteasomal inhibition on GR-
mediated transrepression.  An interesting study by Kinyamu et al. recently showed in microarray 
analysis that proteasomal inhibition results in both up- and down-regulation of GR-mediated 
transcription in a promoter-specific manner (Kinyamu et al., 2008).  It would be tempting to 
speculate that the genes found by Kinyamu et al., to be down-regulated in response to 
proteasomal degradation, are genes regulated by GR-mediated transrepression.  However, this 












Interestingly, results in figure 6.5 C show that inhibition of ligand-selective GR proteasomal 
degradation, still resulted in ligand-selective GR-mediated transactivation, wherein dex had a 
higher efficacy than MPA.  This suggests that ligand-selective GR degradation does not 
determine the rank order of ligand-selective GR transactivation.  However, inhibition of GR 
proteasomal degradation resulted in an increase in dex-mediated, but not MPA-mediated 
transactivation. This result is very interesting and indicates that although ligand-selective GR 
degradation does not determine the rank order of ligand-selective transactivation,  that GR 
degradation influences transactivation of the GR in a ligand-specific manner, wherein ligand-
induced GR degradation decreases transactivation with some ligands, but not all GR ligands.  
However, this study only investigated dex and MPA, and experiments with more ligands would 
have to be performed to get a better understanding thereof.  This still leaves unanswered the 
question as to whether or not transcription is required for GR degradation. 
 
 
6.2.2  Inhibition of transcription  

Since -Amanitin inhibits eukaryotic RNA polymerase II and III (Schultz and Hall, 1976), it was 
used to inhibit transcription in this study.  Before investigating whether or not transcription is 
needed for GR protein turnover, a suitable concentration where -amanitin inhibits transcription 
was first established.  This was done by performing a transactivation reporter-promoter assay 
using increasing concentrations of -amanitin.  In the absence of -amanitin, both dex and MPA 
induced transactivation in a ligand-dependent manner (Fig. 6.6 A).  Increasing the amount of -
amanitin resulted in a decrease of both dex- and MPA-mediated GR transactivation.  At the 











background), indicating that even though transcription was inhibited, it was not blocked 
completely.  However, this ligand-dependent transactivation, at the highest concentration of -
amanitin, was not statistically significantly different from vehicle.  Furthermore, as with GR-
mediated transactivation, it can clearly be seen that with increasing amounts of -amanitin the 
amount of gal activity decreases (Fig. 6.6 B).  At the highest concentration of -amanitin there 
was still some gal activity, however this could possibly be due to gal protein being 
synthesized during the 24 hours post-transfection (before the addition of -amanitin) and not 
being degraded due to a long half-life.  It should also be mentioned that adding -amanitin at 
concentrations higher than 2.5 g/ml caused the cells to die (data not shown). 
 
A       B 




































































































Figure 6.6  The effect of inhibition of GR-mediated transcription on GR degradation.  COS-1 cells 
were plated in 24-well plates at a density of 2.5x104 and transfected with 0.125 µg HA-hGRwt and 0.047 
µg TAT-GRE reporter-promoter and 0.012 g -gal construct per well.  After 24 hours, the cells were pre-
treated with -amanitin for 24 hours before stimulation with vehicle (EtOH) or 100 nM Dex for an 
additional 24 hours.  Thereafter luciferase activity was assayed and Bradford protein determination was 
performed to normalize for equal protein concentrations in each well (A).  After-gal activity was 
measured (B), equal amounts of samples were loaded onto an 8% SDS-PAGE and Western blotting was 
performed probing with an antibody detecting total amounts of GR and an -actin antibody as loading 
control (C).  After quantification and normalisation to -actin, the amount of GR present in EtOH 0 g/ml 
-amanitin was set to 100% and the other samples plotted as a percentage thereof (D).  Graphs (A), (B) 
and (D) are the average of four independent experiments with each triplicate value plotted as the mean  
SEM, while the Western blot (C) shows one representative of four independent experiments. Statistical 
significance is indicated by different lower-case letters, such that all the conditions with the same letter are 
not statistically significantly different from each other (P > 0.05), while those having different letters are 
statistically significantly different from each other (P < 0.05).   
 
Having shown that -amanitin inhibits GR-mediated transactivation (Fig. 6.6 A) and gal 
expression (Fig. 6.6 B), in a dose-dependent manner, the effects of -amanitin on dex-mediated 
GR degradation were examined (Fig. 6.6 C).  In the absence of -amanitin, dex-mediated GR 
degradation was observed, with the amount of GR protein levels decreasing by 70% in response 











mediated transactivation by 40% and gal activity by 30% (Figs. 4.6 A and B), it did not change 
the amount of dex-mediated GR degradation (~80% decrease in GR protein levels in response to 
dex).  With the highest amount of -amanitin, where no statistically significant transactivation 
was observed, the amount of dex-mediated GR degradation was only reduced by ~20%.  
However, the total amount of GR, in the absence of ligand, was also significantly less (~65% 
decrease) than without -amanitin or with 1 g/ml -amanitin.  The change in the amount of 
unliganded GR for 2.5 g/ml -amanitin versus untreated, is likely due to an additive effect of 
the degradation of the unliganded GR and the complete inhibition of transactivation, thereby not 
allowing the synthesis of new GR mRNA and hence protein translation.   
 
Since the 40% reduction in dex-mediated GR transactivation, with 1 g/ml -amanitin, does not 
result in a loss of dex-mediated GR degradation, the results indicate that GR transactivation is not 
required for dex-mediated GR degradation.  Furthermore, if ligand-mediated transactivation was 
required for ligand-mediated GR degradation, then the highest amount of -amanitin where no 
statistically significant transactivation was observed should not show any dex-mediated GR 
degradation, which is not the case.  Taken together, these results show that GR transactivation is 
not required for unliganded or ligand-mediated GR degradation. 
 
The half-life results are in agreement with results obtained for dex with the mGR and rGR in 
COS-1 and rat hepatoma cells, which showed that dex treatment reduced the half-life of the mGR 
and rGR to 9 and 11 hours, respectively (Webster et al., 1997;Dong et al., 1988).  However, 
results in this thesis show for the first time the half-life of the hGR in response to a wide panel of 
ligands and show a direct correlation with ligand-selective GR transcription, wherein the more 











the quickest GR degradation.  By inhibiting ligand-selective GR degradation, it was shown that 
GR degradation ‘restricts’ dex-mediated transcription.  This is consistent with results in the 
literature that showed inhibition of proteasomal degradation, increases dex-mediated transcription 
(Deroo et al., 2002;Wallace and Cidlowski, 2001;Garside et al., 2006). Furthermore, the increase 
in transcription is not due to the proteasome inhibitor influencing the basal transcription 
machinery, as has also been shown by others (Kinyamu and Archer, 2007;Dantuma et al., 2006), 
thereby increasing transcription, since transcription of a constitutively expressed -gal reporter 
did not increase with proteasomal inhibition. These results suggest that GR degradation limits 
GR-mediated transcription, thereby acting as a “shut-down” mechanism to prevent over-
stimulation of GR-mediated transcription.   
 
Results in this thesis showed for the first time that when dex-mediated GR transactivation was 
inhibited, dex-mediated GR degradation was still observed, suggesting that transcription is not 
required for dex-mediated GR degradation, suggesting that GR degradation can occur before or 
after GR-mediated transcription.  Furthermore, the half-life results with the unliganded GR, as 
well as the GR degradation results obtained when transcription was inhibited showed that the 
unliganded GR is also degraded. Since the unliganded GR is not transcriptionally active and does 
not translocate to the nucleus, these results suggest that GR degradation can also occur in the 
cytoplasm. This is consistent with an earlier study showing that GR degradation can occur in both 
the cytoplasm and nucleus (Liu and DeFranco, 2000). Taken together, the results obtained with 
dex, are consistent with a model, wherein dex-stimulated GR can degrade before of after 
initiating transcription and acts as a fine-tuning mechanism that restricts GR-mediated 
transcription. This model is unique for the GR, since proteasomal degradation of the PR, AR and 
ER has been shown to be required for transcription, wherein proteasomal inhibition results in a 











In the results presented in this thesis, dex and MPA had similar efficacies (when degradation was 
not inhibited), making it difficult to determine if GR degradation determines the rank order of 
ligand-selective GR transcription.  When GR degradation was inhibited, dex had a higher 
efficacy than MPA, suggesting that ligand-selective GR degradation does not determine the rank 
order of ligand-selective transactivation. In addition, inhibition of dex-mediated transactivation, 
still resulted in dex-mediated GR degradation, suggesting that the amount of transactivation does 
not determine the rate of GR degradation.  However, further experiments with the whole panel of 
GR ligands are needed to confirm this hypothesis and to determine if it holds for all ligands. 
Nevertheless, inhibition of GR proteasomal degradation resulted in a larger fold-increase in dex-
mediated, than MPA-mediated transactivation. This result is very interesting and indicates that 
although ligand-selective GR degradation does not determine the rank order of ligand-selective 
transactivation,  that GR degradation influences transactivation of the GR in a ligand-specific 
manner, wherein ligand-induced GR degradation decreases transactivation with some ligands, but 
not all GR ligands.  This suggests mechanistic differences in ligand-selective GR transactivation 
and degradation.  However, this study only looked at dex and MPA, and experiments with more 











Chapter 7 Role of agonist-induced GR Phosphorylation in GR 
mechanism of action (Results and Discussion)  
 
 
Phosphorylation of the hGR on S211 was previously shown to be required for maximal agonist-
induced transactivation efficacy on a TAT-GRE reporter-promoter construct ((Stubsrud, 2005); 
table E2 in addendum E).  Results in this thesis, showed that phosphorylation of the hGR on 
S226 inhibits maximal agonist-induced transactivation efficacy on a TAT-GRE reporter-promoter 
construct (Fig. 4.8 in Chapter 4).  Similarly, on a MMTV reporter-promoter, phosphorylation at 
S211 was shown to be required for, whereas phosphorylation at S226 inhibited agonist-induced 
maximal transactivation efficacy (Fig. 4.10 in Chapter 4).  Furthermore, phosphorylation at 
S203/S211/S226 was shown to be required for agonist-induced GR-mediated transactivation on a 
MMTV reporter-promoter (Fig. 4.10 in Chapter 4), indicating that phosphorylation plays an 
important role in the biological function of the GR. The specific aim of this section is to 
determine the role of agonist-induced GR phosphorylation at S211 and S226.   
 
 
7.1 Relationship between phosphorylation and transcription and/or half-life 
 
As mentioned above, GR phosphorylation was shown to be required for (S211), or inhibitory of 
(S226), maximal transactivational efficacy for transcription (Fig. 4.10 in Chapter 4).  These 
results support the hypothesis that there is a functional link between GR phosphorylation and 
transactivation efficacy. However, whether GR phosphorylation is influenced by, or requires GR-











with GR degradation for all the ligands (Fig. 6.4 in Chapter 6), indicating a link between GR 
phosphorylation and degradation.  In the literature, there is conflicting evidence on the role of GR 
phosphorylation on GR degradation (Hoeck et al., 1989;Wallace and Cidlowski, 2001).  
However, whether GR phosphorylation is influenced by GR degradation, is unknown.  In order to 
investigate in more detail the relationship between GR phosphorylation and transcription, as well 
as GR phosphorylation and half-life or degradation, and to determine whether GR 
phosphorylation is influenced by, or requires GR-mediated transcription and/or degradation, -
amanitin and MG132 was used to inhibit transcription and proteasomal degradation, respectively.  
COS-1 cells, transiently transfected with hGR wt, were pre-treated with 2.5 g/ml -amanitin or 
10 M MG132 (concentrations established to inhibit transcription and degradation, see figures 
6.5 and 6.6 in Chapter 6) for 24 or 4 hours, respectively, before stimulation with 100 nM dex for 
1 hour.  Equal amounts of cell extract were separated on SDS-PAGE and Western blotting was 
performed probing for either anti-P-S226 (Fig. 7.1 A) or anti-P-S211 (Fig. 7.1 B).  Interestingly, 
the amount of basal S226 phosphorylation increased when transcription was inhibited and 
increased even further when degradation was blocked.  This result indicates that basal S226 
phosphorylation does not require, but is influenced by GR-mediated transcription and/or 
degradation, wherein transcription and/or degradation restrict basal GR phosphorylation at S226.  
However, the amount of dex-induced S226 phosphorylation decreased slightly when transcription 
or degradation were inhibited, resulting in no statistically significant difference between basal 
and dex-induced S226 phosphorylation (Fig. 7.1 C).  This result indicates that GR-mediated 
transcription and/or degradation is required for agonist-induced GR phosphorylation levels at 












In contrast, the amount of basal S211 phosphorylation did not increase when either transcription 
or degradation was inhibited (Fig. 7.1 D).  Furthermore, inhibition of transcription did not 
influence dex-mediated S211 phosphorylation.  This indicates the GR-mediated transcription is 
not required for agonist-induced GR phosphorylation at S211. However, when degradation was 
blocked, the amount of dex-induced S211 phosphorylation decreased in a statistically significant 
manner, indicating that GR degradation is required for dex-mediated GR phosphorylation at 
S211.  During the one hour incubation with dex, neither -amanitin nor MG132 resulted in a 
change in the total amount of GR protein levels (Fig. 7.1 E), showing that the changes in the 


















































Figure 7.1 Proteasomal degradation and RNA polymerase II activity are differentially required for 











MG132 on GR phosphorylation, COS-1 cells transiently transfected with 1 g HA-hGRwt were pre-
treated with either 10 M MG132 for 4 hours or 2.5 g/ml -amanitin for 24 hours before stimulation 
with vehicle (EtOH) or 100 nM Dex for an additional 1 hour.  Equal amounts of samples were loaded onto 
an 8% SDS-PAGE and Western blotting was performed, probing with either an anti-P-S226 (A) or anti-P-
S211 antibody (B).  After developing, the blots were stripped and re-probed with total GR (E).  The 
amount of phosphorylated S226 and S211 was normalised to total GR and plotted as the average of four 
independent experiments ± SEM (C) and (D). The histograms in C, D, and E also show pooled results 
from four independent experiments, plotted as means ± SEM, while Western blots in A and B each show 
results of one representative experiment. Statistical significance, relative to EtOH without inhibitor, is 
denoted by * or **, to indicate P < 0.05 or P < 0.01.  
 
 
However, caution should be exercised when interpreting this data, since -amanitin and MG132 
are not specific for the GR.  MG132 is known to activate JNK, the kinase reported to 
phosphorylate the GR at S226 (Meriin et al., 1998).  In order to determine whether -amanitin 
and MG132 resulted in activation or inhibition of the kinases, JNK and p38, reportedly involved 
in GR phosphorylation at S226 and S211, respectively, the same cell extracts (as above) were 
separated on SDS-PAGE and Western blotting was performed probing for P-JNK (Fig. 7.2 A) or 
P-p38 (Fig. 7.2 B).  According to the literature, TNF- is known to activate JNK and was 
therefore included in this study as a positive control (Pelaia et al., 2001).   Results show that 
TNF- stimulation induces phosphorylation of JNK1 and JNK2/3, which is inhibited by 
stimulation with dex (Figs. 7.2 C and D).  Although these differences are not statistically 
significant, the results are consistent with other reports in the literature (Pelaia et al., 2001;Zhou 
et al., 2007), as well as the results found in the CASE assay (Fig. 5.7 in Chapter 5).  Furthermore, 
stimulation with MG132 induced phosphorylation of JNK1 and JNK2/3, which is consistent with 
Meriin et al., whereas stimulation with -amanitin did not induce or inhibit JNK1 and JNK2/3 
phosphorylation (Meriin et al., 1998).  Interestingly, contrary to TNF- induced JNK 











neither JNK1 nor JNK2/3.  This suggests the possibility of different mechanisms of activation of 
JNK by TNF- versus MG132.  Phosphorylation of p38 was also slightly increased upon TNF- 
stimulation and increased very strongly upon stimulation with MG132 (Fig. 7.2 E).  Furthermore, 
stimulation with dex did not inhibit TNF- or MG132- induced p38 phosphorylation. The total 
levels of JNK1 and JNK2/3 protein did not change upon stimulation with TNF-, -amanitin or 
MG132 (Figs. 7.2 F and G), whereas the total levels of p38 protein decreased slightly (Fig. 7.2 
H).  The decrease in total p38 does not change the above mentioned p38 phosphorylation results, 
as it was normalized to the total p38 levels.  
 
If JNK phosphorylates the GR at S226, then the increase in phosphorylated or active JNK upon 
MG132 stimulation, could explain the increase in basal S226 phosphorylation with MG132 
stimulation (Fig. 7.1 C).  However, if this is the case, then the amount of dex-mediated S226 
phosphorylation should also increase with MG132 stimulation.  One possible explanation for the 
lack of an increase in dex-mediated S226 phosphorylation, is that dex-stimulation leads to 
“saturation” of S226 phosphorylation and whether or not there is more active JNK, with 
additional MG132 stimulation, the amount of S226 phosphorylation can not increase any further.  
Alternatively, degradation of a phosphatase could also be inhibited, thereby resulting in increased 
phosphatase protein levels and slightly less dex-mediated S226 phosphorylation, however this 
remains to be tested.  It is interesting to note, that the increase in basal S226 phosphorylation was 
not due to an increase in kinase protein levels, but rather activation of the kinase (JNK) by 
MG132 and it would be interesting to determine if MG132 also results in activation of 
phosphatases or if it simply results in increased phosphatase protein levels.  Interestingly, -
amanitin does not seem to increase the amount of phosphorylated/active JNK, but still results in 











total GR or total JNK.  One possible explanation for the increase in basal S226 phosphorylation, 
is that -amanitin blocks transcription of the phosphatase responsible for de-phosphorylating the 
GR at S226 and that the result seen is not due to increased phosphorylation of S226, but rather a 
“lack” of de-phosphorylation.  However, stimulation with -amanitin increased the amount of 
total mitogen-activated protein kinase phosphatase 1 (MKP-1) (data not shown).  Whether MKP-
1 plays a role in GR de-phosphorylation and/or whether -amanitin inhibits transcription of 
another phosphatase responsible for de-phosphorylating S226, has yet to be tested. 
 
Stimulation with MG132 significantly increased p38 phosphorylation and decreased dex-
mediated S211 phosphorylation.  This result is inconsistent with a model in which p38 
phosphorylates the GR at S211 in COS-1 cells, as reported in the literature for different cells 
(Rogatsky et al., 1998b), but is consistent with data presented in this thesis (Figs. 5.1 and 5.3 in 
Chapter 5) showing that p38 is not responsible for S211 phosphorylation in COS-1 cells.  One 
possible explanation for the apparent inconsistency in the decreased S211 and increased p38 
phosphorylation is that other kinases, such as CDKs plays a role in S211 phosphorylation.  
However, overexpression of wt and dominant negative CDK5 constructs, as well as the use of a 
general CDK inhibitor (roscovitine), did not increase or decrease S211 or S226 phosphorylation 
in three different cell lines (See figure 5.7 in Chapter 5).  Additionally, as discussed above for the 
decrease in dex-mediated S226 phosphorylation upon MG132 treatment, degradation of a 
phosphatase, responsible for dephosphorylation of the GR at S211, can be blocked.  However this 
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Figure 7.2 Proteasomal degradation and RNA polymerase II activity influences phosphorylation of 
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Figure 7.2 Proteasomal degradation and RNA polymerase II activity influences phosphorylation of 
JNK and p38.  To test the effect of -amanitin and MG132 on JNK and p38 phosphorylation, COS-1 
cells transiently transfected with 1 g HA-hGRwt were pre-treated with either 10 M MG132 for 4 hours, 
2.5 g/ml -amanitin for 24 hours or 0.02 g/ml TNF- for 15 minutes before stimulation with vehicle 
(EtOH) or 100 nM Dex for an additional 1 hour.  Equal amounts of samples were loaded onto an 8% SDS-
PAGE and Western blotting was performed, probing with either an anti-P-JNK (A) or anti-P-p38 antibody 
(B).  After developing, the blots were stripped and re-probed with total JNK or p38.  The amount of 
phosphorylated JNK and p38 was normalised to total JNK or p38 and plotted as the average of four 
independent experiments ± SEM (C and D) and (E).  Total JNK and p38 is shown in (F and G) and (H), 
respectively.   The histograms in C, D, E, F, G and H show pooled results from four independent 
experiments, plotted as means ± SEM, while Western blots in A and B each show results of one  
representative experiment. Statistical significance is indicated by different lower-case letters, such that all 
the conditions with the same letter are not statistically significantly different from each other (P > 0.05), 













The above mentioned effect of these inhibitors on kinases, and phosphatases, makes 
interpretation of the GR phosphorylation data and requirement of transcription and degradation, 
difficult.  Nevertheless, taken together, these results suggest that protein degradation is required 
for dex-induced GR phosphorylation at S211, but inhibits basal GR phosphorylation at S211, as 
well as S226.  The significance of this on GR function is unclear. One interpretation would be 
that in order for newly synthesized GR to be phosphorylated, the already phosphorylated GR 
needs to first be degraded.  Additionally, different GR ligands result in faster or slower GR 
degradation (Fig. 6.2 in Chapter 6).  If GR degradation is required for ligand-mediated GR 
phosphorylation, then the different rates of GR degradation with the different ligands, will result 
in differential GR phosphorylation, which is consistent with the ligand-selective GR 
phosphorylation results found in Chapter 8.   
 
Phosphorylation is a dynamic process, wherein the amount of phosphorylation observed, is a 
combination of kinases and phosphatases (Wang et al., 2007b). Accordingly, inhibition of protein 
degradation and transcription would also influence the relative kinase and/or phosphatase levels, 
thereby resulting in an indirect effect on GR phosphorylation. For example, without any 
inhibitors, the relative levels of the kinases responsible for phosphorylating the GR, may be 
higher than that of the phosphatases, resulting in the high levels of GR phosphorylation observed.  
If degradation is inhibited, less GR phosphorylation could be observed due to, the kinase-
phosphatase balance being shifted towards less kinase and more phosphatase.  Since degradation 
and transcription of both the kinase and the phosphatase would be inhibited, one interpretation of 
the current data is the presence of a phosphatase that is rapidly synthesized and slowly degraded, 
and a kinase that is slowly synthesized and rapidly degraded.  When degradation is inhibited, the 
rapid synthesis of the phosphatase could result in relatively more phosphatase than kinase 











would be observed.  Similarly, when transcription is inhibited the rapidly degrading kinase and 
the slow degrading phosphatase would also result in relatively more phosphatase than kinase 
being present and less GR phosphorylation would be observed.  This hypothesis is consistent 
with results in figure 7.2 H, where inhibition of transcription and degradation resulted in slightly 
less p38 kinase.  This hypothesis would also explain the effects of inhibition of degradation on 
dex-induced S226 phosphorylation, where a decrease in S226 phosphorylation is observed when 
transcription and degradation is inhibited.  However, the amount of basal S226 phosphorylation 
increases when both transcription and degradation is inhibited. This is not consistent with the 
above mentioned model and could imply that different kinases and/or phosphatases are 
responsible for phosphorylation of the liganded and unliganded GR. However, further 
experiments are needed to test this hypothesis. 
 
Results in figures 7.1 C and D show that transcription is required for dex-induced 
phosphorylation at S226, but not at S211. It therefore seems that the mechanism of ligand-
mediated GR phosphorylation at S226, differs from that of ligand-mediated GR phosphorylation 
at S211. One interpretation is that ligand-mediated phosphorylation at S211 is much more 
‘stable’ than that of S226.  Therefore transcription of new GR molecules is required for a high 
level of ligand-mediated GR phosphorylation at S226, whereas ligand-mediated phosphorylation 
at S211 remains longer and does not require transcription of new GR molecules.  To this extent 
dex-mediated GR phosphorylation at S211 has been shown to be more ‘stable’ than dex-mediated 
GR phosphorylation at S203 (Wang et al., 2007b). In order to get a better understanding of the 
requirement of GR degradation and GR transcription on GR phosphorylation, would require 
more direct means of inhibiting only GR-mediated transcription and degradation specifically.  
For instance, GR mutants wherein the AF-1 and AF-2 domains are mutated and can no longer 

























7.2 The role of GR phosphorylation on GR degradation 
 
In order to more directly determine whether or not GR phosphorylation plays a role in ligand-
mediated GR degradation and whether such effects could be correlated with the changes in 
transactivation efficacy observed in Chapter 4, GR half-life experiments comparing wt and 
phosphorylation mutants (S211A and S226A) were performed.  COS-1 cells transiently 
transfected with hGR wt, S211A or S226A were pretreated with 1 M cycloheximide for 1 hour 
before stimulation with compound.  Equal amounts of cell extract were separated on SDS-PAGE 
and Western blot analysis, probing with anti-GR and anti--actin antibodies, was performed (Fig. 
7.3 A).  Results show no clear difference between the degradation of unliganded or liganded wt 
versus phosphorylation mutant receptors (Figs. 7.3 A-E). As with the previous half-life results 
(Chapter 6), the unliganded GR is degraded slowly over time (Fig. 7.3 B).  Upon stimulation with 
the full agonist dex or full/partial agonist MPA or dissociated ligand RU486 (Figs. 7.3 C-E), the 
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Figure 7.3  Ligand-selective down-regulation of S211A and S226A GR.  COS-1 cells were plated in 
10-cm dish at a density of 2x106cells/dish and transfected with 10 g of either HA-hGRwt, HA-
hGRS211A or HA-hGRS226A.  After 24 hour incubation, cells were replated into 6-well plates at a 
density of 4x105 cells/well. The next day the cells were pre-treated with 1 M cycloheximide for 1 hour 
and then treated with vehicle (EtOH) or 10 M compound.  At the appropriate time, whole cell extracts 
were prepared and equal amounts of lysate (7 l) were analyzed by Western blotting with anti-GR and -
actin antibody (A).  After quantification and normalization to -actin, the amount of GR present at 0 hour 
was set to 100% and the amount of GR present at the other time points were calculated as a percentage 
thereof (B-E).  The histograms in B, C, D and E show pooled results from four independent experiments, 
plotted as means ± SEM. while Western blots in A show results of one  representative experiment 
 
In order to determine if there is any statistically significant difference between the half-life of wt 
GR vs. the phosphorylation mutants, as well as the total amount of degradation over time (the 
amount of GR left at 72 hours), the half-life and end-point values were plotted as bar graphs and 
analysed (Figs. 7.4 A and B).  From figures 7.4 A and B, it is evident that there is no statistically 
significant difference in the half-life or the total amount of degradation over time, in both the 
absence and presence of ligand, for wt versus the phosphorylation mutants. Furthermore, the 
same ligand-selective pattern of GR degradation, that is seen in Chapter 6 (Fig. 6.2), whereby 
agonists (dex) results in the quickest GR degradation, followed by the partial/full agonists (MPA) 
and then the dissociated ligand RU486, was found for wt and the mutant GRs. These results show 











Chapter 4) is not due to an increased rate of GR degradation.  Similarly, the increase in 
transactivation with the S226A mutant on the TAT-GRE and MMTV promoter (Figs. 4.8 and 
4.10 in Chapter 4) is not due to a decreased rate of GR degradation.          
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Figure 7.4  Comparison between the half-life and total degradation of wt, S211A and S226A GR.  
The respective half-life values (A) were calculated from figure 5.3 and the amount of GR left at the 72 
hour time point (B) was taken from figure 5.3.  The histograms in A and B show pooled results from four 
independent experiments, plotted as means ± SEM. Statistical significance is indicated by different lower-
case letters, such that all the conditions with the same letter are not statistically significantly different from 
each other (P > 0.05), while those having different letters are statistically significantly different from each 












In order to rule out the possibility that phosphorylation site compensation could have lead to the 
false conclusion that GR degradation, in the presence or absence of ligand, is not determined by 
GR phosphorylation, half-life experiments comparing the triple phosphorylation mutant with wt 
GR was performed.  Consistent with the results mentioned above, as well as those in Chapter 6 
(Fig. 6.2), the unliganded GR degrades slowly over time and the rate of GR degradation is 
enhanced upon stimulation with the agonist dex (Fig. 7.5 A).  Furthermore, the same pattern of 
ligand-selective GR degradation is found, since the dissociated ligand RU486 degrades slower 
than the full agonist dex and has a longer half-life. In addition, consistent with the results 
obtained with the S211A and S226A mutants, the half-life of the unliganded (Fig. 7.5 B) and 
liganded (Figs. 7.5 C and D) triple phosphorylation mutant is not different to that of wt.  These 
results clearly show that unliganded and liganded GR degradation does not require GR 
phosphorylation at S203, S211 or S226 and that extent of ligand-selective GR phosphorylation 
does not determine the rate of ligand-selective GR degradation. Furthermore, the lack of dex-
mediated GR transactivation with the triple phosphorylation mutant on the MMTV reporter-
promoter construct (Fig. 4.10 in Chapter 4), is not due to phosphorylation increasing the rate of 





























Figure 7.5  Triple phosphorylation mutant degradation. COS-1 cells were plated in 10-cm dish at a 
density of 2x106cells/dish and transfected with either pRS-hGRwt or pRS-hGR3A.  After 24 hour 
incubation, cells were replated into 6-well plates at a density of 4x105 cells/well. The following day the 
cells were pre-treated with 1 M cycloheximide for 1 hour and then treated with vehicle (EtOH) or 100 
nM compound.  At the appropriate time, whole cell extracts were prepared and equal amounts of protein 
were analyzed by Western blotting and probed with anti-GR and anti--actin antibody. A single 
representative Western blot is shown for each GR construct. (A).    After quantification and normalization 











time points was calculated as a percentage thereof (B), (C) and (D).  Graphs show the average of four 
independent experiments, with values plotted as means ± SEM.   
 
Taken together, these results show that GR degradation in the absence or presence of ligand is not 
dependent on GR phosphorylation at S203, S211 or S226.  Furthermore, the extent of ligand-
selective GR phosphorylation does not determine the rate of ligand-selective GR degradation.  
The correlation between ligand-selective GR phosphorylation and degradation (Fig. 6.4 in 
Chapter 6) therefore, does not indicate a direct relationship between GR degradation and 
phosphorylation.  It is likely, that the correlation indicates that both GR phosphorylation and 
degradation is a consequence of the same “ligand-selective determining step”, e.g. ligand-induced 
conformational change upon binding to the GR. For a more detailed discussion on this, see 
Chapter 8 (Conclusions and future perspectives).  
 
Furthermore, the results obtained with the S211A and S226A mutants, are consistent with those 
of Webster et al. who showed in COS-1 cells, that phosphorylation of the individual residues of 
the mouse equivalent of S211 or S226 does not play a role in unliganded and liganded mGR 
degradation (Webster et al., 1997). The triple phosphorylation mutant results presented in this 
thesis, are however in contrast to those of Webster et al. who showed that the combined mutation 
of the mouse equivalent S203, S211 and S226 residues resulted in a decrease dex-mediated mGR 
degradation. However, in these experiments, Webster et al. showed differential expression levels 
of wt and 3A mutant receptor, but did not show the degradation of the unliganded 3A mutant.  In 
the above mentioned study, the 3A mGR could have a similar fold decrease in degradation of the 
dex-mediated vs. unliganded GR, as wt mGR.  Additionally, Webster et al. did not use 
cycloheximide to stop de novo protein synthesis, making it difficult to distinguish between GR 











of Webster et al. is therefore difficult and would have to be done with mGR and hGR in parallel 
to obtain further insight into the apparent species-specific differences. Furthermore, Webster et 
al. also showed that the simultaneous mutation of 7 or 8 phosphorylation sites completely 
abolished ligand-selective mGR degradation.  A more recent paper showed that the mutation of a 
single phosphorylation site, S404 resulted in a complete loss of dex-mediated hGR degradation 
(Galliher-Beckley et al., 2008).  Webster et al. did not include the single mutation of the mouse 
equivalent to S404 in his studies, making it difficult to directly compare these two studies.  
However, with the simultaneous mutation of 7 and 8 phosphorylation sites, Webster et al. 
included the mouse equivalent to S404.  It is therefore likely, that the complete loss in dex-
mediated mGR degradation with the GR mutated at 7 or 8 phosphorylation sites, was due to the 
mutation at S404.  Additionally, in the same paper, Webster et al. showed that mutation of the 
mouse equivalent to S211 reduced GR-mediated transactivation on a simple TAT-GRE 
promoter-reporter construct, but not on a MMTV reporter-promoter construct, whereas, mutation 
of the mouse equivalent to S226 did not influence GR-mediated transactivation on the TAT-GRE 
or MMTV reporter-promoter construct (Webster et al., 1997).  The mouse triple mutant resulted 
in a complete loss in GR-mediated transactivation on the TAT-GRE reporter-promoter, but had 
no effect on the MMTV reporter-promoter (Webster et al., 1997).  These transactivation results 
are inconsistent with the proposed role of GR phosphorylation on GR-mediated transcription, by 
changing GR degradation. Furthermore, the apparent differences in transactivation, as well as in 
GR half-life obtained in this thesis to those of Webster et al. indicate that there are possible 
species-specific differences in the role of GR phosphorylation and warrants further investigation. 
 
Results presented in this thesis, are the first to convincingly show with different GR ligands, by 
inhibiting de novo protein synthesis and with similar hGR expression levels, that hGR 











the unliganded or liganded receptor.  Furthermore, hGR phosphorylation on S203, S211 and/or 
S226 does not influence GR-mediated transcription via increasing or decreasing degradation of 
the unliganded- or liganded-GR and the mechanism of how GR phosphorylation influences GR-













7.3  The role of phosphorylation at S203, S211 and S226 on GR acetylation 
and p300 recruitment 
 
In order to investigate whether phosphorylation at S203, S211 and S226 is required for GR 
acetylation, and recruitment of p300, and thereby influences GR-mediated transcription, an in 
vitro DNA pull down ABCD assay using biotinylated GREs was performed.  Results show that 
the unliganded GR bound the GREs to a similar extent as dex-stimulated GR and that slightly 
more triple phosphorylation mutant GR, versus wt GR, bound to the GREs (Fig. 7.6).  However, 
this is likely due to more concentrated triple phosphorylation mutant cytosols in the input.  Both 
wt and triple phosphorylation mutant resulted in the recruitment of endogenous p300, both in the 
absence and presence of dex.  In two independent experiments the amount of p300 recruited with 
wt GR was similar in the dex stimulated and non-stimulated samples, indicating that in this in 
vitro assay, wt GR does not recruit p300 in a dex-dependent manner. Furthermore, the amount of 
p300 binding with the triple phosphorylation mutant was slightly less than that of wt GR, both in 
the absence and presence of dex. However, this was variable between the two independent 
experiments.  Taken together, the small fraction of p300 in the pull down, versus the extremely 
high levels of endogenous p300 in the input, as well as the fact that p300 was not recruited in a 
dex-dependent manner, makes it unlikely that p300 plays a major role in dex-mediated GR 
transcription via a GRE.  After stripping the GR Western blot and reprobing with an anti-acetyl-













Figure 7.6  GR acetylation and P300 recruitment. COS-7 cytosols (20 l) containing endogenous p300, 
as well as expressed pRS-hGRwt, pRS–hGR3A or empty vector (pcDNA3.1) containing hGR prebound 
with ethanol vehicle (EtOH) or 10 M Dex were incubated with biotinylated GRE oligonucleotides 
attached to Streptavidin beads.  Equal amounts of input cytosol, as well as DNA-bound GR or p300 were 
separated by SDS-PAGE and visualized by Western blotting with anti-p300 or anti-GR antibodies.  
Thereafter the GR blot was stripped and reprobed with anti-acetyl-lysine or anti-P-226 antibodies. The 
Western blots are one representative of two independent experiments.   
 
Results show that wt and the triple phosphorylation mutant were both acetylated in the absence 
and presence of dex, with no clear difference between untreated or dex-stimulated GR, indicating 
that in this in vitro assay, the GR is not acetylated in a dex-dependent manner.  Furthermore, the 
triple phosphorylation mutant was acetylated to a similar extent as wt, even though the triple 
mutant can not be phosphorylated, showing that phosphorylation of the GR at S203, S211 and 
S226 is not required for GR acetylation and does most likely not affect the extent of GR 
acetylation.   
 
Recently, the HAT activity of overexpressed p300 has been shown to decrease GR mediated 











cells (Fonte et al., 2007). However, direct GR acetylation and p300 recruitment by the GR was 
not examined in this study.  Furthermore, Li et al. showed that p300 interacts with the rGR in a 
dex-dependent manner, and that this interaction results in an increase in rGR mediated 
transactivation on a MMTV reporter-promoter construct in HeLa cells (Li et al., 2002). 
Treatment with HDAC inhibitors, sodium butyrate and trichostatin A, decreased GR-mediated 
transactivation on the MMTV-promoter, as well as decreased the interaction between GR and 
p300, indicating that acetylation plays a role in the interaction of the GR and p300, as well as in 
GR transcription.  However, direct GR acetylation was not examined in this study. The above 
mentioned studies indicate that p300 can either increase or decrease GR-mediated transcription in 
a process that seems to be cell-specific, i.e. increased transcription in HeLa cells and decreased 
transcription in astrocytes and schwann cells.  Results presented in this thesis, suggest that p300 
is not recruited to DNA-bound GR in a dex-dependent manner in vitro and is unlikely to play a 
major role in the complete loss in dex-mediated GR transcription found with the triple 
phosphorylation mutant.  Although it seems that there is a small decrease in p300 recruitment 
with the triple phosphorylation mutant, this was highly variable between the experiments. Due to 
the variability of this result, it was concluded that phosphorylation of the GR at S203, S211 and 
S226 does not play a major role in the recruitment of p300. This is in contrast to results obtained 
by Kino et al. which showed that phosphorylation of the GR at S203, S211 and S226, inhibited 
the recruitment of p300, and thereby decrease GR-mediated transactivation on a MMTV 
promoter in HCT116 cells (Kino et al., 2007). Apart from methodological differences, a major 
difference in the above mentioned study and results presented in this thesis, is that different cells 
were used.  It is likely, that the relative abundance of specific co-factors in different cells differ, 
which could form the basis of these apparent cell-specific differences.  Further investigation into 
the role of p300 on dex-mediated GR transcription on different genes and different cells is 











Results presented above, showed that GR acetylation does not occur in a dex-mediated manner. 
These results are inconsistent with a previous report in the literature that showed dex-mediated 
GR acetylation in A549 cells (Ito et al., 2006b).  It is likely that cell specific differences, or 
methodological differences including the length of dex treatment (4 vs. 16 hours) can account for 
the different results obtained in the literature and the present study.  In addition, whether p300 is 
directly responsible for acetylation of the GR has not been shown.  Since the results presented in 
this study showed low levels of p300 recruitment in vitro, as well as low levels of GR 
acetylation, neither of which was dex-dependent, it was not determined whether or not p300 
acetylates the GR.  .    
 
Nevertheless, results in this thesis, show for the first time, that phosphorylation of the GR at 
S203, S211 and S226 is not required for GR acetylation.  Furthermore, in this cell system, GR 
phosphorylation at S203, S211 and S226 is not a major determinant of the recruitment of p300. 
Thus the mechanism whereby GR phosphorylation at S203, S211 and/or S226 influences GR-


















7.4  The role of phosphorylation on GRIP-1 recruitment 
 
Previously a direct correlation between potency and efficacy for transactivation of the GR and 
GRIP-1 co-activator recruitment was shown (Ronacher et al., 2009).  Having shown that 
phosphorylation of the GR at S203, S211 and/or S226 is not required for GR degradation, p300 
recruitment or GR acetylation, the requirement of GR phosphorylation in GRIP-1 recruitment 
was next examined.  When the S226 and S211 phosphorylation results were correlated with 
GRIP-1 binding, as determined by a mammalian two-hybrid assay (data from (Ronacher et al., 
2009); Addendum E), a small but significant correlation for both S226 (R2 = 0.55, p < 0.03) and 
S211 (R2 = 0.66, p < 0.01) was found (Fig. 7.7).   
 
 
Figure 7.7 Correlation between S226 and S211 phosphorylation and GRIP-1 binding.  Ligand-
selective GR phosphorylation at S226 (Chapter 4) and at S211 ((Stubsrud, 2005), Addendum D) results 
were correlated with ligand-selective GRIP-1 binding to the hGR as measured by a mammalian two-
hybrid assay ((Ronacher et al., 2009)).  
 
These correlations and the influence of GR phosphorylation on transactivation efficacy, as well 
as the direct correlation between efficacy and potency for transactivation of the GR and GRIP-1 
recruitment (Ronacher et al., 2009), indicates that phosphorylation of the GR could be required 











 7.4.1 GRIP-1 binding to the GR in vitro 
 
In order to determine whether GR phosphorylation at S211 or S226 is required for GRIP-1 
binding to the GR, COS-1 cells transiently transfected with hGR wt, S211A or S226A, as well as 
HA-GRIP-1, were stimulated with 100 nM dex for 1 hour.  After lysis, the cell extracts were 
immunoprecipitated with anti-GR antibodies and the bound proteins were separated on SDS-
PAGE.  After Western blotting with anti-GR and anti-HA antibodies, it can be seen that the 
unliganded GR does not bind GRIP-1, as no GRIP-1 was co-immunoprecipitated in the absence 
of ligand (Fig. 7.8 A).  However, upon dex-stimulation, GRIP-1 bound to the GR and there seems 
to be less GRIP-1 immunoprecipitated with the S226A mutant than with wt GR.  Furthermore, 
before the immunoprecipitation, all the cell extracts contained the same amount of GRIP-1 and 
GR, which excludes the possibility that less GRIP-1 was immunoprecipitated with the S226A 
mutant simply because it had a lower concentration of GRIP-1 or GR in the input lysate.  After 
quantification and normalisation to the amount of precipitated GR, the S226A mutant (~ 1.5 
fold), as well as the S211A mutant (~ 2 fold) (although to a lesser extent) showed less dex-


























Figure 7.8 The importance of S211 and S226 phosphorylation in GRIP-1 recruitment. COS-1 cells 
transiently transfected with HA-GRIP-1, as well as either HA-hGRwt, HA-hGRS211A or HA-hGRS226A 
were treated with vehicle (EtOH) or 100nM Dex for 1 hour.  After lysis, 1/50 of the cell lysate was 
subjected to SDS-PAGE and Western blotting and analysed for input levels of GR and HA-GRIP-1 (A).  
The remainder of the cell lysate was immunoprecipitated using anti-GR antibody and protein A/G beads.  
Proteins bound to the complex were analysed by Western blotting and probing for GR and HA-GRIP-1 
(A).  The amounts of HA-GRIP-1 and GR immunoprecipitated were normalised to their respective inputs, 
where after the amount of GRIP-1 was normalised to the amount of GR and plotted as the average ± SEM 
of between two to four independent experiments (B). 
 
These results indicate that phosphorylation of the GR at S226 and S211, albeit to a lesser extent, 
plays a role in the interaction between the GR and the co-activator GRIP-1.  However, due to 
relatively large experimental error and variability in the experiment, these results were not 











GRIP-1, the co-immunoprecipitation experiments were repeated with the triple phosphorylation 
mutant in the hope that this mutant would have less experimental variability.  Consistent with the 
results in figure 7.8, the unliganded wt GR did not bind GRIP-1, since no GRIP-1 was 
immunoprecipitated in the absence of ligand, whereas dex stimulation resulted in GRIP-1 binding 
(Fig. 7.9 A).  However, contrary to the small decrease seen in GRIP-1 binding with the single 
phosphorylation mutants, the triple phosphorylation mutant had extremely low levels of GRIP-1 





















Figure 7.9 GRIP-1 co-immunoprecipitation.  COS-1 transiently transfected with HA-GRIP-1, as well 
as either pRS-hGRwt, pRS-hGR3A or empty vector (pcDNA3.1) were treated with vehicle (EtOH) or 100 
nM Dex for 1 hour.  After lysis, 1/50 of the cell lysate was subjected to SDS-PAGE and Western blotting 
and analysed for input levels of GR and HA-GRIP-1 (C).  The remainder of the cell lysate was 
immunoprecipitated using anti-GR antibody and protein A/G beads.  Proteins bound to the complex were 
analysed by Western blotting and probing for GR and HA-GRIP-1 (A).  The amounts of HA-GRIP-1 and 
GR immunoprecipitated were normalised to their respective inputs, and plotted as the average ± SEM of 
between two to four independent experiments (B). Statistical significance is denoted by ***,  to indicate P 
< 0.001. 
 
Quantification and normalisation to the immunoprecipitated GR shows that wt GR had a 4 fold 
increase in GRIP-1 binding upon dex stimulation, whereas the triple phosphorylation mutant 
showed a modest 1.5 fold induction in GRIP-1 binding (Fig. 7.9 B). This difference was not due 
to differential expression of GRIP-1 or GR, since the amount of GRIP-1 and GR was similar in 
the inputs (Fig. 7.9 C).  Furthermore, GRIP-1 binding is specifically mediated by the 
overexpressed plasmids, since the minus GR control did not show any GRIP-1 binding in the 
absence or presence of dex (Figs. 7.9 A and B).  These results clearly show that phosphorylation 
of the GR at S203, S211 and S226 is required for the interaction between the GR and the co-















7.4.2  GRIP-1 and GR recruitment to the MMTV promoter in vivo 
 
Having shown that GR phosphorylation at S203, S211 and S226 is required for the interaction 
between the GR and GRIP-1 in vitro, the requirement of phosphorylation at S203, S211 and S226 
for the interaction between the GR and GRIP-1 on the MMTV promoter, in vivo, was next 
examined.  COS-1 cells transiently transfected with HA-GRIP-1 and MMTV promoter, as well as 
either wt or 3A hGR, were stimulated with dex for 1h and a ChIP assay was performed, 
immunoprecipitating with an anti-HA antibody.  Conventional PCR, using primers to the GRE 
region of the MMTV promoter, shows that all the input levels are the same (Fig. 7.10 A), which 
makes it possible to directly compare the samples with each other.  Additionally, very little DNA 
was immunoprecipitated in the absence of over-expressed GR (-GR) and the IgG antibody 
control did not show any amplified DNA (Fig. 7.10 A).  Results show that wt GR, bound to the 
GRE, recruited GRIP-1 in a dex-dependent manner, while the 3A GR did not show any dex-
dependent effects on GRIP-1 recruitment (Fig. 7.10 A).  Moreover, quantitative real-time PCR of 
the immunoprecipitated DNA revealed that the dex-mediated increase in GRIP-1 recruitment to 
wt GR is 3 fold, while 3A did not show any statistically significant dex-mediated increase in 
GRIP-1 recruitment (Fig. 7.10 B).  These results show that phosphorylation of the GR is needed 
for dex-mediated GRIP-1 recruitment to the GRE of the MMTV-luc promoter in vivo. 
 
To determine whether the triple phosphorylation GR mutant could still bind to the GRE, and 
whether the lack of GRIP-1 recruitment with the 3A mutant is due to less binding of the mutated 
GR to the GRE, a GR ChIP assay was performed.  After the chromatin was immunoprecipitation 
with a GR antibody, it was found that dex stimulation led to the recruitment of wt GR to the GRE 
(Fig. 7.10 C). Interestingly, the triple phosphorylation mutant was also recruited in a dex-


































Figure 7.10 GRIP-1 and GR recruitment to the MMTV promoter.  COS-1 cells transiently transfected 
with HA-GRIP-1, MMTV reporter-promoter and either pRS-hGRwt, pRS-hGR3A or empty vector 
(pcDNA3.1) were treated with vehicle (EtOH) or 100 nM Dex for 1 hour.  ChIP was performed using 
either an anti-HA antibody, an anti-GR antibody or an anti-IgG antibody.  Conventional PCR 
amplification, using PCR primers encompassing the GRE region of the MMTV construct, was performed 
on input chromatin, as well as the chromatin precipitated with anti-HA antibody (A),  or anti-GR antibody 
(C) and products were resolved on agarose gels. Quantitative real-time PCR on the DNA 
immunoprecipitated with the anti-HA (B) or anti-GR (D) antibodies was also performed.  Expression of 
wt and 3A GR in the chromatin was analysed by Western blot probing for total GR (E). Results shown in 
B and D are from three independent experiments, with values plotted as the average ± SEM , normalised 
to input DNA and EtOH set to 1. NTC = no template control. The letters a, b and c are used to denote 
statistically significant differences, such that all the conditions with the same letter are not statistically 
significantly different from each other (P>0.05), while those having different letters are statistically 
significantly different from each other (P<0.05). 
 
Quantitative real-time PCR of the immunoprecipitated DNA revealed that wt GR recruitment to 
the GRE increased 6 fold upon dex-stimulation, whereas the triple phosphorylation mutant only 
increased by 2 fold (Fig. 7.10 D).  This difference in DNA recruitment was not due to less GR 
present in the input, since the amount of wt GR in the sonicated chromatin, as determined by 
Western blotting with a GR antibody, was found to be slightly less than the amount of 3A GR 
(Fig. 7.10 E).   
 
These results show that phosphorylation of the GR at S203, S211, and S226 is required for GRIP-











mutated GR with the GRE could possibly explain the lack of significant detectable GRIP-1 
recruitment observed with the 3A mutant.   
 
 
7.4.3 The role of phosphorylation at S203, S211 and S226 in GR subcellular localisation 
 
Having shown less hGR and GRIP-1 recruitment to the MMTV promoter with the 
phosphorylation mutant after 1 hour dex treatment, it was next determined whether 
phosphorylation of the hGR plays a role in GR nuclear translocation.  COS-1 cells, transiently 
transfected with hGR wt or 3A were stimulated with 100 nM dex or vehicle (EtOH) for 1 hour.  
Thereafter, cytoplasmic and nuclear fractions were prepared and separated on SDS-PAGE, 
followed by Western blotting with anti-GR, anti-GAPDH and anti-Histone H3 antibodies as 
controls.  Wt and 3A GR were expressed similarly in the input (Fig. 7.11 A). The cytoplasmic 
GAPDH and nuclear H3 Western blots show that pure fractions were obtained (Fig. 7.11 B).  In 
the absence of ligand, the hGR is predominantly cytoplasmic, whereas stimulation with dex 
results in GR nuclear translocation with ~50% of the hGR located in the nuclei (Fig. 7.11 C).  
Furthermore, no difference between wt and 3A GR subcellular localisation in the presence or 
absence of dex was detected.  These results show that phosphorylation at S203/S211/S226 does 
not influence hGR nuclear translocation, suggesting that the decrease in GR and GRIP-1 
recruitment to the MMTV promoter in the ChIP assay, is not due to deficient nuclear 
























Figure  7.11 Phosphorylation of the hGR at S203/S211/S226 does not influence GR nuclear 











(-GR) were treated with vehicle (EtOH) or 100 nM dex for 1 hour.  Western blotting with an anti-GR 
antibody was performed on the input samples (A), before cytoplasmic and nuclear fractions were 
prepared.  Thereafter equal amounts of the fractions were separated on SDS-PAGE and Western blotting 
with anti-GR (GR), anti-GAPDH (GAPDH) and anti-Histone H3 (H3) was performed (B).  After 
quantification, the amount of GR in the input was set to 100% and the amount of GR in the cytoplasmic 
and nuclear fractions was calculated as a percentage of input (C).  The blots (A and B) are single 
representative figures from four independent experiments and the graph in C is pooled data from four 
independent experiments, with values plotted as the average ± SEM.  In (C) the letters a, b and c are used 
to denote statistically significant differences, such that all the conditions with the same letter are not 
statistically significantly different from each other (P>0.05), while those having different letters are 
statistically significantly different from each other (P<0.05). C, cytoplasmic fractions; N, nuclear fractions    
 
 
7.4.4  The role of phosphorylation at S203, S211 and S226 in DNA binding in vitro 
 
In order to investigate whether mutation of the three serine residues results in a loss of GR DNA 
binding per se, an in vitro DNA pull down ABCD assay using biotinylated GREs was performed. 
These results showed that the same amount of GR was bound to the biotinylated GRE for wt and 
3A mutated GR (Fig. 7.12 A).  However, consistent with the ChIP and co-immunoprecipitation 
assays, stimulation with dex resulted in recruitment of more GRIP-1 for wt GR than for the 3A 
GR mutant.  Normalisation and quantification revealed that dex stimulation led to a ~4.5 fold 
increase in GRIP-1 binding for wt GR while no significant GRIP-1 binding occurred for the 3A 
GR (Fig. 7.12 B).  Additionally, no GRIP-1 binding was detected in the absence of ligand or in 
the absence of expressed GR, showing a requirement for the GR for GRIP-1 association with the 
DNA.  Both wt and 3A GR were expressed at similar levels (Fig. 7.12 C) and the same GRIP-1 
cytosols were used for wt and GR mutant pull down assays.   These results show that 
phosphorylation of the GR at one of more of residues S203, S211 and S226 is required for GRIP-




















Figure  7.12  GRIP-1 recruitment to the GRE in vitro.  COS-7 cytosols (20 l) containing expressed 
pRS-hGRwt, pRS-hGR3A or empty vector (pcDNA3.1) containing hGR prebound with ethanol vehicle 
(EtOH) or 10 M Dex were incubated with biotinylated GRE oligonucleotides attached to Streptavidin 











input cytosol (C), as well as DNA-bound GR or HA-GRIP-1 were separated by SDS-PAGE and 
visualized by Western blotting with anti-HA or anti-GR antibodies (A).  After quantification and 
normalization to GR levels, the amount of HA-GRIP-1 bound to the GR:DNA complex was plotted (B).  
The graph shows results of three independent experiments, with averages thereof plotted as fold induction, 
relative to vehicle. Statistical significance is denoted by ***, to indicate P < 0.001. 
   
Furthermore, GRIP-1 recruitment to the GR on the MMTV promoter, increases GR-mediated 
efficacy for transactivation (Fig. 7.13).  The lack of GRIP-1 recruitment to the MMTV promoter 
with the GR triple phosphorylation mutant, is therefore likely to result in the complete lack of 
GR-mediated efficacy for transactivation observed with the triple phosphorylation mutant on the 




Figure. 7.13 GRIP-1 recruitment to the MMTV promoter increases GR-mediated efficacy for 
transactivation.  COS-1 cells transiently transfected with 0.125 g pRS-hGRwt, 0.047 g MMTV 
reporter-promoter and 0.012 g gal construct, in the presence or absence of 0.047 g HA-GRIP-1 were 
treated with vehicle (EtOH) or 100 nM Dex for 24 hours.  Luciferase activity in the cell lysates was 
normalised to gal activity per well.  The histogram shows pooled results from two independent 
experiments, where each condition was performed in triplicates, and average values were plotted as means 
± SEM, expressed as fold induction.  The letters a, b and c are used to denote statistically significant 











each other (P>0.05), while those having different letters are statistically significantly different from each 
other (P<0.05). 
 
It is possible that the decreased GR-DNA interaction observed for the triple mutant in the ChIP 
assay was due to changes in nuclear trafficking of the GR mutant. Working in intact cells, 
multiple factors including nuclear export and/or import could influence the ChIP result.  Itoh et 
al. showed that phosphorylation of the GR at S226 enhances nuclear export of the GR (Itoh et al., 
2002).  Accordingly, the 3A triple mutant which contains the S226A mutation would be predicted 
to exhibit a reduced nuclear export resulting in more nuclear accumulation of GR compared to 
wt.  Increased nuclear accumulation of the GR could however not explain less GR-DNA 
interaction, making it unlikely that a reduced nuclear export could explain our results.  Others 
have shown that dex-stimulation leads to the accumulation of phosphorylated S211 in the 
nucleus, which led Wang et al. to postulate that S211 phosphorylation could increase GR nuclear 
import (Wang et al., 2002b).  If S211 phosphorylation increases nuclear import in the current 
study, the 3A triple mutant that contains the S211A mutation should exhibit reduced nuclear 
import of the GR. This would be consistent with the reduced DNA binding found for the triple 
mutant in the ChIP assay.  However, results presented in this thesis show that the wt and triple 
phosphorylation hGR mutant exhibit a similar degree of dex-mediated nuclear accumulation, 
consistent with another report for the mGR.  Webster et al. showed that the combined mutation of 
the mouse residues equivalent to the human S203/S211/S226 GR residues did not influence mGR 
nuclear import, but still led to an almost complete loss of transactivation efficacy on a GRE-
luciferase construct (Webster et al., 1997).  Thus one possible interpretation of these results is 
that phosphorylation of the hGR at S203/S211/S226, in addition to being required for GRIP-1 
interaction, also plays a role in DNA binding in intact cells. If this is the case, then the in vitro 











loss of DNA binding cannot be mimicked in vitro.  Another explanation for the apparent 
discrepancy between the GR DNA binding result in the ChIP compared to the in vitro ABCD 
assay could be that the GR-DNA binding affinity is similar in intact cells and in vitro, but that 
differences are observed due to different incubation times and differential kinetics of wt versus 
triple mutant hGR for binding to DNA Thus the relative amounts of phosphorylated versus 
unphosphorylated hGR bound to DNA and hence the transcriptional response may vary over time 
and represent another mechanism of fine tuning transcriptional responses. Nevertheless, taken 
together, these results clearly show that phosphorylation of the hGR at one or more of residues 
S211/226/203 is required for GR interaction with GRIP-1 in the absence and presence of a GRE 
in vitro, as well as on the MMTV promoter in intact cells.   
 
Interestingly, results in figure 7.8 suggest that the S226A mutant seems to be the dominant site 
involved in GRIP-1 recruitment.  However, this result is inconsistent with the transactivation 
result, where phosphorylation at S226 inhibits transactivation efficacy. One possible explanation 
for the apparent inconsistency is that apart from playing a role in GRIP-1 recruitment, 
phosphorylation on S226 might be involved in the recruitment of corepressors, such as NCoR or 
SMRT and thereby inhibits transactivation efficacy. However, in the literature, there is no 
evidence to suggest S226 phosphorylation is involved in co-repressor recruitment. 
 
Results from Kino et al., using the same triple hGR mutant construct, suggest that 
phosphorylation of S203/S211/S226 inhibits transcriptional activity of the hGR on a MMTV-
promoter in HCT116 cells via inhibition of recruitment of the histone acetyltransferase (HAT) 
co-activator, p300, to the GR bound on a MMTV-luciferase promoter (Kino et al., 2007).  In 
contrast, here it is shown that phosphorylation of S203/S211/S226 is required for maximal 











differential p300 recruitment, but most likely due to reduced GRIP-1 recruitment to the MMTV-
promoter.  Interestingly, phosphorylation of the hGR at S404, by glycogen synthase kinase 3 
(GSK3), was recently shown to be required for the recruitment of p300 (Galliher-Beckley et al., 
2008).  It would thus appear that phosphorylation of the GR at specific selected serine residues 
may be a mechanism for rapid differential gene regulation via increasing or decreasing co-
activator, HAT, and/or mediator complex recruitment in a cell- and promoter-specific manner, 













Chapter 8 Conclusions and future perspectives 
 
 
A central question in the steroid receptor field is how do different GR ligands elicit their 
differential physiological responses on the same gene in the same cell. In order to investigate 
what determines ligand-selectivity, the biological response of a large panel of ligands in 
transactivation and transrepression was determined (Ronacher et al., 2009).  The biological 
response of a particular ligand was then correlated with the behaviour of the liganded GR at a 
particular step in the GR transcriptional pathway.  These correlations do not establish a cause and 
effect, but can be used as a guide to focus on specific steps that could potentially determine 
ligand-selectivity.  This thesis concentrated on the role of two different steps in the hGR 
transcriptional pathway that could potentially determine ligand-selective GR-mediated 
transcription, namely GR phosphorylation at S226 and GR degradation.   
 
 
8.1 Ligand-selective GR phosphorylation 
 
Results presented in this thesis showed that GR phosphorylation at S226 occurs in a ligand-
selective manner. At the time this study was initiated, the effect of different ligands on S226 
phosphorylation was not know, but recently a study has been published with four GR ligands 
being investigated (Chen et al., 2008).  Results in this thesis are consistent with those of Chen et 
al., but showed ligand-selective GR phosphorylation at S226 with eight additional GR ligands.  
In addition, the present study showed for the first time that dose-dependent GR phosphorylation 
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After establishing that GR phosphorylation at S226 occurs in a ligand-selective manner, the 
second aim was to determine if the extent of GR phosphorylation at S226 determines the rank 
order of ligand-selective transcription. Results showed a good correlation between ligand-
selective GR phosphorylation at S226 and S211 with efficacy, but not potency for 
transactivation. However, by examining the effect of GR phosphorylation at S226 on ligand-
mediated GR transactivation, with 12 different GR ligands, this thesis showed for the first time 
that the extent of ligand-selective GR phosphorylation at S226 does not determine the rank order 
of ligand-selective transactivation. At the time this work was performed, the effect of GR 
phosphorylation by different GR ligands on GR-mediated transactivation was not known, but was 
recently shown with dex (Chen et al., 2008). Although ligand-selective GR phosphorylation at 
S226 was shown not to determine ligand-selective transactivation, in this thesis, phosphorylation 
at S226 was shown to inhibit efficacy, but not potency for transactivation, on a TAT-GRE- and 
MMTV promoter. Furthermore, phosphorylation at S211 was shown to be required for full 
transactivational efficacy on the MMTV promoter. This result is consistent with previous reports 
in the literature, showing that phosphorylation at S211 influences maximal efficacy for 
transactivation (Stubsrud, 2005;Chen et al., 2008).  
 
The recruitment of co-factors via the GR, has previously been shown by others to modulate the 
maximal efficacy for transactivation (Li et al., 2002;Rogatsky I, 2001;Ding et al., 1998;Grenier 
et al., 2006). A model to explain the results showing that phosphorylation at S226 inhibits 
transactivation, while phosphorylation at S211 is required for transactivation, is not easy to 
imagine and would involve the combined actions of both co-activators and co-repressors (Fig. 
8.1). In order to explain the increase in transactivation efficacy with the S226A mutant observed 
in the present study (Fig. 4.8 in Chapter 4), it is hypothesised that GR phosphorylation at S226 is 











recruitment of this putative co-repressor Y with the S226A GR mutant, could explain the increase 
in efficacy for transactivation (Fig. 4.8 in Chapter 4). Consistent with this idea, Hong et al. 
recently showed that dex-stimulation resulted in the recruitment of NCoR and SMRT to a GRE-
containing GC-responsive gene and that knock-down of NCoR or SMRT increased dex-mediated 
transactivation on this gene (Hong et al., 2009). In contrast to the results for S226, 
phosphorylation at S211 was shown in the present study (Fig. 4.10 in Chapter 4) to be required 
for maximal efficacy for transactivation. One possible explanation for this result is that 
phosphorylation at S211 could be required for the recruitment of an unknown co-activator (e.g. 
“X” in figure 8.1), thereby increasing efficacy for transactivation.  
 
 
Figure 8.1 Proposed model to explain the role of GR phosphorylation at S211 and S226 in the 
recruitment of GRIP-1 for transactivation on the MMTV promoter. Phosphorylation at S226 is 
hypothesised to be required for the recruitment of a co-repressor (Y), whereas phosphorylation at S211 is 
hypothesised to be required for the recruitment of a co-activator (X). Furthermore, results presented in this 











stimulated with dex, both S226 and S211 are phosphorylated, resulting in the recruitment of GRIP-1, as 
well as possibly both a co-repressor (Y) and a co-activator (X). With the S211A mutant, stimulation with 
dex is proposed to result in the recruitment of co-repressor (Y), since S226 is still phosphorylated, but not 
the recruitment of co-activator (X). Furthermore, GRIP-1 is still recruited, albeit to a lesser extent than wt 
GR. This combination may explain the decrease in dex-mediated efficacy for transactivation with the 
S211A mutant versus wt GR. With the S226A mutant, stimulation with dex is proposed to result in the 
recruitment of co-activator (X), since S211 is still phosphorylated, but not in the recruitment of co-
repressor (Y). Additionally, GRIP-1 is still recruited, albeit to a lesser extent than wt GR. This 
combination may explain the increase in efficacy for transactivation with the S226A mutant vs. wt GR. 
With the triple phosphorylation mutant (3A), neither S211 nor S226 is phosphorylated. Therefore, it is 
proposed that neither co-activator (X), co-repressor (Y) nor GRIP-1 is recruited. GRE = glucocorticoid 
response element; BTM = basic transcription machinery, PS226 = GR phosphorylated at S226; PS211 = 
GR phosphorylated at S211. X = unknown co-activator; Y = unknown co-repressor. The square indicates 
a specific conformation of the GR, bound by dex (the small triangle).   
 
In support of the idea that phosphorylation at S226 is required for the recruitment of a co-
repressor, whereas phosphorylation at S211 is required for the recruitment of a co-activator, 
studies on the ER demonstrated that the phosphorylation status of one specific serine residue 
determines the recruitment of co-activator (SRC-3) versus the co-repressor, stromelysin-1 
platelet-derived growth factor-responsive element-binding protein (Weigel and Moore, 
2007;Likhite et al., 2006;Endoh et al., 1999;Gburcik et al., 2005).  Interestingly, Rogatsky et al. 
showed that GRIP-1 can switch from a co-activator to a co-repressor, depending on the 
composition of the regulatory elements on the DNA (Rogatsky I, 2001). It would be tempting to 
speculate that GRIP-1 can switch between co-activator vs. co-repressor, depending on whether 
S211 or S226 is phosphorylated.  For example, if GRIP-1 is recruited via phosphorylation at 
S211, it could act as a co-activator for transactivation, whereas if it is recruited via 
phosphorylation at S226, it could act as a co-repressor.  The phosphorylation mutant 
transactivation results would be consistent with such a model. However, currently there is no 











In order to test if the above mentioned model (Fig. 8.1) holds for two different promoters, the 
transactivation results with the phosphorylation mutants on the MMTV promoter were compared 
to those on a TAT-GRE promoter. Although the model holds for both promoters, there are some 
numerical differences in the extent to which phosphorylation influences maximal efficacy on the 
different promoters. The inhibitory effect of S226 phosphorylation on transactivation was more 
pronounced on the TAT-GRE (Fig. 4.8 in Chapter 4), than the MMTV promoter (Fig. 4.10 in 
Chapter 4), whereas the requirement for S211 phosphorylation for transactivation was much more 
on the MMTV (Fig. 4.10 in Chapter 4), than the TAT-GRE promoter ((Stubsrud, 2005); Table E2 
in addendum E). These results indicate promoter-specific differences in the role of GR 
phosphorylation on transactivation.  The TAT-GRE promoter, contains two GREs, where GR 
binding to the DNA alone initiates transcription (Reviewed in (Schoneveld et al., 2004;Schmid et 
al., 1987)).  In contrast, the MMTV promoter is much more complex and GR binding to the four 
GREs results in the recruitment of an ATP-dependent chromatin remodelling complex and 
subsequent binding of TBP and additional transcription factors (Hebbar and Archer, 
2003;Schoneveld et al., 2004). It would be tempting to speculate that a putative co-activator (X) 
recruited by S211 is crucial for the recruitment and subsequent binding of TBP and/or additional 
transcription factors to the MMTV promoter.  This would explain the almost complete loss of 
transcription with the S211A mutant on the MMTV promoter, while only a partial loss in efficacy 
is seen on the simpler TAT-GRE, which does not require binding of TBP or additional 
transcription factors. In contrast, on the TAT-GRE, the recruitment of a putative co-repressor (Y) 
via S226 would have a larger effect than on the more complex MMTV promoter, where multiple 
additional transcription factors mediate transactivation. Consistent with this idea, Ronacher et al. 
recently showed that differential co-factor recruitment is a major determinant of promoter-
specific differences in potency and efficacy for transactivation and transrepression (Ronacher et 











thereby differential recruitment of co-factors, can account for some these above mentioned 
promoter-specific differences. 
 
Another aim was to determine if ligand-selective GR phosphorylation at S226 and/or S211 
determines the rank order of ligand-selective transrepression.  Similar to the transactivation 
results, results in this thesis showed good correlations between ligand-selective phosphorylation 
at S226 and S211 and ligand-selective efficacy for transrepression. However, by examining the 
effect of GR phosphorylation at S226 and S211 on ligand-mediated GR transrepression, with 12 
different GR ligands, this thesis showed for the first time that the extent of ligand-selective GR 
phosphorylation at S226 and S211 does not determine the rank order of ligand-selective 
transrepression via AP-1 or NFB. At the time this work was done, the effect of S226, as well as 
S211 phosphorylation on transrepression was also not known, but has recently been shown to 
inhibit transrepression on some but not all genes (Chen et al., 2008).  
 
Although ligand-selective GR phosphorylation at S226 and S211 was shown to not determine 
ligand-selective transrepression in this thesis, phosphorylation at S211 as well as S226 slightly 
inhibited maximal efficacy for transrepression on an AP-1 and NFB promoter. This result is 
very interesting and could possibly indicate that phosphorylation at S211 and S226 inhibits 
binding of the GR to NFB and AP-1 proteins.  Results presented in this thesis also indicate that 
GR phosphorylation at one or more of residues S203, S211 and S226 are required for maximal 
DNA binding on the MMTV promoter (Fig. 7.10 in Chapter 7). This result is not consistent with 
a role for GR phosphorylation at S211 and S226 inhibiting indirect DNA binding via tethering to 
NFB or AP-1 proteins. However, in the literature, deacetylation of the GR by HDAC2 has 











et al., 2006b).  Furthermore, AR phosphorylation and acetylation have been shown to be 
functionally linked (Fu et al., 2004).  Thus a possible hypothesis that could explain the inhibitory 
effect of GR phosphorylation on transrepression is that GR phosphorylation at S211 and S226 is 
required for GR acetylation, thereby inhibiting binding of the GR to NFB and resulting in less 
transrepression.  However, this thesis shows for the first time that phosphorylation of the GR on 
S226, S211 and S203 is not required for GR acetylation.  Whether GR phosphorylation at S211 
and/or S226 inhibits GR binding to NFkB and AP-1 proteins in a manner independent of 
acetylation remains to be tested.     
 
Another possibility is that GR phosphorylation at S211 and S226 could also inhibit 
transrepression via the recruitment of a co-activator. In the present study GR phosphorylation at 
S211 and S226 was shown to be required for recruitment of the co-activator GRIP-1 to the 
MMTV-promoter.  The lack of GRIP-1 recruitment with the single phosphorylation mutants 
could therefore explain the increase in transrepression observed on the AP-1 and NFB 
promoter-reporter constructs (Fig. 4.12 in Chapter 4).  To this extent Rogatsky et al. has shown 
agonist-mediated GRIP-1 recruitment, in U2OS cells with rGR, to the collagenase 3 gene, where 
GR-mediated repression is via tethering to AP-1 (Rogatsky I, 2001).  On an AP-1 luciferase 
construct, GRIP-1 behaved as a co-repressor and recruitment of GRIP-1 increased GR-mediated 
transrepression in U2OS cells (Rogatsky I, 2001). This result of Rogatsky et al. is not consistent 
with a model wherein hGR phosphorylation at S211 and S226 is required for GRIP-1 recruitment 
to the AP-1 and NFB promoter, where GRIP-1 acts as a co-activator (that is causing less 
repression) in COS-1 cells, indicating possible cell-specific differences. Further experiments are 
required to test whether the presence of GRIP-1 results in less transrepression on the AP-1 and 











When comparing the role of GR phosphorylation on transactivation versus transrepression, the 
combined mutation of S211, S226 and S203 only slightly increased efficacy for transrepression 
on the AP-1 promoter (Fig. 4.13 in Chapter 4), whereas a complete loss of dex-mediated 
transactivation on the MMTV promoter (Fig. 4.10 in Chapter 4) was seen. These results indicate 
that GR-mediated transrepression via AP-1 is less sensitive to GR phosphorylation than GR-
mediated transactivation, indicating different mechanisms in the role of GR phosphorylation on 
transactivation vs. transrepression.  These differences could possibly include the recruitment of 
different co-factors to the GR when bound to DNA than when tethered to another transcription 
factor.  Inhibiting the kinases responsible for GR phosphorylation might therefore distinguish 
between GR-mediated transactivation and transrepression and could be used as a strategy for 
anti-inflammatory drugs.    
 
 
8.2 The kinases that phosphorylate the hGR at S211 and S226 in intact cells 
 
In an attempt to determine which kinases phosphorylate the GR in intact cells, GR 
phosphorylation at S211 and S226 was manipulated in vivo, by means of MAPK and CDK 
inhibitors, as well as expression constructs for MAPKs and CDK5.  In this study, no direct 
evidence for a role of JNK, p38 or CDKs in phosphorylating the GR at S226 and/or S211 was 
found, using the above mentioned strategies.  Furthermore, although data on GR and kinase 
phosphorylation kinetics were not inconsistent with a role for JNK and p38 in mediating GR 
phosphorylation at S226 and S211, it did not provide direct evidence in support of such a model.  
Transactivation and transrepression data with the JNK and p38 inhibitors were consistent with a 











since the inhibitors did not reduce GR phosphorylation, it is likely that these effects on 
transactivation are indirect and do not involve inhibition of GR phosphorylation. A careful look 
at the literature reveals that several authors have tried to inhibit GR phosphorylation, by the 
above mentioned strategies, mostly without substantial success (Chen et al., 2008;Miller et al., 
2005;Kino et al., 2007).  Due to the difficulty of inhibiting GR phosphorylation in vivo, in this 
thesis, as well as in the literature, it seems that combinations of MAPKs and possibly CDKs are 
involved in this process or that the kinases can compensate for each other, e.g. inhibition of one 
kinase leads to hyper activation of another kinase (as shown in figure 5.2 in Chapter 5), which in 
turn phosphorylates the GR on S211 and/or S226.  However, further investigation is needed to 
show that the kinases can compensate for each other, as well as to provide a means to inhibit 
phosphorylation of endogenous GR in vivo.   
 
 
8.3 Ligand-selective GR degradation 
 
Similar to ligand-selective GR phosphorylation at S226, another aim of this thesis was to 
determine whether GR degradation occurs in a ligand-selective manner. Results presented in this 
thesis showed ligand-selective GR degradation with a panel of 10 different GR ligands for the 
first time.  By using this panel of GR ligands, it was possible to show that there is a general trend, 
wherein the most potent GR ligands result in the most rapid GR degradation.  The half-life results 
presented in this thesis with hGR are in agreement with results obtained with the mGR and rGR 
in COS-1 and rat hepatoma cells, which showed that dex treatment reduced the half-life of the 
mGR and rGR from 20 and 25 hours to 9 and 11 hours, respectively (Webster et al., 1997;Dong 











After establishing that GR degradation occurs in a ligand-selective manner, the second aim was 
to determine if the extent of GR degradation determines the rank order of ligand-selective 
transcription. Results presented in this thesis showed a good correlation between ligand-selective 
GR turnover and transactivation, as well as transrepression. However, GR degradation was 
further shown to limit dex-mediated, but not MPA-mediated transactivation, indicating that GR 
degradation influences GR-mediated transactivation in a ligand-selective manner.  However, 
when GR degradation was inhibited, dex-mediated efficacy for transactivation was still higher 
than MPA-mediated efficacy for transactivation, i.e. the same relative rank order of ligand-
selective transactivation was maintained, suggesting that ligand-selective GR degradation does 
not determine the rank order of ligand-selective transactivation.  However, further experiments 
with the whole panel of GR ligands are needed to confirm this hypothesis.  Furthermore, when 
dex-mediated transactivation was inhibited, dex-mediated GR degradation was still observed, 
suggesting that dex-mediated GR degradation does not require dex-mediated transactivation.   
 
 
8.4 Determinants of ligand-selective transcription 
 
Statistically significant correlations between ligand-selective GR phosphorylation, and 
degradation, with ligand-selective GR-mediated transcription were obtained.  However, as 
mentioned above, ligand-selective GR phosphorylation, or degradation, does not determine the 
rank order of ligand-selective transcription.  One interpretation of the correlations is that the 
ligand-selective “determining step” influences GR phosphorylation, degradation and transcription 
to a similar extent, and that ligand-selective GR phosphorylation and degradation are a 











responses by steroid receptors are due to different ligands resulting in different conformational 
changes of the GR (Bledsoe et al., 2002;Kauppi et al., 2003;Shiau et al., 2002;Padron et al., 
2007;Kroe et al., 2007).  These conformational changes are believed to be important for the 
differential recruitment and binding of other proteins, e.g. co-factors (Ronacher et al., 2009) and 
the basic transcription machinery (BTM), and can thereby form the basis of ligand-selective 
biological response (Fig. 8.2).  Furthermore, according to the tripartite model, these 
conformational changes allow for allosteric effects on the whole GR-DNA and/or BTM complex 




Figure 8.2 Ligand binding induces different GR conformational changes.  It is generally accepted that 
ligand binding induces different GR conformations. These conformational changes, are proposed to affect 
the efficacy for transactivation via allosteric effects, for example the recruitment of BTM and other co-
factors and form the basis of ligand-selectivity. The particular GR conformation induced with dex, is 
proposed to allow for more favourable interaction with the BTM or other transcription factors, than the 
particular GR conformation induced by ald, thereby resulting in a higher efficacy for transactivation. The 
large square is used to denote a particular conformation of the GR bound with dex (the small red triangle), 
whereas the large triangle is used to denote a different conformation of the GR bound with ald (small 
circle). Similarly, the large circle is used to denote a different conformation of the GR bound with RU486 











Since the same rank order of ligand-selective phosphorylation at S211 and S226 as that for 
transcription was obtained, these ligand-selective conformational changes may determine the 
relative extent of S211 and S226 phosphorylation.  This would explain the correlations between 
ligand-selective GR phosphorylation and efficacy for transactivation and transrepression.  One 
possible explanation is that the different ligand-induced conformational changes allow for 
different extents of interaction between the GR and kinases and/or phosphatases.  This in turn 
could influence the extent of GR phosphorylation in response to a particular ligand (Fig. 8.3). 
The particular conformation induced by dex may allow for better interaction with kinases (or 
worse interaction with phosphatases), resulting in more GR phosphorylation (or less GR de-
phosphorylation). Accordingly, Bruna et al. showed that the extent of GR-JNK interaction is 
ligand-dependent, with dex-bound GR promoting interaction with JNK while RU486-bound GR 




Figure 8.3 Ligand-induced conformational changes are proposed to determine the interaction 
between the GR and kinases.  According to this model, the particular GR conformation induced by dex, 
is proposed to allow for a better interaction with kinases, than the particular GR conformation induced by 
ald, thereby resulting in more GR phosphorylation. In other words the affinity of the kinases of dex-GR is 
proposed to be higher than for ald-GR. In this example, only the proposed interaction between the GR and 











phosphatase, thereby having less de-phosphorylation.  Similarly, only phosphorylation at S211 is shown, 
but the same is proposed to happen with GR phosphorylation at S226. Additionally, since the same ligand-
selective transactivation pattern is obtained with the S211A mutant, as wt GR, the particular GR 
conformation induced by the different ligands, are maintained in the S211A mutant. The large square is 
used to denote a particular conformation of the GR bound with dex (the small red triangle), whereas the 
large triangle is used to denote a different conformation of the GR bound with ald (small circle). Similarly, 
the large circle is used to denote a different conformation of the GR bound with RU486 (small square). 
PS211 = GR phosphorylated at S211.  
 
This thesis shows ligand-selective S226 phosphorylation with a wide panel of ligands, in both 
COS-1 and U2OS cells. Differences in the extent of ligand-selective phosphorylation on S226 
between these two cell lines, with individual compounds, suggest that there are some cell specific 
differences in the extent of GR phosphorylation. This is the first time that cell-specific 
differences in S226 phosphorylation with 12 different GR ligands has been shown. The relative 
amount of specific kinases and/or phosphatases in different cells could modulate differences in 
GR phosphorylation and result in cell-specific differences.  This could form the basis of cell-
specific differences in response to GR phosphorylation.   
 
Different conformational changes could also allow for different extents of interaction between the 
GR and the proteasome.  This in turn would influence the extent of GR degradation in response 
to a particular ligand (Fig. 8.4).  The particular conformation induced by dex may allow for better 
interaction with the proteasome, resulting in more rapid GR degradation.  This would explain 
why a correlation between ligand-selective GR degradation and transcription was obtained 
although ligand-selective GR degradation does not determine the rank order of ligand-selective 
transcription, or vice versa. This model would be consistent with the finding that the S211A and 
S226A phosphorylation mutants have the same ligand-selective pattern of efficacy for 











degradation, as compared to wt GR.  Furthermore, although it was found that ligand-selective GR 
phosphorylation correlates with ligand-selective GR degradation, the phosphorylation mutants 
degraded to a similar extent as wt GR. This implies that the ligand-induced conformational 
change is maintained in the mutants (Fig. 8.4), consistent with the model.  
 
 
Figure 8.4.  Ligand-induced conformational changes are proposed to determine the extent of GR 
degradation. The ligand-induced conformational changes are proposed to determine the extent of the GR 
interaction with the proteasome, thereby resulting in ligand-selective GR degradation. In this example, the 
particular GR conformation induced by dex, would allow for a better interaction between the GR and the 
proteasome, than the particular GR conformation induced by ald, thereby resulting in a faster rate of GR 
degradation. In other words the affinity of the proteasome for dex-GR is proposed to be higher than that 
for ald-GR. Additionally, since the GR phosphorylation mutants showed the same ligand-selective GR 
degradation, as wt GR, these conformational changes are proposed to be maintained in the GR mutants, 
thereby resulting in the same relative interaction with the proteasome. The large square is used to denote a 
particular conformation of the GR bound with dex (the small red triangle), whereas the large triangle is 
used to denote a different conformation of the GR bound with ald (small circle). Similarly, the large circle 
is used to denote a different conformation of the GR bound with RU486 (small square). The faded, dashed 
squares, triangles and circles are used to depict degraded proteins. PS211 = GR phosphorylated at S211; 
PS226 = GR phosphorylated at S226.  
 
To summarise, different ligand-induced GR conformational changes are proposed to form the 
basis of ligand-selective transcription response. Thus dex-GR (i) has a higher efficacy for 











GR (iii) (Fig. 8.5), as is shown in table E5 in addendum E. Transactivation data with the S211A 
and S226A phosphorylation mutants, lead to the hypothesis that GR phosphorylation at S211 is 
required for the recruitment of a co-activator (“X”), whereas phosphorylation at S226 is required 
for the recruitment of a co-repressor (“Y”). This hypothesis is consistent with the S211A and 
S226A transactivation results with dex, where the S211A mutant had a lower maximal efficacy 
(iv), while the S226A mutant had a higher maximal efficacy for transactivation (vii) than wt GR 
(i) (Fig. 8.5). However, these conformations are proposed to be maintained in the 
phosphorylation mutants, for example with S226A GR, dex-GR (vii) has a higher efficacy for 
transactivation than ald-GR (iix), which in turn is higher efficacy for transactivation than RU486-
GR (ix). This is in agreement with the ligand-selective transactivation results with the S226A 
GR, presented in this thesis.   
 
 
Figure 8.5  Ligand-induced conformational changes are proposed to be maintained in the 
phosphorylation mutants. The recruitment of GRIP-1, the co-repressor (Y) or co-activator (X) by wt, 
S211A or S226A GR is the same as proposed in figure 8.1. The proposed ligand-induced conformational 











selective transactivation is explained in figure 8.2. The large square is used to denote a particular 
conformation of the GR bound with dex (the small red triangle), whereas the large triangle is used to 
denote a different conformation of the GR bound with ald (small circle). Similarly, the large circle is used 
to denote a different conformation of the GR bound with RU486 (small square). GRE = glucocorticoid 
response element; BTM = basic transcription machinery, PS226 = GR phosphorylated at S226; PS211 = 
GR phosphorylated at S211. X = unknown co-activator; Y = unknown co-repressor; 
 
 
8.5 Role of agonist-induced hGR phosphorylation in co-factor recruitment 
 
Results presented in this thesis indicate for the first time that phosphorylation of the GR at S211 
and S226 is required for the interaction between the GR and the co-activator GRIP-1 (Fig. 7.4). 
Mutation of either S211 or S226 resulted in a decrease in GRIP-1 binding in vitro, while the 
combined mutation of S211 and S226 resulted in a complete loss in GRIP-1 binding in vitro and 
in whole cells. Whether phosphorylation at S211 is also required for the recruitment of another 
co-activator (i.e. “X” in the above mentioned model) or whether the decrease in GRIP-1 
recruitment with the S211A mutant (Fig. 7.4) can account for the complete loss of dex-mediated 
transactivation on the MMTV promoter (Fig. 4.10 in Chapter 4), remains to be tested.   
 
Interestingly, from results obtained with GRIP-1 recruitment with the single phosphorylation 
mutants (Fig. 7.8), it seems that the S226A mutant is the dominant site involved in GRIP-1 
recruitment.  However, this result is inconsistent with the transactivation data, wherein 
phosphorylation at S226 inhibits transactivation efficacy. One possible explanation for this 
inconsistency is that apart from playing a role in GRIP-1 recruitment, phosphorylation on S226 
might also be involved in the recruitment of corepressors (i.e. “Y”), as proposed above, resulting 











Results from Kino et al., suggest that phosphorylation at S203/S211/S226 inhibits transcriptional 
activity of the hGR on a MMTV-promoter in HCT116 cells via inhibition of recruitment of the 
histone acetyltransferase (HAT) co-activator, p300, to the GR bound on a MMTV-luciferase 
promoter (Kino et al., 2007).  In contrast, here it is shown that phosphorylation of 
S203/S211/S226 is not a major determinant of p300 recruitment, but is required for maximal 
transcriptional activity on the MMTV-promoter in COS-1 cells and does regulate the maximal 
efficacy for transactivation by possibly playing a role in GR DNA binding in vivo, as well as a 
major role in the recruitment of the co-factor GRIP-1.  Interestingly, phosphorylation of the hGR 
at S404, by glycogen synthase kinase 3 (GSK3), was recently shown to be required for the 
recruitment of CBP/p300 (Galliher-Beckley et al., 2008).  It would be interesting to speculate 
that differential GR phosphorylation, induced by different conformational changes and kinase 
interactions (as discussed above), is the underlying mechanism for differential co-factor 
recruitment.   Phosphorylation of the GR at specific selected serine residues may be a mechanism 
for rapid differential gene regulation via increasing or decreasing co-activator, HAT, and/or 
mediator complex recruitment in a cell- and promoter-specific manner, thereby increasing or 
decreasing transcription efficacy. 
 
 
8.6 Future perspectives 
 
In this thesis two specific steps in the GR-regulation pathway, that was hypothesised to be 
involved in ligand-selective effects in gene transcription, were investigated. Although many 
interesting new finding were obtained, results presented in this thesis raised several new 











Results in this thesis, showed cell-specific differences in the results obtained with the COS-1 vs. 
U2OS cells. When ligand-selective GR phosphorylation at S226 was compared in COS-1 vs. 
U2OS cells, there was a general trend in both cells that the agonists (classified in the respective 
cell lines) resulted in the most GR phosphorylation.  However, with some ligands, the extent of 
phosphorylation was different in the two cell lines. For some of these numerical outliers, e.g. the 
partial agonist MPA, these differences could possibly be explained by differences in GR levels.  
Accordingly, if the U2OS cells (stably expressing hGR) contained more GR than the COS-1 cells 
(transiently transfected hGR), the high levels of GR in the U2OS cells could allow the partial 
agonist to shift to a full agonist, as can be seen in figure D1 in addendum D, as well as in the 
literature (Zhao et al., 2003;Zhang et al., 2007).  This would explain the higher levels of GR 
phosphorylation in the U2OS cells than in COS-1 cells with these compounds.  However, in this 
study, a direct comparison between the relative GR levels in the two cell lines was never done.  
Furthermore, some of the numerical differences could not be explained by different GR levels, 
for example the full agonist prednisolone showed very low levels of S226 phosphorylation in the 
U2OS cells, as compared to the COS-1 cells.  This is very interesting and suggests that other cell-
specific differences occur, such as differences in kinases and/or phosphatase expression levels.  
In addition, results presented in this thesis on dex- and TNF--mediated phosphorylation of p38 
contradict previous results obtained in the literature in different cells (Pelaia et al., 2001;Jang et 
al., 2007), suggesting cell-specific differences in kinase activation. Taken together, it seems that 
GR phosphorylation at S226, as well as the crosstalk between the GR and kinase activation 
pathways are cell-specific and warrant further investigation. A direct comparison of GR 
phosphorylation, with similar GR levels, as well as the role of GR in the activation of different 
kinases, and the relative abundance of kinases and phosphatases in different cells would have to 
be done in order to determine the molecular mechanisms underlying these cell-specific 











important role in the recruitment of co-factors and modulating transcription. These cell-specific 
differences in kinase activity and GR phosphorylation could potentially form the basis of cell-
specific differences in GR-mediated transcription. Understanding these cell-specific differences 
in kinase activity and GR phosphorylation is therefore crucial to further our understanding of GR 
mechanism of action. 
 
 
Results presented in this thesis, indicates a role of GR phosphorylation in the recruitment of co-
factors. By investigating the role of GR phosphorylation in GR-mediated transactivation, 
phosphorylation at S226 was hypothesised to be required for the recruitment of a co-repressor to 
the TAT-GRE and MMTV promoters.  Similarly, phosphorylation at S211 was hypothesised to 
be required for recruitment of a co-activator to the TAT-GRE and MMTV promoters. In this 
thesis phosphorylation at both S226 and S211 was shown to be required for the recruitment of the 
co-activator GRIP-1 to the MMTV promoter.  However whether phosphorylation at S226 or 
S211 is required for the recruitment of additional co-repressors or co-activators has not been 
shown.  ChIP experiments with the mutant receptors would have to be done in order to determine 
if phosphorylation at these two residues is required for the recruitment of additional co-factors, 
i.e. NCoR or SRC-1, to the TAT-GRE and MMTV promoters.   
 
Another unlikely, but possible hypothesis to explain the effect of GR phosphorylation at S211 
and S226 on transactivation, is that GRIP-1 could switch between co-activator and co-repressor 
depending on the phosphorylation status of S211 and S226.  This hypothesis would have to be 
tested in transactivation studies (on the TAT-GRE and MMTV promoters) by increasing GRIP-1 
expression or GRIP-1 knockdown and examining the effect thereof on the efficacy for 











GC-regulated genes modulates the maximal GR-mediated transcriptional response (Stoney 
Simons, 2003). Understanding the molecular mechanisms underlying co-factor recruitment, and 
the role of phosphorylation therein, would increase our knowledge of the basic mechanism of GR 
action, which could lead to a better understanding of inflammation and potentially help with the 
design of better GC drugs.    
 
In an attempt to determine how GR phosphorylation modulates transactivation, the role of GR 
phosphorylation in GR acetylation via p300, was investigated. Results presented in this thesis, 
showed that GR phosphorylation at one or more of residues S226, S211 and S203 is not required 
for GR acetylation and does not play a major role in the recruitment of p300.  However, whether 
p300 is directly responsible for GR acetylation and the role thereof on GR-mediated 
transactivation and transrepression, was not determined.  The use of HDAC inhibitors, as well as 
p300 siRNA on GR-mediated transcription and acetylation, as well as ChIP experiments showing 
p300 recruitment to the GR (in the presence and absence of HDAC inhibitors) should provide a 
more direct way of determining whether p300 acetylates the GR and whether this post-translation 
modification plays a role in GR-mediated transcription. 
 
 
While investigating the role of GR phosphorylation on transrepression, results obtained with the 
single phosphorylation mutants on AP-1- and NFB-mediated transrepression suggest that GR 
phosphorylation inhibits transrepression via a mechanism whereby GR phosphorylation inhibits 
GR binding to AP-1 and NFB proteins. The ability of the phosphorylation mutants, as well as 
wt GR, to bind to NFB and AP-1 proteins would therefore be interesting to investigate.  This 











AP-1 proteins.  Additionally, ChIP experiments showing more phosphorylation mutant GR 
recruited to the AP-1 and NFB promoters would also determine if phosphorylation inhibits GR 
binding to AP-1 and NFB proteins, thereby resulting in less transrepression. 
 
Another possible explanation for the inhibitory effect of GR phosphorylation at S226 and S211 
on transrepression is that GRIP-1 is recruited as a co-activator.  Thereby the loss of the co-
activator GRIP-1 recruitment would result in more transrepression.  However, as mentioned 
above, GRIP-1 has been shown to act as a co-repressor on an AP-1 luciferase construct 
(Rogatsky I, 2001), i.e. the presence of GRIP-1 results in more repression in the presence of dex.  
Therefore, transrepression studies on the AP-1 and NFB promoters, with increasing amounts of 
GRIP-1 would first have to be investigated in order to determine if GRIP-1 acts as a co-activator 
or co-repressor in COS-1 cells on these promoters.  Thereafter, recruitment of GRIP-1, by wt and 
the phosphorylation mutants, to the AP-1 and NFB promoters would have to be investigated, by 
means of ChIP assays. Additionally, it is possible that phosphorylation at S211 and S226 is 
required for, or inhibitory of, the recruitment of other co-factors to the AP-1 and NFB 
promoters, thereby inhibiting transrepression.  For a better understanding of the role of GR 
phosphorylation on GR-mediated transrepression, recruitment of additional co-factors, e.g. SRC-
1, could be investigated. Furthermore, all of these ChIP assays could be repeated on endogenous 
genes, in order to verify the results obtained on the synthetic reporter-promoters.  
 
Interestingly, ligand-selective GR-mediated transrepression, as well as the role of GR 
phosphorylation in transrepression, seems to be dependent on the relative GR levels. To this 
extent, with wt HA-hGR on the AP-1 promoter, results presented in figure 4.12 showed less 











al., 2009). However on the same AP-1 promoter, results in figure 4.13 did not show a big 
difference between dex- and prog-mediated repression with wt pRS-hGR, indicating that the 
amount of repression with prog in figure 4.13 was already maximal and that dex could not result 
in more repression.  In addition, in figure 4.12, phosphorylation at S211 or S226 was shown to 
inhibit maximal repression on the AP-1 promoter, while the combined mutation of S211 and 
S226 had only a minimal effect in transrepression.  Taken together, these results could indicate 
that the relative GR levels in figure 4.13 (with pRS-hGR) were higher than in figure 4.12 (with 
HA-hGR), thereby resulting in maximal repression with wt and that an increase in repression 
with the combined mutant could not be obtained.  However, a direct comparison between the 
relative expression levels of HA-hGR vs. pRS-hGR was not done and would have to be examined 
in order to determine if increased expression of GR resulted in maximal repression in figure 4.13.  
Thereafter, the effect of the combined mutation of S211, S226 and S203 on AP-1 mediated 
transrepression could be repeated at lower GR levels in order to determine more accurately the 
role of GR concentration in transrepression. The relative expression levels of endogenous GR 
have been shown to vary considerably between tissue or cell types (Miller et al., 1998).  
Understanding the molecular mechanisms whereby GR levels influence ligand-selective GR-
mediated transrepression, as well as the role of GR phosphorylation in GR-mediated 
transcription, would significantly enhance our understanding of cell-specific differences in GR-
mechanism of action.   
 
Promoter-specific differences in the role of GR phosphorylation in transactivation and 
transrepression have previously been shown (Webster et al., 1997;Chen et al., 2008).  Results 
presented in this thesis also showed promoter-specific differences in the role of GR 
phosphorylation in transactivation and transrepression.  Although GR phosphorylation at S211 











MMTV promoter, the relative extent thereof was different on the two promoters.  The 
requirement for S211 phosphorylation for transactivation efficacy, was much more on the 
MMTV promoter than on the TAT-GRE promoter.  In contrast, the inhibitory effect of S226 
phosphorylation on transactivation efficacy was much more on the TAT-GRE promoter. 
Furthermore, on the AP-1 promoter, mutation of S226 resulted in an increase in transcription 
with CpdA, UDCA and NET.  This was not observed on the NFB promoter, further suggesting 
promoter-specific differences in the role of GR phosphorylation at S226 in transrepression.  In 
order to shed more light on these promoter-specific differences, a direct comparison with a range 
of different GC-regulated promoters (for both transactivation and transrepression) with a few 
selected GR ligands (e.g. a full-, full/partial- and partial agonist, as well as a dissociated ligand 
and an antagonist) could be performed.  This should be done on the synthetic reporter-promoters 
(used in this study) and should also be confirmed on endogenous genes. Additionally, the 
composition of the promoters, e.g. ‘simple-acting’ vs. complex promoters, as well as the 
additional transcription factors and the co-factors recruited to these promoters, could be further 
investigated in order to determine the mechanistic details of these promoter-specific differences.  
This could most easily be performed using different GC-regulated promoters, where the 
composition has already been determined, and examining the effect of phosphorylation mutants 
on transcription.  Additionally, the recruitment of additional transcription factors and co-factors 
could be determined by means of ChIP analysis. 
 
When the role of GR phosphorylation at S211 and S226 on transrepression was investigated, it 
was found that wt GR simulated with CpdA did not result in transrepression (Fig. 4.12).  This is 
contrary to the literature on different genes and in different cells (De Bosscher et al., 2005).  It is 
possible that CpdA-mediated transrepression might be promoter-specific, wherein the specific 











mediated transrepression or not. Furthermore, De Bosscher et al. used TNF- to induce 
transcription of the genes, whereas results presented in this thesis were obtained with PMA.  
Furthermore, De Bosscher et al. pre-treated with CpdA before stimulation with TNF-, whereas 
results obtained in this thesis were done by pre-treatment with PMA before stimulation with 
CpdA.  These apparent inconsistencies are interesting and may indicate that CpdA can only 
repress genes that are induced by the TNF- and not the PMA pathway.  On the other hand, these 
differences could indicate differences in the molecular mechanism of CpdA repression, wherein 
stimulation with CpdA has to precede induction of the genes, in order for CpdA to result in 
repression thereof.  Since CpdA is currently being investigated as a potential anti-inflammatory 
drug, because of its ability to distinguish between GR-mediated transactivation and 
transrepression, it is crucial to determine the basis of the above mentioned inconsistencies.  This 
could easily be done by a direct comparison, in the same cells and on the same promoter, of the 
ability of CpdA to repress TNF- or PMA induced genes, wherein induction of the genes 
precedes or follows CpdA stimulation. 
 
Due to the fact that GR phosphorylation can result in the differential regulation of GC-responsive 
genes, as discussed above, it is important to determine which kinases is responsible for 
phosphorylation of the GR in vivo. Many publications have reported the use of in vitro kinase 
assays to identify the kinases responsible for phosphorylating the GR in vitro.  However to date 
there are only a few publications that have, with limited success, inhibited phosphorylation of 
endogenous GR in vivo. Future studies could include the use of kinase inhibitors for different 
kinases, other than JNK, p38 and CDK and determining the amount of GR phosphorylation in the 
presence and absence of the inhibitors. Additionally, different JNK-, p38- and CDK inhibitors, 











down of the kinases, by siRNA could also be investigated as a means of inhibiting GR 
phosphorylation. Additionally, the physiological effects of GR phosphorylation mutants in mice 
(or in embryonic cells) could also be investigated. Only thereafter, can the role of GR 
phosphorylation in mediating the interaction between the GR and GRIP-1 (as well as other co-
factors), be studied on endogenous genes, with endogenous GR and co-factors. Throughout the 
thesis most of the results were obtained by using transiently transfected proteins and reporter 
plasmids. This is not optimal, since it relies on the assumption that the multiple plasmids 
transfected co-distribute equally, which is not necessarily the case. It is therefore important that 
these results are confirmed on endogenous genes with endogenous proteins. Verifying the role of 
GR phosphorylation on co-factor recruitment and the effect on GR-mediated transcription would 
enhance our understanding of GR function and provide possible “tools” for developing better GC 
drugs. 
 
The role of GR degradation in GR-mediated transcription was also investigated in this thesis. 
Results presented here with dex and MPA, as well as in the literature (Stavreva et al., 2004), 
suggest that proteasomal degradation of the GR influences GR-mediated transactivation in a 
ligand-specific manner.  Furthermore, results presented in this thesis showed various promoter-
specific differences in transactivation and transrepression.  In order to more accurately determine 
the effect of proteasome-mediated GR degradation on GR-mediated transcription, the effect of 
proteasomal inhibition on transcription, with a few selected GR ligands (e.g. a full-, full/partial- 
and partial agonist, as well as a dissociated ligand and an antagonist), on different GC-responsive 
transactivation and transrepression promoters would have to be investigated.  
 
Interestingly, results obtained in this thesis on the role of hGR phosphorylation at S211 and S226 











phosphorylation at S211, S226 and S203 in GR degradation, contradict previous results obtained 
for the mGR (Webster et al., 1997). These differences do not appear to be due to cell- or 
promoter-specific differences, since COS-1 cells and the same TAT-GRE and MMTV promoters 
were used in both studies. The results rather suggest species-specific differences. Rogatsky et al. 
has previously suggested that there are species-specific differences in the role of GR 
phosphorylation on transactivation (Rogatsky et al., 1998a). However, a direct comparison 
between the role of hGR phosphorylation at S211 and S226, and the mouse equivalent thereof, in 
transactivation has not been done.  Similarly, the role of hGR and mGR phosphorylation in GR 
degradation has not been directly compared. These studies warrant further investigation by means 
of a direct comparison, in parallel, in the same cells and with similar methodological conditions 
in order to examine the role of species-specific differences in GR phosphorylation and the role 
thereof in transactivation and GR degradation. 
 
Last, but not least, ligand-binding induces different conformational changes, as determined by 
GR crystal structures (Bledsoe et al., 2002;Kauppi et al., 2003) which are believed to be 
important for differential co-factor recruitment and ligand-selective biological responses.  Results 
presented in this thesis are consistent with a model where these different conformational changes 
induce more and/or less favourable interactions between the GR kinases and/or phosphatases, as 
well as with the proteasome. Results suggest that these interactions, indirectly result in ligand-
selective GR phosphorylation at S211 and S226, as well as ligand-selective GR degradation. 
Furthermore, results in this thesis show that GR phosphorylation is important for co-factor 
recruitment.  It is likely that ligand-selective GR phosphorylation could form the basis for 
differential co-factor recruitment.  However, whether ligand-induced conformational changes 
form different interactions between the GR and kinases and/or phosphatases, as well as the 











been shown.  In order to accurately determine this, ligand-selective interactions between the GR 
and different kinases and/or phosphatases, as well as the proteasome, would first have to be 
shown.  This can be done by means of co-immunoprecipitation experiments.  Furthermore, these 
ligand-dependent interactions would then have to be shown to be a direct consequence of 
different ligand-induced GR conformational changes.  This would require computer analysis of 
specific three dimensional crystal structures of the GR bound by the different ligands, as well as 
the kinases and/phosphatases, or the proteasome.  Since the crystal structure of the whole GR 
protein has not been solved and crystal structures of the LBD of the GR in complex with only a 
few GR ligands are known, this would be more difficult and would require more investigation.  
 
Taken together, variations in receptor and co-factor concentration, as well as GR 
phosphorylation, modulates GR-mediated transcriptional regulation, which has significant 
clinical implications (Reviewed in (Stoney Simons, 2003)). For endogenous hormones, variations 
in receptor and co-factor concentration, as well as GR phosphorylation are likely to be beneficial, 
as they could account for some of the promoter- and cell-specific differences seen on GR 
mechanism of action. These promoter- and cell-specific differences could provide for differential 
gene induction, in different cellular environments, by the same endogenous hormone (Reviewed 
in (Stoney Simons, 2003)). However, these promoter- and cell-specific differences in GR 
mechanism of action are likely to contribute to the various side-effects observed with 
pharmacologically administered GCs and complicate the design of better GC drugs. In order to 
better predict the biological outcome of pharmacological drugs, an improved understanding of the 
fundamental mechanisms and determinants of promoter-, cell- and ligand-specific differences in 
GR mechanism of action, is required.   











Addendum A Basic principles for evaluating transcriptional 
responses  
 
To evaluate the transcriptional response mediated via steroid receptors and their ligands, some 
basic principles and terminology are used.  Steroid receptor-ligand complexes are characterised 
by three parameters, namely affinity, potency and efficacy, each of which can be measured 
quantitatively in any given cell system. 
 
The strength, with which a particular ligand binds to its receptor, is the affinity of the ligand for 
the receptor. The receptors bind their corresponding ligands according to the laws of mass action, 
which is a kinetic process in which ligand molecules bind to and dissociate from the receptor at 
defined rates (Fig. A1). The fraction of the receptor occupied by ligand at any given time is 
dependent on the relative rates of onset (kon) and offset (koff) of ligand attachment to the receptor.  
When the amount of ligand molecules that bind the receptor is equal to the amount of molecules 
that dissociate from the receptor, the reaction has reached equilibrium.  At equilibrium, the 
concentration of ligand that results in half the receptors being occupied, is called the equilibrium 
dissociation constant, Kd (Reviewed in (Neubig et al., 2003)). 
 
 
Figure A1 Kinetics of ligand binding to the GR. The affinity of a ligand for its receptor is determined 













The Kd can be determined by different experimental procedures.  For example, the Kd can be 
determined via kinetic experiments, wherein the association (Kon) and dissociation (Koff) rates are 
determined. Specific binding of a fixed concentration of radiolabelled ligand is measured over 
time.  It is important that the law of mass action applies. Therefore, it is more accurate to 
determine association rates at different radiolabelled concentrations. If the law of mass action 
applies, a linear increase in association rates will be observed.  Kd can then be calculated from the 
measured Kon and Koff values (Kd = Kon/Koff).   
 
Additionally, the Kd can be determined by saturation binding experiments (Fig. A2). Although 
more tedious and expensive, saturation binding curves are thought to be more accurate.  In these 
experiments, specific binding of increasing amounts of radiolabelled ligand is measured at 
equilibrium. By subtracting the amount of non-specific binding (with very high levels of non-
radiolabelled ligand) from the total amount of binding that is measured, the specific binding of 
the radiolabelled compound is determined.  Thereafter the amount of specific binding is plotted 















Figure A2  Determining the Kd from saturation binding experiments.  The Kd is taken as the 
concentration of ligand (nM) needed to result in 50% binding. Taken and modified from GraphPad Prism 
5 manual. 
 
Experimentally, it is also important to determine the Kd of other ligands, of which no 
radiolabelled form is available, for the same receptor.  Also called heterlogous competive 
binding, two ligands compete for binding on the same receptor where the radiolabelled ligand and 
the competing ligand are different. In these assays, increasing concentrations of the desired ligand 
(unlabelled) is used to compete with binding of the radiolabelled reference ligand. This type of 
experiment is used to determine relative affinities (these are not constants) (IC50 or Ki’s) of 
various different types of ligands. The IC50 value is the concentration of unlabelled ligand that is 
needed to displace 50% of the radiolabelled ligand from the receptor (Fig. A3). Relative binding 
affinities (RBAs) are commonly used in the literature and are calculated as a percentage of the 
IC50 value of the reference ligand, often used [RBA = IC50 (ref ligand) / IC50 (ligand of 
interest) x 100]. However, these IC50 values are not true dissociation constants, since the values 
will vary depending on the concentration of radiolabelled ligand and receptors used in the study. 
When the concentration of radiolabelled ligand is less than half the IC50, it is possible to 











heterologous competition binding curves. The Ki value is the concentration of competing ligand 
that will bind to half the receptor at equilibrium (Cheng and Prusoff, 1973).   
 
 
Figure A3 A schematic representation of a competitive binding curve.  Binding affinity is expressed 
as the concentration of unlabelled ligand (of interest) needed to displace 50% of the radiolabelled ligand 
from the receptor and is measured in molar units (IC50 value), if the x-axis is given in M. Taken and 
modified from GraphPad Prism 5 manual. 
 
Fractional occupancy describes the relative receptor occupancy for any given ligand at 
equilibrium as a function of the ligand concentration and the Kd of the specific ligand (Fig. A4). 
When there is no ligand present the fractional occupancy of the receptor will be zero. At 
saturating concentrations of ligand, i.e. where the ligand concentration is much higher than the 
Kd, the fractional occupancy is close to 100%. Furthermore, when the ligand concentration used 
is equal to the Kd, the fractional occupancy will be 50%.  Fractional occupancy is often used 
when comparing different ligands at sub-saturating concentrations of ligand.  
 
 











Efficacy is used to describe and quantify the maximal transcriptional response for a given ligand 
(Fig. A5). When a full agonist is used as a reference ligand and the efficacy of the other ligands 
are calculated as a percentage of the efficacy of the reference ligand (which is set to 100%), the 
term relative efficacy is used.  In figure A5 ligand A is the reference ligand, a full agonist with a 
relative efficacy set to 100%.  Ligand B has the same relative efficacy as ligand A and is 
therefore also a full agonist, whereas ligand C has a relative efficacy much lower than ligand A, 
but still gives a response, and is therefore a partial agonist (Reviewed in (Neubig et al., 2003)).  
   
 
Figure A5 Efficacy and potency. Taken and modified from 
http://glutxi.umassmed.edu/lectures/dynamics.pdf 
 
Potency is used to describe and quantify the molar concentration of ligand needed to elicit half of 











The lower the concentration of ligand needed to give half the maximal response, the more potent 
the ligand.  Potency is also referred to as the EC50 value, when the potency is taken by reading 
the concentration of ligand, at 50% of the maximal response, from a sigmoidal dose-response 
curve (a log10 scale of ligand concentration plotted against percentage response).  The relative 
potency is the ratio of the potency of a specific ligand to that of a standard reference ligand.  In 
figure A5 ligand A has a smaller numerical EC50 value than ligand B, and is therefore more 
potent than ligand B, whereas ligand C has a similar numerical EC50 value, as ligand A, and is 
therefore as potent as ligand A (Reviewed in (Neubig et al., 2003)).  
 
For the purpose of this thesis, correlation analysis between the GR transcriptional response and 
other steps in the GR pathway will be performed.  This is done by performing a Pearson’s 
correlation analysis (GraphPad Prism 5 manual) of the numerical values (potency (expressed as –
log [ligand in nM]) and efficacy (expressed as % relative to agonist dex) of the transcriptional 
response with the numerical values obtained for another step in the GR pathway.  In figure A6, 
numerical data obtained for step A (e.g. efficacy for transactivation) is correlated with the 
numerical data obtained for step B (e.g. nuclear translocation of the receptor) using GraphPad 
Prism 5 correlation analysis.  From the correlation analysis a R2 value, or the coefficient of 
determination which ranges from zero to 1, is given.  This is the fraction of variance that is 
shared in the two steps, for example a R2 = 0.88 means that 88% of the variance in step A can be 
explained by variation in step B, or vice versa. In addition, correlation analysis also calculates the 
p value that indicates if the R2 value is statistically significant.  Furthermore, this correlation 
analysis does not assume linearity, however it is slightly influenced thereby (GraphPad Prism 5 
manual).  In the above mentioned example, if the numerical values from step A are correlated 














Figure A6 An example of the correlation analysis.  Numerical data obtained from step A is correlated 
with numerical data obtained from step B, using Pearson’s correlation analysis by GraphPad Prism 5 
software.  The data used in this figure was not determined experimentally, but is hypothetical data to 
illustrate the point.  
  
However, a good correlation (i.e. R2 close to 1) between step A and step B, does not necessary 
mean that step A determines step B, or vice versa.  It could also mean, that both step A and step 
B are equally influenced by another step, e.g. step X (ligand-induced conformational change of 
the receptor), and that step A and step B are not functionally linked to each other.  In this 
example, the ligand-induced conformational change of the receptor could influence the ability of 
the receptor to result in nuclear translocation, as well as efficacy for transactivation.  Therefore, 
since the same trend in ligand-induced conformational change is “mimicked” in nuclear 
translocation and efficacy for transactivation, a good statistically significant correlation between 
nuclear translocation and efficacy for transactivation will be obtained, even though the one does 











Addendum B  Panel of GR ligands 
 
 
A.1 Full agonists 
 
A.1.1  Dexamethasone (dex) 
 
Dex is a potent, steroidal, synthetic GR agonist and since its synthesis in 1959, dex has been used 
in the treatment of a variety of diseases, including rheumatoid arthritis and cancer (Fig. B1) 
(Stein et al., 1999;Cook et al., 2004;Richardson et al., 2005;Koutsilieris et al., 2004).  Dex is the 
most commonly used GR agonist, with a strong relative binding affinity for the GR, Kd ranging 
between 5 and 10 nM, and a potent agonist for transactivation, EC50 ranging between 1 and 10 
nM, depending on the cell system, promoter and the amount of GR used in the studies (Stubsrud, 
2005;Driver et al., 2001;Then Bergh et al., 1999;Charmandari et al., 2005;Hammer et al., 
2003;Attardi et al., 2004;Muller et al., 2004;Einstein et al., 2004;Smit et al., 2005).  In addition, 
dex is also a potent agonist for transrepression, with an EC50 ranging between 0.05 nM and 15 














Figure B1 Structure of dexamethasone [(9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-
trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one)]. Structure from 
http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells, with the hGR on the TAT-GRE promoter, dex has an EC50 of 0.23 nM and a 
relative binding affinity of 14 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in 
addendum E).  Furthermore, in the same cell system, dex has an EC50 of 0.005 nM and 0.003 
nM on the NFB and AP-1 promoters, respectively ((Ronacher et al., 2009); Table E5 in 
addendum E).  Additionally, dex bound-GR recruited the co-activators GRIP-1, TIF-2 and SRC-1 
(~75%), as well as the co-repressors NCoR( ~25%) and SMRT (~150%), as compared to RU486 
(100%), in a mammalian two-hybrid assay (Ronacher et al., 2009).     
 
A.1.2  Cortisol (cort) 
 
Cortisol is the endogenous GR ligand produced in humans and its production is under control of 
the HPA axis (Fig. B2). Cortisol is secreted into the blood stream in a continuous pulsatile pattern 
at a frequency of approximately 20 pulses per day which forms the basis of the diurnal rhythm in 
humans (Windle et al., 1998;Lightman et al., 2008).  Excessive and insufficient production of 











disorders, respectively (Whitworth et al., 2000;Lovas and Husebye, 2003).  Cortisol has a high 
binding affinity for the GR and is a potent GR agonist for transactivation and transrepression, 
with an EC50 ranging between 10 and 40 nM, depending on the system being investigated 
(Stubsrud, 2005;Lind et al., 2000;Mulatero et al., 1997;Grossmann et al., 2004;Lim-Tio et al., 
1997;Rebuffat et al., 2004;Muller et al., 2004;Zhao et al., 2003).   
 
 
Figure B2 Structure of cortisol [11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-
1,2,6,7,8,9,10,11,12, 13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one].  Structure from 
http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells, with the hGR on the TAT-GRE promoter, cort has an EC50 of 16 nM for 
transactivation and a relative binding affinity of 152 nM (IC50) ((Ronacher et al., 2009); Tables 
E5 and E4 in addendum E).  Furthermore, in the same cell system, cort has an EC50 of 7 nM and 
2 nM on the NFB and AP-1 promoters, respectively ((Ronacher et al., 2009); Table E5 in 
addendum E). Additionally, cort bound-GR recruited the co-activators GRIP-1 (~80%), TIF-2 
(~80%), SRC-1 (~90%), as compared to dex (100%), while it recruited the co-repressors NCoR 
(~30%) and SMRT (~150%), as compared to RU486 (100%), in a mammalian two-hybrid assay 













A.1.3  Prednisolone (predn) 
 
Predn is a potent, steroidal, synthetic GR agonist and is mainly used for treatment of asthma and 
rheumatic disorders (Fig.B3) (Qureshi et al., 2001;Haugeberg et al., 2004). Predn has a high 
binding affinity for the GR, with an IC50 ranging between 20 and 85 nM and is a potent GR 
agonist for transactivation and transrepression, with an EC50 ranging between 1 to 200 nM and 5 
to 20 nM, respectively, depending on the system being investigated (Stubsrud, 2005;Ko et al., 
2000;Ko et al., 2002;Schacke et al., 2004;Lind et al., 2000;Smit et al., 2005;Ali A et al., 
20040;Grossmann et al., 2004). 
 
 
Figure B3  Structure of prednisolone [11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-
6,7,8,9,10,11, 12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one].  Structure from 
http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells, with the hGR on the TAT-GRE promoter, predn has an EC50 of 0.1 nM and a 
relative binding affinity of 68 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in 
addendum E).  Furthermore, in the same cell system, predn has an EC50 of 0.05 nM and 0.002 
nM on the NFB and AP-1 promoters, respectively ((Ronacher et al., 2009); Table E5 in 
addendum E).  Additionally, predn bound-GR recruited the co-activators GRIP-1 (~100%), TIF-2 











NCoR (~50%) and SMRT (~150%), as compared to RU486 (100%), in a mammalian two-hybrid 
assay (Ronacher et al., 2009).     
 
 
A.2  Full/partial agonists 
 
A.2.1  Aldosterone (ald) 
 
Aldosterone (ald) is the endogenous mineralocorticoid and was first isolated in 1953 (Fig. B4) 
(Reviewed in (Williams and Williams, 2003).  Ald is produced by the adrenals and the level of 
circulating ald is monitored by the kidneys.  Ald regulates the absorption of sodium and 
potassium, mostly in the kidney, and thus regulates blood pressure and heart function.  
Furthermore, ald can bind to, and act via, both the GR and the mineralocorticoid receptor 
(Williams and Williams, 2003;Heymes et al., 2004). Ald has a low affinity for the GR, with a Kd 
ranging from 15 to 290 nM, and has partial agonist activity for transactivation, with EC50s 
ranging from 150 to 500 nM (Stubsrud, 2005;Martinez et al., 2005;Hellal-Levy et al., 
















Figure B4 Structure of aldosterone [11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-
oxo1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-13-carbaldehyde].  
Structure from http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells, with the hGR on the TAT-GRE promoter, ald has an EC50 of 138 nM and a 
relative binding affinity of 1130 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in 
addendum E).  Furthermore, in the same cell system, ald has an EC50 of 27 nM and 18 nM on 
the NFB and AP-1 promoters, respectively ((Ronacher et al., 2009); Table E5 in addendum E).  
Additionally, ald bound-GR recruited the co-activators GRIP-1 (~90%), TIF-2 (~100%), SRC-1 
(~130%), as compared to dex (100%), while it recruited the co-repressors NCoR (~50%) and 
SMRT (~125%), as compared to RU486 (100%), in a mammalian two-hybrid assay (Ronacher et 
al., 2009).     
 
A.2.2  Medroxyprogesterone acetate (MPA) 
 
MPA is a steroidal, synthetic progestin used in contraception, as the injectable Depo Provera, as 
well as in hormone replacement therapy (Fig. B5) (Kaunitz, 1998;Blossey et al., 1984;Yamashita 
et al., 1996;Affandi, 2002;Brunelli et al., 1996;Irahara et al., 2001;Taitel and Kafrissen, 1995).  
Both MPA and another synthetic progestin, NET, are used in preference to the natural progestin, 











synthetic progestins have been shown to correlate with severe side-effects, such as such as 
increased risk of cardiovascular complications, stroke and breast cancer (Beral, 2003;McKenzie 
et al., 2004;Rossouw et al., 2002;Valdivia et al., 2004).   MPA has been shown bind to the GR 
and agonist or partial agonist activity for GR-mediated transactivation has also been shown for 
MPA, with a potency ranging from about 10 nM to 90 nM (Stubsrud, 2005;Koubovec et al., 
2005;Kontula et al., 1983;Tabata et al., 2003;Zhang et al., 2000b;Koubovec et al., 2004). In 
addition, MPA has also been shown to have agonistic activity in transrepression, with EC50 
values varying from about 2.5 nM to 90 nM (Stubsrud, 2005;Koubovec et al., 2004;Koubovec et 
al., 2005;Zhao et al., 2003).   
 
 
Figure B5 Structure of MPA [acetic acid (17-acetyl-6,10,13-trimethyl-3-oxo-
1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetra-decahydrocyclopenta[a]phenanthren-17-yl)ester]. Structure from 
http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells, with the hGR on the TAT-GRE promoter, MPA has an EC50 of 2 nM and a 
relative binding affinity of 19 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in 
addendum E).  Furthermore, in the same cell system, MPA has an EC50 of 0.7 nM and 0.0005 
nM on the NFB and AP-1 promoters, respectively ((Ronacher et al., 2009); Table E5 in 
addendum E).  Additionally, MPA bound-GR recruited the co-activators GRIP-1 (~75%), TIF-2 











(~25%) and SMRT (~25%), as compared to RU486 (100%), in a mammalian two-hybrid assay 
(Ronacher et al., 2009).     
 
 
A.3 Partial agonists 
 
A.3.1  Abbott-Ligand 438 (AL438) 
 
AL438 is a potent, synthetic, non-steroidal agonist for selective promoters, in both GR-mediated 
transactivation and transrepression (Fig. B6) (Coghlan et al., 2003).  AL438 has a strong binding 
affinity for the GR, Ki 2.5 nM and is a partial agonist for transactivation and transrepression, 
with an EC50 from 500 to 800 nM and 10 to 60 nM, respectively (Coghlan et al., 2003).  
Additionally, AL438 bound-GR binds the co-activator GRIP-1 to a similar extent as the GR 
agonist prednisolone, whereas it binds the co-activator PGC-1 less effectively than prednisolone 
(Coghlan et al., 2003).  
 
 
Figure B6   Structure of AL438 [2, 5-dihydro-10-methoxy-5-(2-propenyl)-2, 2, 4-trimethyl-1H-[1] 











In COS-1 cells, with the hGR on the TAT-GRE promoter, AL438 has an EC50 of 8 nM and a 
relative binding affinity of 61 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in 
addendum E).  Furthermore, in the same cell system, AL438 has an EC50 of 13 nM and 0.05 nM 
on the NFB and AP-1 promoters, respectively ((Ronacher et al., 2009); Table E5 in addendum 
E).  Additionally, AL438 bound-GR recruited the co-activators GRIP-1 only (~50%), TIF-2 
(~30%), SRC-1 (~75%), as compared to dex (100%), while it recruited the co-repressors NCoR 
(~25%) and SMRT (~125%), as compared to RU486 (100%), in a mammalian two-hybrid assay 
(Ronacher et al., 2009).   
 
A.3.2  Progesterone (prog) 
 
Progesterone (Prog) is the endogenous hormone for the progesterone receptor (PR) and in women 
is produced primarily in the ovaries, adrenal glands and the placenta (during pregnancy) (Fig. 
B7).  Prog plays an important role in maintaining the monthly menstrual cycle, pregnancy and the 
nervous- and cardiovascular systems (reviewed in (Panay and Studd, 1997).  Recently, prog has 
also been implicated in playing a protective role in brain function and traumatic brain injury 
(Roof and Hall, 2000;Gibson et al., 2008;Wright et al., 2007;Pan et al., 2007).  Prog has a weak 
affinity for the GR, with a Ki ranging from 95 to 215 nM, and has been shown to switch between 
partial agonist activity and no activity for transactivation and transrepression, with EC50s 
between 280 to 930 nM and 26 to 470 nM, respectively, depending on the system and amount of 
GR in the assay (Stubsrud, 2005;Koubovec et al., 2004;Koubovec et al., 2005;Selman et al., 
1996;Bamberger et al., 1999;Kurebayashi et al., 2003). 












Figure B7 Structure of progesterone [17-acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13, 14,15,16,17-
tetra-decahydrocyclopenta[a]phenanthren-3-one]. Structure from http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells, with the hGR on the TAT-GRE promoter, prog has an EC50 of 1688 nM and a 
relative binding affinity of 274 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in 
addendum E).  Furthermore, in the same cell system, prog has an EC50 of 384 nM and 0.004 nM 
on the NFB and AP-1 promoters, respectively ((Ronacher et al., 2009); Table E5 in addendum 
E).  Additionally, prog bound-GR recruited the co-activators GRIP-1 only (~50%), TIF-2 
(~60%), SRC-1 (~85%), as compared to dex (100%), while it recruited the co-repressors NCoR 
(~20%) and SMRT (~80%), as compared to RU486 (100%), in a mammalian two-hybrid assay 


















A.4  Dissociated GCs 
 
A.4.1  Roussel-Uclaf 38486 (RU486) 
 
RU486, also know as mifepristone, is a potent, steroidal antagonist or partial agonist, depending 
on the cell system, and has a very high binding affinity for the GR, as well as the PR (Fig. B8).  
By antagonizing the effects of progesterone, which is needed for pregnancy, RU486 terminates 
pregnancy and is therefore used in emergency contraception and abortions (Cadepond et al., 
1997).  RU486 also has a very high binding affinity for the GR roughly 4 times as high as dex, Kd 
0.68, and is a strong agonist for transrepression, but not transactivation, with an EC50 for 
transrepression ranging from 0.3 to 1 nM (Stubsrud, 2005;Wagner et al., 1999;Attardi et al., 
2004;Einstein et al., 2004;Zhao et al., 2003).   
 
 
Figure B8  Structure of RU486 [11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-
1,2,6,7,8,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one]. Structure from 
http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells, with the hGR on the TAT-GRE promoter, RU486 does not show any activity, but 
has a relative binding affinity of 1 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in 











nM on the NFB and AP-1 promoters, respectively ((Ronacher et al., 2009); Table E5 in 
addendum E).  Additionally, RU486 bound-GR did not recruit the co-activator TIF-2, while it 
recruited the co-activators GRIP-1 and SRC-1 only (~20%) and (~40%), respectively, as 
compared to dex (100%).  The corepressor NCoR was very strongly recruited with RU486 
bound-GR, while it recruited the co-repressor SMRT only (~60%), as compared to dex (100%), 
in a mammalian two-hybrid assay (Ronacher et al., 2009). 
 
A.4.2  Compound A (CpdA) 
 
CpdA, is a synthetic non-steroidal analogue of a plant derivative that was developed at the 
University of Stellenbosch in the Department of Biochemistry in 1997 (Fig. B9) (Louw et al., 
1997).  CpdA interacts with steroidogenic enzymes and steroid-binding globulins and has been 
shown to have anti-androgenic and anti-progestogenic properties (Louw et al., 2000;Louw A, 
2000;Tanner et al., 2003).  More recently, CpdA has been shown to compete with dex for binding 
to the GR and initiate GR nuclear translocation, but not GR dimerisation, and to repress NFB-
mediated, but not AP-1, mediated gene expression in the presence of the GR (De Bosscher et al., 
2005;Dewint et al., 2008). Furthermore, CpdA does not cause GR-mediated transactivation and is 




Figure B9 Structure of CpdA [2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride]. 












In COS-1 cells, with the hGR on the TAT-GRE promoter, CpdA does not show any activity, but 
has a relative binding affinity of 0.003 nM (IC50), and shows an atypical binding curve 
((Ronacher et al., 2009); Tables E5 and E4 in addendum E).  Furthermore, in the same cell 
system, CpA has an EC50 of 1543 nM on the NFB promoter and no activity on the AP-1 
promoter ((Ronacher et al., 2009); Table E5 in addendum E).  Additionally, CpdA bound-GR did 
not recruit the co-activators GRIP-1, TIF-2 or SRC-1, and only minimally recruited the co-





A.5.1  Norethisterone acetate (NET) 
 
NET is a steroidal synthetic progestin and is widely used in contraception, as injectable 
Noristerat, and hormone replacement therapy (Fig. B10). It has previously been shown to 
compete with dex for binding to the GR (Koubovec et al., 2005) and has a very weak affinity for 
the GR, Ki 270 nM, with no activity for transactivation and very weak partial activity for 
transrepression via the GR (Koubovec et al., 2005).  NET has also been shown to antagonise dex-













Figure B10 Structure of NET [acetic acid (17-ethynyl-13-methyl-3-oxo-
1,2,6,7,8,9,10,11,12,13,14,15,16,17tetra-decahydrocyclopenta[a]phenanthren-17-yl)ester]. Structure from 
http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells, with the hGR, NET does not show any activity in transactivation or 
transrepression on the TAT-GRE, NFB- or AP-1 promoters, and has a very low relative binding 
affinity of 1688 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in addendum E).  
Additionally, NET bound-GR did not recruit the co-activators GRIP-1, TIF-2 and SRC-1, or the 
co-repressors NCoR and SMRT, in a mammalian two-hybrid assay (Ronacher et al., 2009). 
 
A.5.2  Abbott-Ligand 082D06 (D06) 
 
DO6 is a synthetic non-steroidal ligand that binds the GR with low affinity (Ki 210 nM), has 
been shown to antagonize the effects of dex-mediated GR transactivation and transrepression, has 
no known agonist activity, does not induce GR nuclear translocation and does not induce DNA 
binding by GR in vitro or in vivo (Fig. B11) (Miner et al., 2003). D06 has also been shown to 














Figure B11  Structure of D06 [bis (4-N, N-dimethylaminophenyl) (2-chloro-5-nitrophenyl) methane]. 
Taken from (Ronacher et al., 2009). 
 
In COS-1 cells, with the hGR DO6 does not show any activity in transactivation or 
transrepression on the TAT-GRE, NFB- or AP-1 promoters, and has a very low relative binding 
affinity of 6500 nM (IC50) ((Ronacher et al., 2009); Tables E5 and E4 in addendum E).  
Additionally, DO6 bound-GR did not recruit the co-activators GRIP-1, TIF-2 and SRC-1, or the 
co-repressors NCoR and SMRT, in a mammalian two-hybrid assay (Ronacher et al., 2009). 
 
In this study, DO6 was used for the initial ligand-selective S226 phosphorylation studies, but due 
to limited availability, not all experiments in this thesis included DO6. 
 
A.5.3  Ursodeoxycholic acid (UDCA) 
 
UDCA is a hydrophilic bile acid used for dissolution of gallstones and chronic liver diseases 
(Fig. B12).  UDCA behaves like a weak partial agonist in GR-mediated transactivation with an 
efficacy of only 10% as compared to dex (Weitzel et al., 2005;Tanaka et al., 1996).  However 
UDCA behaves like a full agonist for GR-mediated transrepression with an efficacy of 100% as 












Figure B12 Structure of UDCA [4-[(3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13, 
14,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)]pentanoic acid]. Structure from 
http://pubchem.ncbi.nlm.nih.gov 
 
In COS-1 cells with the hGR, UDCA did result in GR-mediated transactivation, transrepression 
or co-factor recruitment (Stubsrud 2005; K. Ronacher; J. Hapgood; unpublished data) and was 
therefore classified as a GR antagonist in this cell system. UDCA was included in the initial 
ligand-selective GR phosphorylation at S226 work, but has recently been shown not to bind 
directly to the GR ((Weitzel et al., 2005); K. Ronacher and J. Hapgood unpublished data), 
suggesting an interesting mechanism of action, not via the classical GR mechanism of action and 


























Addendum D  Supporting data from the present author 
 
Figure D1  The amount of GR shifts partial agonist activity to that of a full agonist.  COS-1 cells 
were plated in 10-cm dishes at a density of 2x106 cells/dish in DMEM, containing 10% fetal calf serum 
and antibiotics. After 24 hours, the cells were transiently transfected with TAT-GRE, as well as either 10 
g or 1 g HA-hGRwt and incubated for an additional 24 hours. The following day, the cells were re-
plated into 24-well plates at a density of 5x104 cells/well and incubated for 24 hours, before stimulation 
with vehicle or increasing amounts of test compound for 24 hours.  Thereafter luciferase activity was 
determined and normalised to protein levels, as determined by the standard Bradford protein 
determination assay. The amount of luciferase activity with the vehicle control was subtracted and the 
amount of 1 g GR with 10 M dex was set to 100% and the values for the rest calculated as a percentage 
thereof.  The graph represents pooled results from three independent experiments; each performed in 


















Addendum E  Supporting data from other researchers 
 
Table E1 Ligand-selective GR phosphorylation at S211.  COS-1 cells transiently transfected with HA-
hGRwt were treated with vehicle (EtOH) or 10 mM test compound for 1 hour.  Equal amounts of protein 
(typically 20 g) were separated on 10% SDS-PAGE and Western blotting probing with an anti-phospho-
S211-specific (P-S211) antibody was performed.  Thereafter the amount of basal phosphorylation 
(vehicle) was subtracted and the amount of phosphorylation with dex set to 100%.  Data is presented as 
the average or three independent experiments and is presented as the average ± SEM. Results were 













Table E2 Phosphorylation at S211 is required for maximal efficacy in transactivation.  COS-1 cells 
transiently transfected with HA-hGRwt or HA-hGRS211A, as well as TAT-GRE reporter-promoter 
construct were treated with vehicle (EtOH) or test compound for 16 hours.  Thereafter luciferase activity 
was measured and normalised to the amount of protein, as determined by the standard Bradford protein 
determination method.  The relative efficacy for transactivation of each ligand with wt receptor was set to 
100% and the S211A mutant results calculated as a percentage thereof.  Results present the average of 
three independent experiments, each performed in triplicate and values are given as the average ± SEM. 






Table E3  Correlation analysis of S211 phosphorylation with transcription.  The S211 
phosphorylation results were correlated with the efficacy and potency for transactivation and 
transrepression.  Transactivation data was obtained by E. Stubsrud (Stubsrud, 2005) and the 
transrepression results were obtained by K. Ronacher. R2 values are shown, while statistical significance is 














Table E4  Ligand-selective GR binding affinity and fractional occupancy§.  Results were obtained by 
performing competitive binding with [3H] dex in COS-1 cells transiently transfected with HA-hGRwt in 
the presence and absence of increasing amounts of test compound.  The IC50 values were obtained 
separately from curves of the individual experiments and the mean ± SEM calculated from several 
experiments performed by K. Ronacher and is already published (Ronacher et al., 2009).  The fractional 
occupancy was calculated according to the following equation:  fractional occupancy = [ligand] / ([ligand] 




                                                  











Table E5  Efficacy and potency for transactivation and transrepression by the panel of ligands 
compared to dex expressed in relative efficacy and relative potency (-logEC50) in nM.**  Results 
were obtained in COS-1 cells transiently transfected with HA-hGRwt, as well as TAT-GRE, AP-1 or 
NFB reporter-promoter constructs. Values are given as relative efficacy and potency (nM) as 
compared to dex and are from three independent experiments, each performed in triplicate. 
Transactivation results were obtained from E. Stubsrud (Stubsrud, 2005) and transrepression results were 














                                                  











Figure E1  Effect of kinase inhibitors on transactivation and transrepression.  COS-1 cells were 
transiently transfected with HA-hGR and either TAT-GRE (A), AP-1- (B) or NFB- (C) reporter-
promoter constructs and pre-treated for 15 minutes with 10 M p38- or 50 M JNK inhibitor and then 
stimulated with vehicle or 10 M dex for 24 hours in the presence of the inhibitors. Thereafter luciferase 
activity was measured.  The amount of luciferase activity with no test compound was subtracted, the 
amount of dex induction without inhibitor was set to 100% and the rest was calculated as a percentage 
thereof.  Graphs represent the average of three independent experiments, each performed in triplicate and 
is given as the mean ± SEM. p38i = p38 inhibitor; JNKi = JNK inhibitor.  These experiments were 
performed by K. Ronacher. Statistical significance is denoted by *, ** and ***, to represent p < 0.05, p < 
0.01 and p < 0.001, respectively. 
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